The relationship between docohexanoic acid (DHA) and L-serine, providing an insight into the biochemistry of meningioma by Hatchell, Hayley
 
The relationship between docohexanoic acid (DHA) 
and L-serine, providing an insight into the 
biochemistry of meningioma. 
 
 
 
by 
 
 
 
 
 
Hayley Hatchell  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A thesis submitted in partial fulfilment for the requirements for the degree of              
Doctor of Philosophy at the University of Central Lancashire  
 
 
 
 
 
 
 
 
December, 2017. 
1 
 
Student declaration form  
 
 
 
 
Type of Award    PhD 
 
School    Pharmacy and Biomedical Sciences 
 
I declare that no material contained in the thesis has been used in any other 
submission for an academic reward and is solely my own work.   
 
No proof-reading service was used in the compilation of this thesis. 
 
Signature of Candidate     ________________________ 
 
Print name:      ________________________ 
 
 
 
 
 
2 
 
Acknowledgements 
 
Firstly, I would like to thank Brain Tumour North West, Royal Preston Hospital Tissue 
Bank and Inbetween Ears for their backing throughout this research project.    This 
dissertation would not have been possible without the support from Dr Charles 
Davis, Dr Tim Dawson, Professor Bob Lea, Kate Ashton and Dave Griffiths.  I am 
sincerely grateful for the experimental skills shared by Dave Griffiths, Dr Iftikar Khan, 
Dr Kerry Ann Rostron, Dr Andrea Burrows and Dr Sarah Dennison which I have 
implemented throughout this study.   
 
I am truly indebted and thankful for the continual guidance and advice from Dr Steve 
Beeton throughout my undergraduate and postgraduate studies.  I would also like to 
show my sincerest thanks to Clare Altham, Fiona Mair and Professor Peter Seville 
who have made this experience as least stressful as possible!  Finally, I would like 
to show my gratitude to Proffesor Colin Davidson, Dr Frederick Harris and Dr Sarah 
Dennison for their recommendations over the past 12 months.   
 
In addition to the fond memories I have gained, these individuals have also given 
me the strength over the past year to continue; Dr Vikesh Chhabria, Shofiya Salim, 
Murassa Sheikh, Roshini Mathews, Mehak Raja, Joud Sabouni, Muraf Jalab, Dr 
Iftihar Khan, Dr Sakib Yousaf.  I honestly cannot thank you enough! 
 
 
 
 
“It always seems impossible until it's done” 
3 
 
Abstract 
 
As far back as the 1920s, Otto Warburg observed that cancerous cells display an 
altered state of metabolism surrounding lipid biosynthesis.  However, only until 
recently has metabolic reprogramming been a recognised hallmark of the disease. 
The number of cancer cases diagnosed is set to triple by 2030, demonstrating the 
need for disease prevention, improved diagnostic testing and personalised treatment 
therapies.  However, with some cancers occurring in the brain and spinal cord, the 
type of treatment available can become challenging due to their locality. Such cancer 
types include meningioma and glioma which are the most common brain tumours 
diagnosed.   
 
An initial study involving human meningioma tissue revealed unusually high levels 
of the phosphatidylserine enriched with docosahexaenoic acid (DHA).  In this study, 
the metabolism surrounding lipid biosynthesis was examined to establish if such 
alterations in lipid profiles were related to an altered state of metabolism. From the 
results gained, it can be suggested that meningioma does have an altered state of 
metabolism, evolving around serine as opposed to DHA.  From the grade I and grade 
II meningioma tissues immunochemically examined, positive expressions of 
pyruvate kinase isoform 2 (PKM2) and phosphoglycerate dehydrogenase (PHGDH) 
were shown.  Therefore, the results demonstrated that within meningioma tissues, 
serine can allosterically regulate the flux through glycolysis.  The association that 
serine presence alone can alter the metabolic flux was demonstrated in the model 
organism, Lipomyces starkeyi.   
 
Those L. starkeyi cells supplemented with serine, displayed a 50% reduction in the 
amount of radiolabelled acetate taken up during exponential and stationary growth 
phases.  The radiolabelled study also highlighted that with serine presence, de novo 
lipid biosynthesis was altered.  Once synthesised, these neutral lipids go on to be 
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stored in membrane bound organelles.  Within the phenotype of cancerous cells, 
such storage of neutral lipids into lipid droplets prevent lipotoxicity. The light 
microscopy study of L. starkeyi cells supplemented with serine demonstrated that 
the formation of such lipid droplets was enhanced during lipid accumulation.  These 
findings suggest that the production, storage and mobilisation of lipids within serine 
supplemented cells are adapted to cellular requirements, promoting a cancerous 
phenotype.   
 
In order to gain an insight into the potential impact that an altered metabolic state 
may give to meningioma, a liposomal study was developed.  Supplementation of 
both phosphatidylserine-consisting liposomes, as well as tumour-derived liposomes, 
enhanced the cellular viability of the non-cancerous cell line, SVG, during 
exponential phase.  The supplementation of meningioma-derived liposomes also 
increased the viability of the non-cancerous human fetal glial SVG cell line, similar 
to that observed with phosphatidylserine containing liposomal preparations.  
Therefore, the data suggest that in fact, the phospholipid (phosphatidylserine), rather 
than the fatty acid (DHA) plays a role in cellular viability.   
 
It is concluded that the results gained from this study can be used clinically in the 
diagnosis and management of meningioma as well as other diseased cells 
displaying ectopic lipid accumulation.  The observation that meningioma has an 
altered biochemistry may provide guidance when histologically grading meningioma 
tumours.   For those tumours expressing the enzymes involved in serine 
biosynthesis, such as PKM2 and PHGDH, a targeted treatment therapy surrounding 
enzyme inhibitors can be examined.  By targeting serine biosynthesis, the resources 
needed to enable a cancerous phenotype are depleted.   Future research can 
examine such targeted therapies utilizing either the developed model organism, L. 
starkeyi or the conventional SVG and U87 cell lines.   
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1.1 INTRODUCTION 
 
Cancer cases are expected to triple per annum by 2030 to 26 million diagnosed 
cases coupled with 17 million deaths (Thun et al., 2010).  Demographic changes in 
the increasing ageing population are one of the many factors accounting for this 
ever-increasing statistic on cancer diagnosis.  The risk of cancer development is 
heightened with several associated risk factors surrounding an adoption of unhealthy 
lifestyle choices i.e. smoking, poor diet and reduced physical activity.      One cancer 
type, which often embodies relatively rare, but serious health-associated risks, is 
those that are in the central nervous system (CNS).  According to the World Health 
Organisation (WHO) there are a multitude of brain tumour types (>125) which can 
be histopathologically assessed (Eberlin et al., 2013).  Under the umbrella of brain 
and spinal cord tumours, gliomas and meningiomas are the most common 
diagnosed per year (Taylor et al., 2009).       
 
1.1.1 Meningioma 
Meningioma is the most common primary intracranial tumour diagnosed in the adult 
population; accounting for 13-26% of all CNS tumours (Alexiou et al., 2010; Eberlin 
et al., 2013). Interestingly, Harvey Cushing first described it in 1915 and at that time 
arachnoidal cap cells were believed to be the point of origin of the meningeal brain 
tumour.  Cushing further defined the tumour in 1922 with the term ‘meningioma’, 
which has retained its global acceptance until the present day. The cells, previously 
referred to as the arachnoidal cap cells, are now known as the non-neuroepithelial 
progenitor cells which cover the brain and spinal cord.  
 
The work by Cushing and Bailey (1915) in the meningioma classification laid the 
foundation in the WHO classification of the disease.  This included a 
histopathological classification system with four subclasses of meningioma, 
consisting of: meningiothelial, fibroblastic, angioblastic and osteoblastic.  
Remarkably, even with the recent scientific advances, the histopathological basis for 
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meningioma diagnosis, reported by the WHO in 2007, remains like that originally 
described by Cushing and Percival (1915).  
 
1.1.2 Current Epidemiology of Meningioma  
The WHO classification is used clinically to diagnose meningioma tumours.  In 2012 
alone, an estimated 57,000 new cases of brain and other CNS tumours in Europe 
were diagnosed.  Europe wide occurrence of brain and other CNS tumours was 
reviewed in a seven-year EUROCARE-5 study (Visser et al., 2015).  From this study, 
an observed gender-bias was displayed in the diagnosis of CNS tumours with many 
cases being diagnosed in males (57%) as opposed to females (43%). Interestingly, 
the proportion of CNS cases diagnosed which originating from the United Kingdom 
accounted for over a third of the total diagnosed cases in Europe in this seven-year 
period. Disappointingly, UK and Ireland was ranked at the bottom of the survival 
rates in comparison to other European countries.   
 
The five year prognosis of individuals with benign meningioma is high with 80% of 
individuals diagnosed reaching this period (Taylor et al., 2009).  A marked difference 
between meningioma and glioma is the five-year survival rate.  Those individuals 
who are diagnosed with meningioma have a higher chance of reaching the five-year 
survival (70-95%) as opposed to those diagnosed with glioma (<3%) (Sehmer et al., 
2014) demonstrating the marked difference in the aggressive nature of these 
tumours. 
 
A ten-thousand patient case-control study of UK residents on meningioma diagnosis 
demonstrated an incidence rate of 5.30 per 100,000 persons (between 1996 and 
2008).  Similar incidence rates were demonstrated in a review by Sehmer et al. 
(2014) on glioma diagnoses between 2006 and 2010; 7.10 per 100,000 persons.  
Within the meningioma diagnosis cohort, the incidence rate in women was shown to 
be twofold higher compared to males, with the incidence rate of women being 7.19 
compared to 3.05 found in males per 100,000.  This study suggests a meningioma 
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female gender basis in diagnoses.  Interestingly, this is opposite to that reported by 
the EUROCARE-5 study (Visser et al., 2015).  However, to keep in mind, the 
EUROCARE-5 study gathered information from a variety of cancer types including 
liver, pancreas etc., not just meningioma. Therefore, this supports the postulation 
that meningioma risk can be related to the individuals’ gender especially that of 
women.  Incidence rates of meningioma is shown to increase with age; indifferent of 
gender, peaking in individuals ranging from 70-80 in years.  However, a study by 
Nielsen et al. (2009) demonstrated a link between medical advances including the 
use of computerised tomography (CT) scanning and oligodendroglioma incidence 
rates (a glioma variant).  From 1943 to 2002, diagnoses in Denmark nearly doubled 
to 0.45 cases/100,000 persons presumably through improved diagnostic techniques.    
 
1.1.2.1 Tumour Anatomy  
The anatomy of a tumour can be observed using recent medical advances, including 
that of CT.  Meningioma can reside in various locations within the brain and spinal 
cord. This is important as the origin of tumour site aids not only meningioma 
classification, but also the appropriate treatment avenue available.  Furthermore, the 
tumour location is also an important factor clinically when considering if surgery is a 
viable option; the associated risk of tumour removal can be too great if the tumour is 
too deep. Illustrations of the most common locations of meningioma in the brain are 
shown in Figures 1.1 and 1.2.  
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Figure 1.1:  Diagrams showing the common locations of Meningioma in the Coronal 
and Sagittal planes (taken from The Mount Sinai Hospital, 2017). Legend: 1. 
Intraventricular, 2. Parasagittal, 3. Falcine, 4. Suprasellar, 5. Clivus, 6.  Foramen 
Magnum, 7.  Convexity, 8. Olfactory Groove and 9.  Cerebellar.   
 
 
Figure 1.2:  Diagrams showing common locations of Meningioma in the Skull Base 
planes Locations (taken from The Mount Sinai Hospital, 2017).  Legend: 1.  
Paranasal/ Olfactory, 2. Optic Sheath, 3. Sphenoid Wing, 4. Suprasellar, 5. Clivus, 
6.  Foramen Magnum, 7.  Tentorial and 8. Posterior Fossa.  
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Although meningioma tumours can occur at any point along the meninges, some 
areas are more common than others, namely the Falx and Parasagittal regions (refer 
to Figure 1.1 and 1.2).  The majority of meningioma’s are located intracranially (90%) 
in the supratentorial compartment; along the dural venous sinuses in the cerebral 
convexity; parasagittal and in the spheroid wing regions (Cea-Soriano et al., 2012).  
These supratentorial tumours account for approximately 20% of the total intracranial 
tumours diagnosed (Cea-Soriano et al., 2012).  Other locations where meningioma 
tumours can be found include the optic nerve sheath, choroid plexus and the 
cerebellopontine angle. Therefore, the position of the meningioma tumour can 
provide an indication of its type during diagnosis.  
 
1.1.2.2 Recent imaging and histological markers aiding diagnosis 
Brain tumour detection via modern imaging techniques display the position of the 
meningioma tumours.  The use of such medical advances, as opposed to the 
interpretation of tumour symptomatology alone, have enabled earlier detection and 
diagnosis of meningioma.  Often, meningioma patients display wide-ranging 
location-related symptoms, including seizures, impaired vision, headaches, anosmia 
and mental changes.  Consequently, a postponement of diagnosis can occur, due 
to a misdiagnosis (Nakasu et al., 1987).    
 
The result of either misdiagnosis or undetected symptomology of meningioma is 
highlighted with the number of cases diagnosed post-death, during autopsy.  A 
review by Nakasu et al. (1987) of autopsies between 1950 to 1982, highlighted a 
meningioma incidence rate of 1-2% with a 3:1 female to male ratio.  Increasingly, the 
unexpected meningioma findings during autopsy demonstrated a trend between age 
and the tumour size and older the individual the larger the tumour.  Similar 
observations were described in a study by Sugiyama et al. (1996), whereby the main 
meningioma histological variant observed was psammomatous.  The observation of 
psammomatous meningiomas being found during autopsy may be as a result of their 
reduced nature of proliferation compared to other meningioma variants.  Hence, due 
to psammomatous meningiomas reduced growth rate, associated symptomology 
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due to the tumour may not have occurred. Therefore, the postulation from both 
studies as to why these meningioma tumours have gone undetected until autopsy 
may be due to the specific tumour variant which delays meningioma associated 
symptomology in addition to recent medical advances i.e. CT not being utilised pre-
death.     
 
The use of current imaging techniques would be important if an individual was to 
have a recent onset of seizures or had focal neurological signs.  Novel imaging 
techniques  which can aid meningioma diagnosis include magnetic resonance 
imaging (MRI) (Cea-Soriano et al., 2012).  Accurate diagnosis of meningioma is 
achieved by a MRI scanner, as the characteristic meningioma features are displayed 
to the clinician.  Such markers of the tumour in plain radiographs include 
hyperostosis, increased vascular markings and psammomatous calcifications.  The 
benefit of such imaging techniques such as CT and MRI scans, is the ability to detect 
the tumour before the symptoms are present.  This is especially important for highly 
aggressive tumours whereby symptoms can be presented at a late stage of 
malignancy where treatment is limited.  By detecting the tumour earlier via imaging, 
a better prognosis can be achieved as treatment intervention occurs earlier.  Once 
the mass is identified, a biopsy is taken which will enable the tumour classification 
to be identified which will in turn direct the anti-tumour therapies available.  
     
1.1.2.3 World Health Organisation Grading System   
The WHO tumour grading objectives have been constant since its existence 
(Scheithauer, 2009) to categorise and establish the grading of human neoplasms; 
such as meningioma (Louis et al., 2007).   In each new published classification 
edition to aid accurate tumour diagnosis the WHO included new advances in the 
field.  Such examples of the incorporation of recent medical advances include the 
immunohistochemistry introduction in diagnostic pathology including the signs and 
symptoms alongside prognosis and predictive factors being taken into account when 
classifying the tumour (Louis et al., 2016; Louis et al., 2007).   
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The most recent 2016 WHO classification was an updated version of the 2007 
edition, the details can be found in the review of CNS classification by Louis et al. 
(2016).  In brief, the molecular alterations previously used as prognostic markers 
have now been incorporated in the diagnostic classification, the review by Louis 
(2006) details the spectrum of malignant glioma in terms of genetic alterations.  
Interestingly, meningioma did not undergo re-classification in this sense, only glioma.  
Hence, the 2016 WHO edition has significantly updated the classification codes 
including integrating molecular parameters with microscopy.  Interestingly, the 
observation of a tumour having invasive characteristics will override the previously 
diagnosed atypical meningioma, which is currently classified via the 2007 WHO 
edition via several histological characteristics (Louis et al., 2016).  However, unlike 
glioma which had molecular parameters considered in the new 2016 WHO edition, 
meningioma did not.  Currently, meningioma is diagnosed and classified into three 
Grades (I-III) per the WHO grading system as summarised in Table 1.1. 
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Table 1.1: Meningioma classifications in terms of grade (I-III) based on histomorphological features, according to the 2007 
WHO diagnostic criteria.
WHO 
Grade 
Histomorphological Features 
I Predominant histological variant  
- Meningothelial 
- Fibrous 
- Transitional 
- Psammomatous 
- Secretory 
- Microcystic 
- Angiomatous 
- Lymphoplasmacyte-rich 
- Metaplastic 
II Any Grade 
I histologic 
variant with 
brain 
invasion 
OR Atypial by elevated mitoses  
(4-19 mitoses/10 high 
powered fields) 
OR ≤3 atypical features 
including: 
- Hypercellularity 
- ‘Sheet-like’ growth 
- Spontaneous 
necrosis 
- Small cell change 
OR Predominant histologic variant 
- Clear cell 
- Chordoid 
III Frank 
anaplasia 
(Sarcoma-, 
carcinoma-
, or 
Melanoma-
like 
histology) 
OR Anaplasia by elevated 
mitoses (≥20 mitoses/10 high 
powered fields) 
OR Predominant histologic 
variant 
- Rhabdoid 
- Papillary 
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On the premise of the 2007 WHO classification as shown in Table 1.1, benign (grade 
I) meningioma was the predominant grade diagnosed (80%); depending on its 
location  this can be cured via surgical resection (Riemenschneider et al., 2006).     
Meningioma tumours which display more aggressive clinical features are classified 
as grade II.  This variant only accounts for 15-20% of diagnosed meningioma cases.  
However, in circumstances where infiltrating malignant behaviours are displayed, 
diagnoses of grade III (malignant) occur (1-3%).   
 
1.1.2.4 Histological classification  
When reviewing histological meningioma sections distinctive histological findings are 
customary due to the cellular origination of meningioma, the arachnoidal cap cells.  
This is in-part due to arachnoidal cap cells metabolically-active subgroup which is 
responsible for cerebrospinal fluid reabsorption.  The position of these arachnoidal 
cap cells are perfect for venous blood flow exposure hence cerebrospinal fluid 
reabsorption.  A full review on the function and structure of the arachnoidal villi was 
done by Pollay (2010).  With the basis of arachnoidal cap cells function in mind, the 
WHO histological classification of meningioma is imperative to enable accurate 
diagnosis in terms of grade and histological variance (Table 1.1).      
 
Within the three grades (I-III) of meningioma, there are 11 histologic subtypes 
(Backer-Grondahl et al., 2012).  Clinically, these histomorphological features of 
meningioma (Table 1.1) can be diagnosed using a light microscope.  Images of 
meningioma tissue sections of various grades and histomorphological features that 
were described in Table 1 are illustrated in Figure 1.3. 
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Figure 1.3: Samples of photographs showing the histomorphological features of (1) 
grade I meningioma, (2) grade II meningioma and (3) grade III meningioma in 
accordance with the WHO classification (2007).  These features aid diagnosis and 
thereafter, grade classification which in turn gives an indication of the tumours 
behavior adapted from Riemenschneider et al. (2006).   
Legend: Grade I, meningioma variants (Adapted from Riemenschneider et al., 
2006): meningiothelial (A), fibrous (B), transitional (C), psammomatous (D), 
angiomatous (E), microcystic (F), secretory (G), lymphoplasmacyte-rich (H) and 
metaplastic (I).  Grade II, atypical variants (Adapted from Riemenschneider et al., 
2006): atypical meningioma with increased mitotic activity (J), clear-cell with 
glycogen-rich cytoplasm (K) and choroid showing chordoma-like growth in myxoid 
matrix (L).   Grade III, anaplastic (malignant) variants ( Adapted from 
Riemenschneider et al., 2006): anaplastic meningioma with cellular anaplasia and 
mitotic figures (M), rhabdoid meningioma with large tumour cells with eccentric nuclei 
(N) and papillary meningioma showing a pseudopapillary growth pattern (O). 
G
. 
 
H
. 
 
I 
 
1. Histology of WHO grade I meningioma  
A CB ED F
3. Histology of WHO grade III meningioma (Anaplastic and malignant)  
2. Histology of WHO grade II meningioma (Atypical)  
J K L 
M N O 
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The histomorphological features of meningioma as depicted in Figure 1.3, are 
clinically used in the process of diagnosing and predicting the biological behaviour 
of the neoplasm.  On closer inspection from the neoplasm sections (Figure 1.3), 
three histological growth patterns have been concluded, namely; meningiothelial, 
fibroblastic and transitional.  In accordance with several other factors stated in the 
WHO classification, the meningioma grade can be determined using the tumour 
location and histological growth pattern.  This in turn, aids the appropriate treatment 
avenues for the diagnosed tumour grade. The appropriate treatment avenue for a 
meningioma tumour is dependent primarily on its location, as this determines the 
likelihood of surgical viability.  Unfortunately, even with aggressive intervention, to 
date, effective treatments for malignant meningiomas are still unavailable.      
 
1.1.2.5 Tumour grade as a prognostic factor 
In combination with WHO classification, other factors are taken into consideration in 
predicting the response to a particularly therapy.  These factors which determine the 
likelihood of therapy outcome include the individual’s clinical history, their age, 
neurological performance alongside the tumour location and size and the presence 
of neoplastic mutations (genetic).  To enable an accurate diagnosis of tumour type, 
grade and histological variance, a pre-work up is carried out whereby the tissue 
sections are examined histologically in terms of morphology and the presence of 
progesterone, oestrogen and invasiveness marker (Ki67) receptors.  Going forward, 
the tumour progression, before-, during- and after treatment can then be measured 
using the same observations of receptor presence alongside tumour size which 
together provide an indication of therapy outcome.    
 
1.1.3 Risk Factors  
The aetiology of meningioma is generally unknown.  However, there have been 
suggestions of a relationship between increasing age and exposure to other risk 
factors upon meningioma development (Alexiou et al., 2010).  These risk factors 
include, but not limited to; ionising radiation, gender (female: male, 2:1 basis), 
genetic mutations and pre-existing medical conditions such as diabetes and 
37 
 
previous cancer history.  These risk factors are summarised in detailed reviews by 
Barnholtz-Sloan and Kruchko (2007) and Riemenschneider et al. (2006). 
 
1.1.4 Treatment  
Standard level of care treatments for meningioma considers all aspects already 
ascertained and they include; but not limited to: the neoplasm site of origin, its’ size 
and growth rate, the medical history of patient alongside their age and any 
neurological symptomologies due to neoplasm and, the histopathological biopsy 
profiles (if any have been taken in previous surgery) to aid determination of grade 
classification.  Available treatment avenues for meningioma currently involve 
surgery, radiotherapy, stereotactic radiotherapy, hormonal therapy, chemotherapy 
and antiangiogenic therapy (Alexiou et al., 2010). 
 
1.1.4.1 Surgery and Preoperative meningioma embolization  
After initial diagnosis of meningioma, patients generally opt for surgical removal of 
the tumour.  This is due to surgery being the standard therapeutic option, as excision 
alone cures the clear majority of meningioma cases.  This reflects upon the recent 
neurosurgery advances i.e. micro-neurosurgery and image-guided surgery where 
the tumour removal can be more completed enabling lower reoccurrence rates 
(Alexiou et al., 2010). As discussed by Alexiou et al. (2010), the rate of tumour 
reoccurrence is observed to be higher when the surgery for resection is poor, 
however the option for surgery is dependent on tumour locality.  In 1957, Simpson 
proposed the evaluation of the surgical reception in terms of grade to establish the 
likelihood of a tumour reoccurring.  The proposed tumour resection quality scheme 
is described in Table 1.2. 
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Table 1.2: The proposed method of assessing tumour resection quality, via the 
Simpson Grade classification scheme grading from stage 1-5. 
Stage Resection Quality 
1 Complete excision extending to the dura and bone. 
2 Complete excision alongside dural attachment coagulation. 
3 Solid tumour complete excision but insufficient excision of dura and 
bone and dural attachment coagulation.  
4 Incomplete resection thus macroscopic tumour residue visible 
5< Biopsy only.  
 
Staging of Simpson grade (1-5) corresponds with resection quality, as shown in 
Table 1.2. This has been proven to be an invaluable clinical asset in predicting 
meningioma reoccurrence after surgical resection.  A clinical study demonstrated a 
correlation in meningioma grade I patients whereby a reduced reoccurrence rate 
was observed in those individuals which had a lower a Simpson grade (Saito et al., 
2012).  To reduce further the reoccurrence of meningioma, other therapeutic 
treatment avenues need to be available. By gaining a better understanding of the 
biochemical processes of the cancerous cells in relation to its behaviour, 
individualised treatment avenues can be sought.   
 
There has been a plethora of studies examining brain tumours, as far back as the 
19th century with Cushing and Percival Bailey to the present day.  At this time, Otto 
Warburg described cancer to be an altered energy state of metabolism (Warburg, 
1956).  Interestingly, this has only recently been recognised in the cancer 
classification list (Hanahan and Weinberg, 2011).   
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1.2 IS CANCER A METABOLIC DISEASE? 
 
Work pioneered by Otto Warburg as far back as the 1920s, recognized that tumour 
cells exhibited an altered state of metabolism, for which he won a Nobel prize in 
1931 for Medicine (Warburg, 1925; Warburg, 1956).  However, cancer is still to an 
extent viewed as a proliferative disease, which is often observed to be 
uncontrollable.  Fueling the sustainability of this uncontrollable proliferation requires 
intermediary metabolites including proteins, nucleic acids and lipids such that the 
biochemical pathways ensuring growth are maintained.  
 
1.2.1 Warburg and Crabtree effect 
The observation that cancerous cells have altered metabolism was denoted nearly 
a century ago by Otto Warburg, terming these the Warburg and Crabtree effect.  
Warburg suggested that mitochondrial metabolism was suppressed in cancerous 
cells (Warburg, 1956).  The mitochondria are often referred to as the ‘power-house’ 
of the cell due to the role they play in cellular processes and energy metabolism. 
 
Several studies have demonstrated Otto Warburg’s theory.  These include the 
observation that cancerous cells display a decreased respiration in parallel with a 
heightened lactate production, proposing that the adenosine triphosphate (ATP) 
supply is dependent upon fermentative metabolism.  Furthermore, the increased 
cellular proliferation of the cancerous cells was in line with reduced energy yield.  
Subsequently, the suppression of oxidative metabolism with oxygen presence 
occurs with such, the glycolysis is aerobic in nature hence termed the “Warburg 
effect” (Diaz-Ruiz et al., 2011; Zhou et al., 2010).   
 
Energy demands of the cancerous cells are enabled by the result of the ‘Warburg 
effect’ long term on metabolic reprogramming (Zhou et al., 2010).  Hence, the 
proliferative nature of the cancerous cells will continue. However, the specific 
40 
 
advantages the cancer cells ascertain by undergoing these metabolic alterations are 
unidentified.  Several theories have been proposed and they include: 1) proliferation 
being supported in hypoxia and 2) apoptosis is prevented via the reduction of 
oxidative metabolism.  These metabolic alterations are advantageous for the 
cancerous cells to survive especially in in such conditions as hypoxia where nutrients 
required for proliferation maybe limited.   Opposing this purely ‘glycolytic’ cancerous 
cell view is the growing body of evidence of cancer cell lines possessing functional 
mitochondria.  By possessing such, this would suggest that these cancerous cells 
are able to obtain their ATP via oxidative phosphorylation.  Interestingly, some 
cancerous cells have been shown to reversibly switch between fermentative and 
oxidative metabolism depending on the tumours environment i.e. glucose status 
aiding their survival and ability to proliferate. 
 
Cancerous cells can metabolically adapt to their environment. This is referred to as 
the ‘Crabtree effect’ whereby respiration and oxidative phosphorylation are 
suppressed by glucose. These short-term reversible switches occur between 
glycolysis and oxidative phosphorylation. The possibility of an intra-neoplasm 
metabolic switch in relation to the tumour environment i.e. oxygen availability etc. 
was recently displayed with reports of cancerous cells of differing subpopulations 
mutually co-existing: one subtype producing lactate (Warburg, 1956), whereas the 
other was utilizing lactate (Kennedy and Dewhirst, 2010). Hence, demonstrating the 
hypoxia conditions cancerous cells reside in, result in the production of lactate.  This 
is contrary to those oxygen-rich cancerous cells, which have the capacity to take up 
lactate as its’ preferred energy source.  Similar results have been found in the study 
of cancerous breast cells by Park et al. (2016), whereby the deprivation of glucose 
did not affect the proliferative nature of the cells, as the preferred energy source was 
that of lactate not glucose. Interestingly, a link was found between lactate preference 
and the expression of ERRα (estrogen-related receptor alpha).  With this in mind, 
cancerous cells’ energy metabolism has been investigated as a possible anti-tumour 
therapy. One of the many anti-tumour therapy avenues researched surround energy 
metabolism, especially that of lipids, as these have been shown to be altered in many 
diseases including that of cancer. 
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1.2.2 Lipid metabolism  
The process of nutrient-derived carbons being converted to fatty acids is referred to 
as lipid synthesis.  Once thought as just an energy source, fatty acids have proven 
to be active molecules with roles ranging from; protein synthesis regulation, signal 
transduction and the involvement in membrane fluidity thus permeability.  These fatty 
acids act as lipid mediators regulating both metabolic pathways and responses to 
inflammation.  In many cancerous tissues, lipid biosynthesis is described as 
‘reactivated’; illustrating an example of disease lipid dysregulation (Coller, 2014; 
DeBerardinis et al., 2008b).  An overview of the pathways involved in lipid 
metabolism is represented in Figure 1.4 below. 
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Figure 1.4: Flow diagram showing an overview of lipid biosynthesis pathways and their cross-talk.  The fundamental precursor 
for all lipid classes (fatty acids, cholesterol, sphingolipids etc.) is the small molecule, acetyl-CoA which arises from the tricarboxylic 
acid (TCA) cycle (Adapted from Baenke et al., 2013; and Yamashita and Nikawa, 1997). Legend:  triacylglycerides (TAGs) and 
diacylglycerols (DAGs). 
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The main precursor of all the lipid classes is a small two carbon unit called acetyl-
CoA (Figure 1.4).  Lipid classes are defined and based on their components, 
including: cholesterol and cholesterol esters, glycerol including triacylglycerides, 
diacylglycerols and monoacylcerols, eicosanoids, and sphingolipids.  These lipid 
classes all have specific roles in proliferation, signalling and structural support.  Full 
detailed reviews on lipid biosynthesis can be found in Zweytick et al. (2000) and 
Yamashita and Nikawa (1997). 
 
1.3 FATTY ACIDS: CENTRAL LIPID 
 
Lipids make up a large proportion of biological matter.  From this, fatty acids are the 
main embodiment.  This is good on several fronts since: 1) as they provide an 
invaluable energy source where excesses are stored for later use; 2) cellular 
membranes are mainly comprised of phospholipids which in turn are made from fatty 
acids and, 3) as they are involved in prostaglandin production which are involved in 
the inflammatory process.   Fundamentally, fatty acids are carboxylic acids, varying 
in carbon length from 2-36 forming either a saturated or unsaturated structure.  Their 
RCOOH structure is comprised of a methyl end, hydrocarbon chain and finally a 
carboxylic terminus, as shown below. 
 
 
Figure 1.5:  Diagram showing the structural formula of a fatty acid including the 
hydrocarbon backbone, a methyl end and a carboxylic terminus. The example 
illustrated is that of palmitic acid (sixteen carbons with no double bonds, 16:0). 
Figure 1.5 shows the structural formula of a fatty acid within eukaryotes, there are 
several fatty acid types each serving a specific role and some examples of their 
structures are shown in Figure 1.6. 
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Figure 1.6: Flow chart showing a wide variety of eukaryotic fatty acids exist, many 
of which are illustrated above.  The nomenclature of fatty acids are dependent on 
their structural characteristics, which in turn affects a range of; physical, chemical 
and biological properties.  Double bond presence within the hydrocarbon chain 
(C=C), classifies these fatty acids as unsaturated, unlike saturated fatty acids which 
contain no double bonds.   The number of these double bonds, further defines them 
as; monounsaturated (one double bond present) or polyunsaturated (> than one 
double bone present) fatty acids.  Within the polyunsaturated pool, the position at 
the methyl terminal (ω:n) of the double bond, further classifies these either as 
omega-3 (ω:n-3) or omega-6 (ω:n-6) fatty acids.  Figure drawn by hand. 
 
As illustrated in Figure 1.6, the fatty acid structure alone can be used in the 
identification of their fatty acid subtype.  For example, monounsaturated fatty acids, 
have one double bond whilst polyunsaturated fatty acids like, arachidonic acid have 
four (more than one). In most eukaryotic cells, fatty acids are stored as 
triacylglycerides, the conversion of which is shown below.      
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Figure 1.7: Diagrams of chemical structures, which provide energy in eukaryotic 
cells. The highly energy-rich triacylglyceride molecules provide stored energy and 
essential fatty acids via lipolysis in times of requirement such as membrane 
biosynthesis.  Triacylglycerides are produced when fatty acids are esterified to a 
glycerol backbone and these fatty acids may be of differing lengths and saturation 
(Adapted from, Santos and Schulze, 2012 and Yen et al., 2008a). 
 
After each successive fatty acid addition to the glycerol backbone, the final step is 
catalyzed via diacylglycerol acyltransferases (DGAT) which aid the conversion from 
diacylglycerols to triacylglycerides (Yen et al., 2008b). Once triacylglycerides are 
produced, this neutral lipid serves as cellular storage molecule that is highly enriched 
with ATP and essential fatty acids required for cellular events including membrane 
biosynthesis. However, due to the hydrophobic nature of triacylglycerides, they are 
stored in the core of a lipid droplet (LD) alongside sterol esters (Walther and Farese 
Jr, 2009).  Therefore, to utilize these lipids, several organelles and key enzymes 
need to be orchestrated. 
 
1.3.1 Lipid droplets  
In the environmentally changing landscape of nutrient availability, the ability of a cell 
to store energy would be advantageous.  A summary of the LDs’ anatomy and their 
alliances with other organelles, which enable such storage of lipids in a cell is 
illustrated in Figure 1.8. 
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Figure 1.8:  Diagram showing the anatomy and LD interactions with the mitochondria (MT) and endoplasmic reticulum (ET) 
provides an insight into its role as a high-energy storage organelle preventing lipotoxicity. Neutral lipids are stored within the core 
of the LD; sterol esters (SEs) and TAG are surrounded by a phospholipid monolayer consisting of; phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) with minor sterol (S) traces.  LD size is paralleled with neutral lipid storage and mobilization; close 
proximity with other organelles enriched with enzymes within membranes aids such a process.  Proteins are targeted to the LD, 
including; Phosphocholine cytidylyltransferase (CCT), perilipin, Rab18 and Diacylglycerol O-Acyltransferase 2 (DGAT2) (Adapted 
from Farese and Walther, 2009 and Walther and Farese Jr, 2009).   
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As depicted in Figure 1.8, the alliance of several cellular organelles enable the 
efficient storage of lipid within LDs.  The benefit of grouping such lipids into a 
separate cellular organelle is to ‘buffer’ the free lipid cytoplasmic content which would 
usually become lipotoxic when levels become raised (Walther and Farese Jr, 2009). 
When the cell requires these stored lipid resources with the LDs, lipolysis is initiated 
whereby several lipases and LD proteins act in unison to mobilize the required lipids 
Thiele and Spandl (2008).  An overview of triacylglyceride lipolysis is shown in Figure 
1.9 where energy is released subsequently.   
Figure 1.9:  Chemical structures depicts lipolysis of triacylglycerides to produce (1) 
diacylglycerides then (2) monoacylglycerides, at each one of these stages fatty acids 
are released.  The mobilization of these fatty acids enables membrane biosynthesis 
and other cellular processes.  The diagram is adapted from Yen et al. (2008b).  
 
In cancerous cells, the number of LDs are higher in comparison to non-cancerous 
cells (Accioly et al., 2008).  Alterations in lipases have been associated in cancer, 
for example monoacylglycerides lipase (MAGL) has been observed to be 
overexpressed in cancerous cells, resulting in the mobilization of neutral lipids to 
enable energy production (Beller et al., 2010).  Therefore, it can be suggested that 
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if this was a continuous state alongside the increased fatty acid production 
triacylglyceride would be accumulated in LD.  Subsequently, the observed number 
of LDs in cancerous cells may be a sign of the cancerous cells adaptation to the 
raised cytosolic lipid content: mobilization demand.  
 
Until recently, the role LDs play within the nervous system was quite sparse.  It has 
been suggested however, that LD formation and neurodegeneration are paralleled.  
A study on Drosophila by Liu et al. (2015) demonstrated the knock-on effect of 
neuronal mitochondrial dysfunction and reactive oxygen species upon glia. The 
study demonstrated how glia with dysfunctional mitochondria increase their ability of 
storing neutral lipids within LDs. Furthermore, the onset of the neurodegeneration 
was shown to be paralleled with such lipid accumulation.  Promisingly though a 
reduction of such lipid accumulation delayed the onset of neurodegeneration, 
therefore providing an insight into future treatment options focused upon lipid 
metabolism.          
 
1.4 CANCERS ALTERED LIPID LANDSCAPE  
 
As previously outlined, alterations in lipid metabolism have been observed in cancer. 
This dysregulation of lipid metabolism has been linked with chemo-resistance in 
many types of cancer, including; breast, cervical and colon (see Zhao et al. 2013 for 
review). 
 
1.4.1 Altered metabolism: at a glance  
One area of altered lipid metabolism that has gained research interest is that of fatty 
acids. In cancerous cells, carbon is diverted away from the production of energy to 
supply fatty acid metabolism (Currie et al., 2013).  The observed increase in fatty 
acid metabolism provides supply into several fundamental processes which enable 
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membrane biosynthesis thus proliferation.  In addition to this, the production of 
phospholipids is affected by the altered state of fatty acid metabolism. 
 
1.4.1.1 Fatty acids 
To examine fatty acid production within cancerous cells, some studies have looked 
at a transcriptional level.  Studies by Li et al. (2014b) on hepatocellular carcinoma 
displayed the relationship upon the three-year survival rate of patients who showed 
an expression of Sterol Receptor Binding Protein-1 (SREBP-1). The study 
demonstrated the paralleled relationship of SREBP-1 expression with increasing 
tumour size, aggressiveness (grade) and the observation of metastasis. This 
transcription factor regulates the synthesis of cholesterol, fatty acids and 
phospholipids.  Therefore, the overexpression of SREBP-1 within a cancerous cell 
will enable the required lipid source for the tumour to thrive in terms of growth and 
resistance to its microenvironment.  
 
Interestingly, cancerous cells have the capability to generate fatty acids de novo, 
unlike non-cancerous cells which source their fatty acids exogenously (Currie et al., 
2013). Further studies however, have demonstrated this may not be the case in all 
cancer types. Recent research on ovarian tumours have shown adipocytes near the 
tumour provide fatty acids to the cancerous cells via the lipid chaperone, fatty acid 
binding protein 4 (FABP4) (Nieman et al., 2011).  Another point that the study by 
Zaugg et al. (2011) examined was the influence the cells accessibility to the 
produced fatty acids. Those tumour cells expressing carnitine palmitoyltransferase 
1C (CPT1C) brain isoform had the ability to transport fatty acids across the 
mitochondrial membrane. This transportation of fatty acids to the mitochondria aided 
the oxidation of fatty acids therefore ATP generation needed for cellular processes. 
The overexpression of carnitine palmitoyltransferase 1C (CPT1C) has also shown 
to increase the cellular resistance to both glucose deprivation and hypoxia 
conditions.  This demonstrates that fatty acid mobilization aids tumour resistance to 
environmental stressors i.e. oxygen and nutrient availability.  
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1.4.1.2 How lipid microenvironment relates to cancer progression  
Cellular processes are dependent upon lipid availability to function. Such processes 
are tightly regulated by preventing lipotoxicity and membrane dysfunction. An 
example of which is the SREBP family, often described as master regulators of lipid 
homeostasis by targeting fatty acid and cholesterol biosynthesis (Camargo et al., 
2012; Horton et al., 2002).  The link between cancer progression and the presence 
of lipids surrounding the tumours microenvironment are summarized in Figure 1.10.  
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Figure 1.10: Diagrams showing how the normal epithelium can be used to 
demonstrate the influence lipid presence in the microenvironment of tumour may 
have upon cancer progression (stages 1-5). During transformation (1), fatty acids 
and triacylglycerides are released due to SREBP and mevalonate activation.  
Lipases overexpression exaggerates fatty acid release, which in turn aids migration 
(2) via the production of protumourigenic signalling molecule(s).    Migration (3) is 
propagated by increased fatty acid synthetase expression with Wnt pathway 
involvement.  Presence of certain fatty acids aid angiogenesis (4). Adipocytes 
release cytokines, which aid homing (5). Lipolysis in adipocytes produce a desirable, 
high energy-dense product, lipids.  In ovarian cancerous cell, these lipids are 
observed to be chaperoned to them (5) (Adapted from Baenke et al., 2013).  See 
text for detailed studies.   
 
In tumour microenvironments, disease progression has been shown to be influenced 
by lipid presence. This is important to consider when considering previous findings 
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of altered lipid profiles in brain tumours (Eberlin et al., 2013; Hill, 2011).  Using 
epithelial cancer development as a platform, the presence of lipids upon the stages 
of disease progression including the following: 1) transformation, 2) cell migration, 
3) invasion, 4) angiogenesis, 5) homing and 6) metabolic coupling are summarized 
in Figure 1.10.     
 
The breakdown of normal epithelial tissue during cellular migration and invasion are 
highlighted as part of Hanahan and Weinberg (2011) classification of cancer (Figure 
1.09, Stage 1 and 2). Cellular transformation is promoted by the dysregulation of the 
mevalonate pathway, which is responsible for cholesterol and isoprenoids 
production as shown in mice by Clendening et al. (2010) (Figure 1.10, Stage 1).  The 
growth of epithelial cells was observed to be induced by the rate-limiting enzyme, 
hydroxymethylglutaryl-CoA receptor (HMGCR), during the stage of transformation 
(Figure 1.10, Stage 1).  Therefore, disruptions to the architectural tissue occurred 
leading to the activation of both SREBP and the mevalonate pathway.  This leads to 
the release of both fatty acids and triacylglycerides into the microenvironment of the 
tumour.    
 
The release of fatty acids has been associated with the promotion of migration 
(Figure 1.10, Stage 2). Studies by Nomura et al. (2010) highlighted overexpression 
of the monoglyceride-lipase in several human cancer cells and primary tumours 
including ovarian, melanoma and breast. With this overexpression, 
monoacylglycerols are hydrolyzed releasing free fatty acids into the tumour’s 
microenvironment. This release of free fatty acids into the tumour microenvironment 
results in the release of additional protumourigenic signalling molecules including; 
diacylglycerols, lysophosphatidic acids (LPAs) and prostaglandins (Baenke et al., 
2013). As such, initiation of cancerous cell migration occurs (Figure 1.10, Stage 2).   
Stromal cells aid neoplasm progression by a specialised group within the fibroblasts 
known as the cancer associated fibroblasts (CAFs) which aid such cellular 
invasiveness (Kuzet and Gaggioli, 2016).  Studies by Santolla et al. (2012) revealed 
53 
 
the lipid exchange with tumour stroma.  The increased expression of fatty acid 
synthetase (FASN) subsequently led to the migration and invasion (Figure 1.10, 
Stage 3).  Similarly, studies by Wang et al. (2016) found that FASN regulates 
colorectal cancer invasion and migration via the Wnt pathway which is involved in 
the cellular polarity (Komiya, 2006). Furthermore, FASN expression has been 
correlated with the malignancy of prostate cancer in a recent study by Hamada et al. 
(2014) (Figure 1.10, Stage 3). Therefore, demonstrating the paramount importance 
fatty acids in the lipid microenvironment in regards to cancer progression. 
 
Angiogenesis (Figure 1.10, Stage 4) is an essential process in maintaining the 
tumours’ supply of nutrients and oxygen.  Moreover, it too has been shown be can 
affected by lipid presence.  Work by Seguin et al. (2012) on B16-F10 melanomas 
demonstrated that synthesis of fatty acids led to tumour-induced angiogenesis via 
the utilisation of orlistat, a FASN inhibitor.  Because of angiogenesis, the tumour then 
has an optimal environment with a resource of oxygen and nutrients whilst at the 
same time; such waste products i.e. lactate can be retrieved. 
 
Furthermore, adipocytes within the tumours microenvironment can encourage 
homing of cancerous cells to the bone (Figure 1.10, Stage 5) via the release of 
cytokines (Baenke et al., 2013).  Studies have linked disease progression and 
altered lipid metabolism with this cytokine release.  Research by Nieman et al. (2011) 
found co-culturing adipocyte-ovarian cancerous cells led to the transfer of lipids from 
the adipocytes to the ovarian cells, which in turn supported their growth.  
Observations of adipocytes lipolysis to transfer such lipids were observed.  In this 
case, adipocytes can be viewed as a lipid source providing energy for the ovarian 
cells (Figure 1.10, Stage 6).     
 
With the increasing knowledge that lipid presence within the tumours’ 
microenvironment effects disease progression and initiation, coupled with Warburg’s 
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observations of metabolic re-programming in cancer, research surrounding cancers 
lipid biochemistry is ever increasing.    
 
1.5 BRAIN LIPID ALTERATIONS 
 
After adipose tissue, the brain is the most enriched lipid organ of which 50% dry 
weight is accountable (Mitchell and Hatch, 2011).  Taking this into consideration for 
this study, the phospholipid profile as described by Hill (2011) may provide great 
clinical insight into a range of disorders including neurodegenerative diseases.  
Further to this, mammalian cells have been estimated to contain >9600 phospholipid 
species (Yetukuri et al., 2008).  These phospholipid species not only serve in a role 
securing the integrity of biological membranes, but also they act in several biological 
systems including as precursors for second messengers. 
 
1.5.1 Altered lipid brain tumour profiles   
Because of multidisciplinary approaches, characterization of modern analytical 
applications has been developed.  Desorption electrospray ionization mass 
spectrometry (DESI-MS) is one of these technologies which have shown promising 
results. Using this application, glioma and meningioma tumours have been classified 
from non-cancerous tissue based on type and grade.  Interestingly, the component 
which aided the differentiation of such tissues was in fact a lipid specifically 
phospholipids (Eberlin et al., 2013).   
  
Similar research on lipid profiles have been carried out at the University of Central 
Lancashire on meningioma.  A study by Hill (2011) examined the phospholipid 
relative distributions including their particular molecular species.  In comparison to 
other areas of the brain, meningioma grade II tissues were shown to have an altered 
phospholipid profile.  An overview is illustrated in Figure 1.11. 
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Figure 1.11: Bar chart showing meningioma grade II tissue phospholipid profile of, 
PE, phosphatidylserine (PS), phosphatidylinositol (PI) and PC in comparison to other 
areas of the brain.  Meningioma grade II tissue displayed an altered phospholipid 
profile compared to other areas of the brain; increased proportions of PS and PC 
with a paralleled reduction in PE and PI (Adapted from Murphy et al., 2000 and Yao 
et al., 2000). 
 
In contrast to other areas of the brain, meningioma grade II tissue had an overriding 
presence of PC (49%) when compared to other areas of the brain which was 
reported to be led by PE (>50%).  Hill (2011) observed the relative proportions of PS 
to be triple that, when compared to other areas of the brain.  Enrichment of 
docosahexaenoic acid (DHA) within PS was also observed to be elevated via Liquid 
Chromatography Mass Spectrometry (LCMS) analysis.  Hence, research displayed 
two biological molecules of interest within the meningioma grade II tissue namely, 
DHA and serine (Hill, 2011).    
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1.5.1.1 Phospholipids  
Basic architecture of eukaryotic membranes are lipid bilayers of which, the main 
components are phospholipids, cholesterol and glycolipids.  The amphiphilic nature 
of phospholipids helps the formation of such bilayers in aqueous environments.  
Within eukaryotes, lipids are either in a bilayer form such as the plasma membrane 
or in a monolayer fashion like that observed in cellular LDs. Alterations in membrane 
phospholipid composition can hinder its ability to function, as the fluidity and plasticity 
of the membrane are dependent on the nature of the phospholipids present within 
the membrane. In relation to their role in the membrane, phospholipids serve as 
structural components protecting and isolating the cell from the external 
environment, in addition to isolating the intracellular organelles from the cytoplasmic 
domains of the cell (Zweytick et al., 2000; Vance and Vance, 2008; Musille et al., 
2013).  In this section, several areas are covered in relation to phospholipids 
including their structure, type, function and their relation to this study.  Detailed 
reviews will be noted in each sub-subsection.  
 
1.5.1.2 Structure 
Architecturally, lipids contain a phosphorus, polar a non-polar portion. As 
demonstrated in Figure 1.12, a phospholipid molecule comprises of two hydrophilic 
tails linked via an alcohol group  with a hydrophobic head group (Musille et al., 2013).    
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Figure 1.12:  A simplified overview of phospholipid structure. 
 
The alcohol, which the phospholipid has as a backbone, whether a glycerol or 
sphingosine, further categorizes these phospholipids as glycerophospholipids and 
sphingomyelins, respectively.  Within eukaryotes, those phospholipids with a 
glycerol backbone make up most the phospholipid cellular makeup.   An umbrella of 
phospholipids exist due to head group variation.  The proportions of phospholipid 
variety is of interest to this study, as previous research by Hill (2011), Eberlin et al. 
(2013) have shown phospholipids to be altered within cancerous tissue. To 
investigate the impact of possible alterations in phospholipids in this study upon the 
behavior of meningioma, it is necessary to first consider the membrane lipid 
metabolism in eukaryotic cells. 
 
1.5.1.3 Phospholipid membrane biosynthesis  
In eukaryotic cells, membrane phospholipid synthesis is carried out in a few of the 
cellular organelles including that of the endoplasmic reticulum and the golgi 
apparatus. Full details of phospholipid metabolism can be found in detailed reviews 
by Lagace and Ridgway (2013); Hagen et al., (2010) and Hapala et al., (2011). An 
overview of phospholipid metabolism is illustrated in Figure 1.13.    
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Figure 1.13:  Diagram to show how the originating organelle determines the phospholipid synthesized. The close proximity of the 
membranes of those organelles involved in the lipid transport and biosynthetic pathways within the cell; endoplasmic reticulum 
(ET, colored grey), golgi apparatus (GR), MT, peroxisome (PEX) and the LD aid this process.  In the ER, the CDP-choline pathway 
aids PC synthesis, whilst CDP-DAG helps PI production.  PS is moved across the ER to the PEX.  In the LD interface, PC is 
produced and stored as a main component of the LD phospholipid monolayer via CDP-choline synthesis.  Whereas at the interface 
of the ER and the plasma membrane, PI is produced with choline being transferred into the ER.  The PC, PS and PE 
interconversions are demonstrated at the MT and ER membrane interface.  In contract to the golgi apparatus, in which cholesterol, 
PC and PI enter from the ER (Adapted fro Lagace and Ridgway, 2013 and Fagone and Jackowski, 2009).    
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As shown in Figure 1.13, the phospholipid type produced is dependent upon the 
originating organelle where it is synthesized. For example, specialized phospholipids 
such as plasmalogens are only synthesized in the PEXs whereas phosphoglycerate 
and cardiolipin are synthesized in the mitochondria of the cell.  The proximity of 
organelles within the cell involved in phospholipid biosynthesis aid the variety and 
mobilization of phospholipids within the cell. Some of these organelles, specifically 
the endoplasmic reticulum have been associated with cancer. 
 
1.5.1.4 Link between cancer and endoplasmic reticulum? 
Studies have suggested a link between endoplasmic reticulum stress and cancer via 
the unfolded protein response involving phosphatidylcholine (Lagace and Ridgway, 
2013) (see Table 1.4).  The unfolded protein response is initiated when the glucose-
regulated proteins (GRP) become activated with the presence of cellular stress. 
Such cellular stresses include changes in Ca2+, nutrient levels and protein synthesis. 
The unfolded protein response aims to restore normal cellular function in several 
ways including inhibition of protein translation, degradation of misfolded protein and 
increasing protein folding.  However, if this is not achieved, apoptosis is initiated.  
 
Interestingly, increased GRP-78 expression has been observed in glioblastoma in 
accordance with poor rates of patient survival (Lee et al., 2008). The presence of 
endoplasmic reticulum stress within cells has been shown to result in an altered lipid 
metabolism.  For example, SREBP is observed to be activated leading to cholesterol 
and triacylglyceride synthesis (Werstuck et al., 2001). Hence, the unfolded protein 
response which is initiated due to endoplasmic reticulum stress has become a 
therapeutic target especially due to its role in phospholipid biosynthesis (Wang et 
al., 2014).  
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1.5.1.5 Phospholipid remodeling  
Due to the pivotal role phospholipids play in cellular function, a re-modelling system 
exists enabling a plethora of phospholipid molecular species to be motion 
(Yamashita et al., 2014). Phospholipid function (Table 1.3) is not only determined by 
head group, but also by the fatty acid chains which are esterified to the positions sn-
1 and sn-2.  These fatty acids are usually 16-24 carbons in length, both in saturated 
and unsaturated variants (Isaac et al., 2006).    In mammalian systems to date, there 
have been over 100 phospholipid species identified; dependent on cell type and 
tissue (Yamashita and Nikawa, 1997).   
 
The phospholipid remodelling system enables molecular species of variation in each 
phospholipid category. In brief, the phospholipid de novo remodelling pathways of 
the glycerophospholipids variant share a common intermediate with triacylglyceride 
synthesis; namely, glycerol-3-phosphate precursor (G-3-P) and phosphatidic acid 
(PA). Therefore, due to the common PA precursor, the molecular species of newly 
synthesized phospholipids will be a reflection this.  A summary of the key 
physiological roles of major phospholipids is shown in Table 1.3.      
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Table 1.3:  Overview of phospholipid characteristics including net charge and 
summarized functions. 
 
Phospholipid 
Net 
charge 
(pH 7) 
 
Functions 
 
PC 0 
Neurons of the cholinergic nature use choline in the 
PC component as a precursor in their 
neurotransmitter acetylcholine synthesis (Blusztajn et 
al., 1987).  Involved in the unfolded protein response 
in the endoplasmic reticulum; essential for secretion 
and expansions of the membrane (Lagace and 
Ridgway, 2013). 
PE 0 
Aids membrane fusion but negatively impacts the 
curvature of the membrane  (Haque et al., 2001) 
PG -1 
With the aid of Cardiolipin synthase 1, PG and CDP-
DAG are condensated, producing Cardiolipin (Morita 
and Terada, 2015). 
PI -1 
Precursor of the second messengers involved in the 
transmission of neural messages (Lodish H, 2000). 
PS -1 
Neuronal survival and differentiation promoted with 
PS interaction which is located in the cytoplasmic 
leaflet of the plasma membrane (Kim et al., 2014).  PS 
extracellular exposure involved in apoptosis cascade 
(Hampton et al., 1996). 
SM -2 
Coupled with cholesterol, aids the lipid raft structural 
stability, which are responsible for signal transduction, 
protein transport and sorting membrane components 
(Kolter and Sandhoff, 2006; Gulati et al., 2010; Goñi 
and Alonso, 2006). 
CL 0 
Makes up one fifth of the mitochondrial inner leaflet 
phospholipids.  Cardiolipin plays a role in maintaining 
optimal conditions such that he enzymes involved in 
energy metabolism can function (Morita and Terada, 
2015). 
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From Table 1.3, the major phospholipids are shown to play differing roles within the 
mammalian system. For example, PC aids the cell to expand its membrane (Lagace 
and Ridgway, 2013), whereas PE is involved with the ability of membranes to fuse 
(Haque et al., 2001). Both of these would be beneficial to proliferating cells such as 
cancerous cells. When considering these factors with previous observations that 
show an altered energy metabolism and lipid profiles within cancerous tissue, the 
role of phospholipids and their possible connection to a cancerous phenotype is the 
subject of this study. 
 
1.5.1.6 PC, PE and PS interconversion 
The noted enrichment (13-15%) of the major acidic phospholipid PS in the human 
cerebral cortex, is pertinent to this study. An overview of the inter-conversion is 
depicted in Figure 1.14.    
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.Figure 1.14:  Flow diagram shows enrichment of PS, PC and PE in the brain in particular reference to mitochondria and 
microsome regions which have high levels of PS, PC and PE.  These regions are especially important in disease states, as they 
are involved in energy metabolism.  Their inter-class interconversions, as depicted above, are catalyzed via the enzymes PSS1 
and PSS2.  The fatty acid chain saturation type is determined by the locality of the molecular species, usually the sn-2 fatty acid 
is esterified by an unsaturated fatty acid (contains double bonds) whereas the sn-1 contains a saturated fatty acid.  Legend:  P 
– phosphate head group and PSS - phosphatidylserine synthases 1 and 2, respectively. 
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In the brain, PS synthesis is a Ca2+-dependent head-group exchange process 
located in the endoplasmic reticulum. During this inter-conversion reaction, the head 
group of the substrate phospholipid namely, PS or PE is replaced with serine.  This 
process of head group exchange is catalyzed by PSS I and II, respectively (Figure 
1.14). Enrichment of these enzymes that enable such phospholipid interconversion 
are heightened on the membranes associated with the mitochondria and 
endoplasmic reticulum. This phospholipid inter-conversion allows the conservation 
of molecular species within each phospholipid class (Musille et al., 2013).   
 
It has also been hypothesized that the PSS1 enzyme shown in figure 1.14 may be 
responsible for the enrichment of polyunsaturated PS within the CNS.  However, to 
supply such unsaturated fatty acids in this exchange, a polyunsaturated PC 
synthesized from a three-step methylation PE process is needed to produce a 
polyunsaturated PS. This three-step process, producing polyunsaturated PC, is 
known as the PE N-methyl transferase reaction. Studies have suggested that 
neuronal levels of this reaction are however low, therefore the only other tissue 
capable of producing such output is that of the liver. Therefore, demonstrating that 
to meet the supply-demand of PS biosynthesis in the brain, the best substrates are 
in fact PE and PC.       
 
1.5.1.6 Choline 
Studies by Usenius et al. (1994) on brain tumours’ displayed a cholinergic phenotype 
different to that observed in non-cancerous tissue. The cholinergic specific 
phenotype can be detected using non-invasive procedures such as magnetic 
resonance spectroscopy (MRS) and positron emission tomography (PET) which can 
examine levels of choline containing compounds.  Compared to the non-cancerous 
tissue, brain tumours were shown to display an increased abundance of PC and total 
choline-containing compounds by 50% and 85%, respectively.  The intricacy of the 
cholinergic profile was brought back to the forefront with the work of Glunde et al. 
(2011) whereby several key enzymes involved in choline production were shown to 
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be overexpressed.  These studies alongside those previously discussed 
demonstrate the clinical relevance lipid metabolism can play in cancerous tissue.  
Therefore, to understand the implications of such altered lipid metabolism, the 
regulations and profiles of the brain need to be discussed. 
 
1.6 BRAIN ENRICHMENT OF PS CONTAINING 22:6  
 
Throughout life, the human brain maintains PS levels within a range of 13-14%.  
Within the gray matter, the abundance of the ‘neuroprotective’ agent DHA (also 
referred to as 22:6), is raised in both PS and PE phospholipids by 29.9% and 27.4%, 
respectively.  The abundance of DHA within PS and PE are ten-fold higher when 
compared with the levels of PC within the gray matter which have DHA enrichment 
(Calder, 2016).  A possible theory for this specific DHA enrichment to PS and PC 
includes either 1) the aided interconversion of a 22:6 molecular species containing 
PE resulting in DHA enriched PS or 2) the mitochondrial PS decarboxylase reaction 
converts the PE containing 22:6 phospholipids into 22:6 containing PS.     
 
The importance of lipid composition is further highlighted with the characteristics of 
the blood-brain barrier (BBB). The unaided as opposed to the aided movement 
substances raise important questions into their role of the lipids in the brain which 
have aided movement. Both serine and DHA have essential roles in brain 
development, yet one has facilitated transport across the BBB but the other has not. 
Similarly, the abundance of PS DHA enrichment within brain fractions are shown to 
increase with age, specifically in the microsomal and mitochondrial locations by a 
third (Norris et al., 2015). 
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1.7 THE POLYUNSATURED FATTY ACID, DHA. 
 
DHA is an important omega-3 polyunsaturated fatty acid.  Due to the chain length of 
DHA, 22 carbons consisting of 6 double bonds (see Figure 1.15), this makes it the 
longest polyunsaturated fatty acid in biological systems.   
 
 
 
Figure 1.15:  Chemical structure of DHA, also referred to as 22:6 due to the number 
of carbons (22) and there being six double bonds in its structure which also gives its 
nomenclature of a polyunsaturated fatty acid with their locality in relation to the 
methyl end (ω:n-6). Image drawn by hand.  
 
The concentration of DHA is thought to enable brain development, cellular survival 
and neuroinflammation regulation (Domenichiello et al., 2015; Wang et al., 2016).  
Research by Sidhu et al. (2016) displayed that DHA is involved in ageing. This 
research was built on their previous findings, which showed that the polyunsaturated 
fatty acid was involved in synaptogenesis and neurite outgrowth.      
 
1.7.1 Enrichment of DHA within membranes   
DHA is embedded in eukaryotic cell membranes on the sn-2 position of PS and PE 
(Isaac et al., 2006). However, a ‘perfect fit’ for those membranes enriched with DHA 
is prevented due to the steric restrictions associated with the structural double-bonds 
present. This presence within the membranes of a polyunsaturated fatty acid can 
affect the properties underpinning the structural integrity of the membrane, including: 
acyl-chain order (fluidity), stage behavior, fusion, flip-flop, elastic compressibility and 
permeability. As previously discussed, human DHA enrichment is high due to its 
neuroprotective role, for example in the brain DHA is accountable for half of the 
neurons’ plasma membrane weight. To maintain essential neurocognitive function, 
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the brain requires 2.4-3.8mg/day of DHA.  DHA is not only enriched in the brain, but 
also the retina from which over 60% of polyunsaturated fatty acids found are that of 
DHA (Kim, 2008).  With such high demand of DHA in the body, dietary sources are 
exploited i.e. fish and krill oil as de novo DHA synthesis in mammals does not occur 
(Domenichiello et al., 2015).  Having said that, DHA can be synthesized from its 
precursor, α-linolenic acid, within the body.        
 
1.7.1.1 Liver: α-linolenic acid precursor of DHA synthesis  
In terms of meeting the supply-demand of DHA within the body, the conversion of α-
linolenic acid to DHA only accounts for <1% of the required DHA needed to maintain 
functional cognition (Domenichiello et al., 2015).  Hence, debates as to whether this 
conversion is solely adequate for cognitive function has been fought. An overview of 
the conversion between α-linolenic acid and DHA found in the liver is illustrated in 
Figure 1.16. 
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Figure 1.16: Diagrams showing the essential omega-3 polyunsaturated fatty acid, 
DHA, is essential for a range of cognitive functions.  Much of the DHA is accountable 
from dietary sources within the body. However, in the liver via sequential steps of: 
desaturation and elongation in the ET followed by; β-oxidation in the PEX, DHA can 
be synthesized by α-linolenic acid (18:3).  Enzymes, which are used in the process, 
include elongases and desaturases (see depiction for details).    After production, 
DHA is packaged into a very low-density lipoprotein in the ET to be circulated 
systemically, an example of a possible destination may be the brain if the DHA is to 
be released and bound to albumin (Adapted from, Domenichiello et al., 2015). 
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Synthesis of polyunsaturated fatty acids, like DHA, occurs in the liver from α-linolenic 
acid.  As show in Figure 1.16, the enzymes which aid the conversion from α-linolenic 
acid to DHA include the elongases and desaturases.  In comparison to other organs 
such as the heart and brain, the expressions of such elongases and desaturases 
enzymes within the liver are much greater suggesting an organ specific role.  Initially, 
in the endoplasmic reticulum the rate-limiting process of α-linolenic acid desaturation 
occurs aided by Δ6-desaturase forming 18:4n-3.  DHA is produced via elongation 
and desaturation steps shown in Figure 1.16 followed by the movement of 24:6n-3 
into the peroxisome from the endoplasmic reticulum, where it is then β-oxidized. 
DHA is then transported back into the endoplasmic reticulum where it goes on to be 
esterified and packaged into lipoproteins.  These packaged DHA-lipoproteins are 
then secreted into the blood.   
 
In the circulatory system, DHA can be present in either it un-esterified form bound to 
albumin, or esterified variant as a phospholipid, cholesteryl esters or 
triacylglycerides.  To enter the brain, DHA must cross the BBB, the rate of which is 
determined by the amount previously consumed by the brain therefore requiring 
replacement.  
 
1.8 BLOOD-BRAIN BARRIER (BBB) 
 
To enable optimum conditions for neuronal function as per discussed by Campos-
Bedolla et al. (2014), the BBB regulates the selective transport of molecules into the 
CNS.  A dysfunctional blood-brain barrier is often observed in neurological diseases 
such as Alzheimer’s disease. In such diseases, observations of substance transport 
deregulation occur due to the BBB breakdown.  Consequently, the optimum 
conditions previously regulated by the BBB, which enable cognitive and neuronal 
function, are hindered.   
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In 2014, an orphaned transporter was observed to play an important physiological 
role in the normal formation and upkeep of the BBB. This was found to be solely 
expressed on the endothelium of the blood-brain barrier (Ben-Zvi et al., 2014).  In 
the same year, DHA was observed to have facilitated movement across the blood-
brain barrier via this same transporter, which is now referred to as Msfd2a (Nguyen 
et al., 2014).       
 
1.8.1 DHA, facilitated movement across blood-brain barrier  
Due to the essential neuronal function DHA plays, it can either be obtained via 
dietary sources or synthesized from α-linolenic acid in the body. However, DHA 
enriched in the brain is mainly sourced from the diet.  DHA movement across the 
BBB is enabled by the Mfsd2a transporter (Campos-Bedolla et al., 2014).  However, 
fatty acids with a 14-carbon or shorter side chain cannot be transported across the 
BBB by this Mfsd2a transporter (Nguyen et al., 2014). Studies by Nguyen (2014) 
demonstrated that the loss of this Msf2da transporter reduced the proportion of 
lysophophatidylcholine-DHA found in mice brains by 90%.    
 
Recent studies have shown conflicting evidence as to whether DHA is solely 
delivered to the BBB or whether it is coupled with lysophophatidylcholine. However, 
the main consensus is that the affinity of DHA to the Mfsd2a transporter is greater 
when it is packaged with lysophosphatidylcholine in the lysophophatidylcholine-DHA 
complex (Subbaiah et al., 2016).  The proposed DHA mechanism of crossing the 
BBB is illustrated in Figure 1.17. 
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Figure 1.17:  Diagram showing the facilitated transport of DHA across the BBB. The 
lysophotidylcholine, which is bound to albumin, releases the 
lysophosphatidylcholine-DHA complex once it reaches the BBB.  The 
lysophosphatidylcholine-DHA complex then crosses the BBB by the Mfsd2a 
transporter to the astrocytes (Taken from Subbaiah et al., 2016). 
 
To enable the facilitated movement of DHA to the BBB, as shown in Figure 1.17, 
albumin only releases the carrier of DHA upon reaching its destination. The carrier, 
lysophophatidylcholine, is coupled with DHA forming a lysophophatidylcholine-DHA 
albumin complex.  This lysophophatidylcholine-DHA complex detaches from 
albumin and is absorbed in the outer lipid leaflet of the endothelial cell membrane 
(depicted in Figure 1.17) upon arriving at the BBB.  The Mfsd2a transporter then 
binds to the LPC-DHA complex, transferring the complex to the inner lipid leaflet.   
72 
 
 
It is interesting to note that, targets of DHA in the brain are still under investigation.  
However, DHA usually resides in PS as 1-steroyl-2-docosahexaenoyl-PS (18:0, 
22:6-PS) (Kim and Edsall, 1999). Studies have shown that neuronal cells with 
phospholipid DHA incorporation have inhibited release of such polyunsaturated fatty 
acids which is in contrast to astroglia (Garcia and Kim, 1997).  This provides insight 
into the neuronal development which requires DHA maintained enrichment to 
prevent enzymatic oxygenation (Sawazaki et al., 1994). This therefore, illustrates 
that in fact the transport protein, Mfsd2a, plays a dual role in not only the integrity of 
the BBB but also the facilitated transport of the neuroprotective polyunsaturated fatty 
acid, DHA to the brain.  Interestingly, deletion of the Mfsd2a transporter has been 
shown to result in the breakdown of the blood-brain, which in turn demonstrated it 
pivotal role in maintaining cognitive function thus, survival (Chow and Gu, 2015).       
 
1.9 DHA’S RELATIONSHIP WITH CANCER  
 
In clinical trials, omega-3 polyunsaturated fatty acids such as DHA have shown 
protective effects upon prostate and colon cancers (Lee et al., 2014). The ratio of 
omega-3/omega-6 presence upon tumour development has long been the object of 
cancer biology investigations. Tumour growth has also been observed to be 
heightened with altered omega presence.  Similarly, the presence of omega-6 fatty 
acids compared to omega-3 fatty acids are increased in cancerous tissue.  This 
therefore implies that there is a paralleled relationship between, the tumour omega 
fatty acid profile and tumour growth rate.   
 
Investigations to examine the effect of unbalanced dietary omega-6 and -3 fatty acids 
across a variety of cultures upon disease have been studied.  In Western culture, 
the ratio of dietary omega fatty acids which is omega-6 in nature, is higher with 10-
20:1 compared to other cultures with 1-2:1. This finding that western culture has an 
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altered omega-3: omega-6 fatty acid profile provides scope for future research, as 
this alteration was positivity correlated with disease prevalence.  In comparison to 
the Western culture, the Japanese population have a traditional diet which is 
naturally sourced in omega-3 fatty acids (such as DHA). This heightened omega-3 
diet has been shown to decrease cancer development risk specifically in colon, 
prostate, kidneys and the breast.   
 
The effect of dietary omega fatty acids upon the incidence rate of cancer has been 
recently displayed in Japan. Traditionally, the food culture in Japan has been 
towards the omega-3 fatty acids as opposed to omega-6 fatty acids. However, with 
recent adoption of an omega-3 fatty acid Western diet, the incidence of cancer has 
steadily increased.  Whether this increased incidence rate if because of raising 
population obesity is under speculation.  In one study by Park et al. (2010) mice 
obesity, both genetically and dietary induced, were shown to be positively correlated 
with hepatocellular carcinoma development. Therefore, it may be speculated that 
reduced DHA intake, positively effects the development of cancer due to its 
involvement in inflammation, apoptosis and oxidative stress, especially when it is 
esterified to lipids such as PS.   
 
1.10 L-SERINE, THE PRECURSOR OF PS 
 
L-serine is an essential amino acid which is involved in several key processes some 
of which involve the production of L-serine-derived lipids, including that of PS 
(Tabatabaie et al., 2010; Damseh et al., 2015). L-serine has a functional capacity of 
the CNS by aiding stages of development and cognitive function (Damseh et al., 
2015; Tabatabaie et al., 2010).  Dysfunctional uptake or biosynthesis of L-serine has 
been observed in several developmental diseases.  Research carried out by 
Damseh et al. (2015) presented three recessive mutations encoding the alanine, 
serine and cysteine transporter (ASCT1) which were paralleled with cognitive 
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impairment and hypo-myelination. Similar results have been described by de Koning 
et al. (2000) on the inborn error of serine metabolism.   
 
The machinery required for serine biosynthesis in the CNS is localized only within 
the astrocytes and radial glia (Yamasaki et al., 2001).  This is an important point to 
consider, as in contrast to DHA, which has facilitated movement across the BBB, L-
serine has poor permeability across the BBB (Damseh et al., 2015). Instead, the 
CNS availability of L-serine is provided by the ability of astrocytes to shuttle pre-
formed L-serine by transporters (Kim et al., 2014).  A summary of the shuttling of L-
serine from the astrocytes is shown in Figure 1.18.  
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Figure 1.18:  Flow diagram showing that neurones do not possess the rate-limiting 
enzyme for L-serine synthesis, phosphoglycerate dehydrogenase (PHGDH).  The L-
serine shuttle from the astrocyte to the neurons aids L-serine derived lipids to be 
synthesized.  The glucose is taken up from the cerebra via the glucose transporter-
1 (GLUT1) astrocyte transporter; glycolytic diversion aids L-serine production.  Once 
produced, the Na+ dependent ASCT1 releases L-serine for the Alanine-serine-
cysteine-1 (Asc1) neuron transporter to take up (Na+ dependent).  (Adapted from 
Hirabayashi and Furuya, 2008).   
 
 
76 
 
As depicted in Figure 1.18, the diversion of 3-phosphoglycerate (3-PHG) from the 
glycolytic pathway, enables the conversion of serine via a same three-step-process.  
Once synthesized, serine is released into the extracellular fluid by the specialized 
astrocyte Na+-dependent ASCT1 transporter.  Importantly, ASCT1 are proportionate 
to that of PHGDH suggesting that, astrocytes release L-serine to replenish 
neighboring neurones. The serine depleted neurones become replenished when 
they uptake serine either from the extracellular fluid or the cerebral circulation.  This 
uptake of serine is facilitated by the neurone-specific transporter, Na+-dependent 
ASC1 (Hirabayashi and Furuya, 2008).  Interestingly, exogenous L-serine presence 
stimulates PS and PE enrichment in neuronal membranes suggesting a mechanism 
of membrane regulation with serine presence. 
 
1.10.1 Serine’s relationship with cancer  
The key enzyme involved in serine biosynthesis is PHGDH.  The gene for PHGDH 
is localized on chromosome 1p.  It has received a lot of attention surrounding its 
relationship between serine and cancer progression (Sun et al., 2015; Amelio et al., 
2014a).  This enzyme aids the glycolytic diversion in the cell, such that the demand 
for L-serine is met.  Therefore, it can be said that as glycolysis diversion itself aids 
L-serine synthesis, glucose itself can be deemed a precursor of L-serine lipids 
(Hirabayashi and Furuya, 2008).   
 
In brain tumours, such as meningioma, increased expressions of glucose 
transporters such as glucose transporter-3 (GLUT 3) are observed. Such increased 
GLUT3 expression in tumours aids the flux through glycolysis and subsequently the 
production of L-serine via PHGDH. The presence of L-serine itself has been 
implicated in the orchestration of metabolic re-programming in a range of 
mammalian tumours (Sun et al., 2015).  
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The glycolytic diversion observed in cancerous cells can also lead to glycine 
biosynthesis (Hirabayashi and Furuya, 2008; Sun et al., 2015). Studies by  
Labuschagne et al. (2014) was built on the work of Arends et al., (1995) which 
displayed how serine and glycine could irreversibly interconvert via L-serine 
hydroxymethyl transferase. The work by Labuschagne et al. (2014) of cancerous 
cells undertaking one carbon metabolism suggested that in fact serine was the key 
player over glycine.  The cancerous cells preference of serine over glycine was 
shown in them selectively consuming serine. Therefore, supporting the suggestion 
that in fact, some cancerous cells are supported by serine presence solely in one 
carbon metabolism. 
1.11 THE RELATIONSHIP BETWEEN DHA AND PS  
 
In several mammalian systems, a unique relationship between DHA and PS has 
been shown.  Dietary DHA supplementation has been known to modulate cellular 
PS concentrations; of relevance to this study, glial cells have already displayed this 
phenomenon (Kim and Choi, 2010; Garcia and Kim, 1997).  It is therefore plausible 
to suggest, that the specific phospholipid profile observed by Hill (2011) may be 
because of DHA’s relationship with PS. An overview of the effect of key PS-
dependent pathways upon neuronal survival and differentiation are illustrated with 
coupled DHA presence in Figure 1.19 (Kim et al., 2010; Kim, 2008; Steelman et al., 
2011). 
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Figure 1.19: Diagram showing DHA induced synthesis and plasma membrane 
localization of PS. DHA enriched PS localized on the cytoplasmic side of the plasma 
membrane gather forming anionic micro-domains, crucial for signal transduction 
proteins, leading to neuroprotection (Image adapted from Kim et al., 2010; Kim, 
2008). 
 
Studies have demonstrated PS to be pivotal in key CNS signalling pathways.   
Furthermore, DHA enriched PS has also been shown to be highly localized in the 
inner leaflet of the plasma membrane.  Unlike other signalling molecules producing 
active products for the end effect, as an inner anion domain member of the plasma 
membrane, PS acts as binding/activation site for cytosolic proteins involved in 
neuronal signalling.  The fundamental molecular characteristics of PS aid this protein 
interaction, because of which neuronal signalling is activated via electrostatic 
interactions or Ca2+ bridges. Hence, the previous research on meningioma tissue 
comprising of an altered phospholipid profile of heightened PS with DHA enrichment 
will be of interest in terms of the effect upon cellular events shown in Figure 1.19 in 
this study. 
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1.12 YEAST AS A MODEL ORGANISM 
 
For a cell to be classified as cancerous, alterations have to occur in cellular 
processes including induction of senescence and apoptosis prevention as 
defined by Hanahan and Weinberg (2011). Interestingly, similarity between 
phospholipid membrane profiles amongst three differing domains of life e.g. 
archaea, bacteria and eukaryotic cells has suggested an evolutionary 
conservation as discussed by Lombard et al. (2012).  Additionally, lipidomic 
studies within fungi (yeast) have shown similar lipid accumulation characteristics 
when compared to cancerous eukaryotic cells.  Detailed reviews can be found by 
Natter and Kohlwein (2013) and Diaz-Ruiz et al. (2009).  Therefore, a paradigmic 
organism including that of yeast can be utilised in this study to determine the 
effect of DHA and/or serine upon cellular processes.   
 
A yeast paradigm has several ‘good model features’ including its unicellular 
nature, which not only permits higher cultivation turn-over in comparison to a 
mammalian model, but it also provides cost effective experimental outlines.  One 
limitation to consider however, is the unicellular nature of the yeast species as 
opposed to the multi-cellular nature of mammalian systems.  Nevertheless, in 
regards to this study, this can be viewed as an advantage, as the mammalian 
system complexities are stripped away.  With such ability to strip away these 
system complexities in the yeast paradigm, the effect upon cellular processes 
can be examined in further detail.   
 
In many human diseases, ectopic lipid accumulation has been recognised and 
hence, the model organism must be able to accrue lipids. From the 1600 known 
yeast species, only 50-160 have been identified to accumulate lipids at the level 
to be classified as oleaginous in type; at least 20% of their dry weight (Sitepu et 
al., 2014; Calvey et al., 2016).  Typically, yeasts of oleaginous nature are found 
in the following genera including but not restricted to Rhizopus, Trichospron, 
Lipomyces and Yarrowia (Beopoulos et al., 2011).  For this study, the oleaginous 
yeast, Lipomyces starkeyi (L. starkeyi), was utilised as the paradigmic model.  
Oleaginous yeasts like L. starkeyi have a growth cycle consisting of a lag-, log-, 
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diauxic- and stationary phase.  Figure 1.20 (A and B) summarises the growth 
cycle of a typical oleaginous yeast, Rhodotorula gracilis, alongside a depiction of 
the effect media nutrient status has upon lipid accumulation.   
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A) An example of a growth phase profile exhibited by yeast (adapted from 
Herman, 2002). 
 
B)  Effect of media type upon Ramaria gracilis (R. gracilis) lipid accumulation 
during stationary phase (adapted from Rolph et al. 1989). 
  
 
 
 
 
 
 
 
Figure 1.20:  Growth curve shows the relationship between growth profile (A) 
and photographs displaying lipid accumulation (B) in yeast.  With increasing 
culture density during log-phase (2) nutritional sources were reduced as a result. 
Thus, to re-supply the energy reserves a respiratory mode were promoted (3) but 
consequently this slows the growth rate.  After these sources were exhausted 
true stationary phase (4) is reached.  During such phase, lipid accumulation is 
observed (B) in the fat vacuole (FV).   
i) Carbon-limiting media   ii) Nitrogen-limiting media  
Key: Scales have been corrected such that compared directly, was originally 
1.5cm: 500 nm and 2 cm: 500 nm respectively. 
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During log-phase (G1) demand for nutrients are high and this is to fulfil cellular 
process requirements such as proliferation (Figure 1.20, A).  However, with 
increasing cellular community, the nutritional sources within the media become 
depleted.  To replenish the nutrient source required for cellular processes, activation 
of a respiratory mode of energy production is promoted, short-term.  Because of 
nutritional depletion, transcriptional rates reduce by 3.5 fold leading to the rate of 
proliferation to reduce (Choder, 1991).  After the diauxic-shift (Figure 1.20, A. 3) 
energy sources are provided via the by-products of fermentation (ethanol).  
Therefore, only after this energy supply via fermentation is exhausted, the true 
stationary phase is reached.   
 
Entry into the ‘non-resting state’ termed stationary phase is regulated by the Ras 
and Tor signal transduction pathways which become activated with nutrient media 
reductions in nitrogen, phosphorus and carbon. During stationary phase, lipid 
accumulation of neutral lipids occurs in a fat vacuole.  Lipid accumulation during this 
growth phase is demonstrated in the freeze-fracture electron micrographs of R. 
gracilis (Figure 1.20, B).  Cultivation of R. gracilis in nitrogen-limiting media (NLM) 
(Figure 1.20, B. ii) increased de novo lipid accumulation within the mono-fat vacuole 
in comparison to the carbon-limited R. gracilis culture (Rolph et al., 1989). Within the 
fat vacuole, the main lipid class stored include the neutral lipids, triacylglyceride 
followed by a small portion of sterol esters.     
 
The main metabolic activities in oleaginous yeast are re-tailored during nitrogen 
limitation towards lipid accumulation. Under the same conditions of nutrient 
limitations, similar alterations towards lipid accumulations have been observed in 
cancer. In L. starkeyi once the stationary phase of growth is reached, such 
intracellular stores of lipids reach >65% in comparison to its dry cellular weight.  The 
key modulators involved in lipid metabolism in oleaginous yeast like L. starkeyi are 
summarised in Figure 1.21, both with and without nutrient availability.   
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Figure 1.21:  Diagram showing the metabolic pathways re-tailored in oleaginous 
yeast in response to nutrient depletion (highlighted in red) leading to lipogenesis.  
With nitrogen depletion, adenosine monophosphate deaminase (AMPD) is activated 
which in turn causes citrate to be translocated via the citrate/malate translocase from 
the mitochondria to the cystol which is utilised in the Kennedy pathway for neutral 
lipid production (Adapted from Patel et al., 2016).     
 
The ability to accumulate lipids under nitrogen limitation in oleaginous yeasts as 
opposed to non-oleaginous yeasts is accountable to the conserved mechanism of 
ammonia scavenging, as demonstrated in Figure 1.21. The activity and/or activation 
84 
 
of AMPD increases with nitrogen depletion. This in turn reduces mitochondrial AMP 
levels. Due to the functional dependence of isocitrate dehydrogenase (ICDH) on 
AMP, a number of knock-on effects occur with the reduction of mitochondrial 
adenosine monophosphate (AMP) levels including 1) the conversion of isocitrate to 
α-ketoglutarate is suppressed, and 2) an altered balance between oxygen 
consumption and carbon dioxide output is observed.  Because of the metabolic 
retailoring, the citrate/malate translocase aids the transfer of cytosolic malate for 
mitochondrial citrate.  Once in the cystol, citrate is then cleaved with acetyl-CoA and 
oxaloacetate via ATP citrate lyase (ACL), which is then converted to malonyl-CoA 
via acetyl-CoA carboxylase (ACC).  As a result, lipid accumulation via the Kennedy 
pathway can be promoted, leading to triacylglyceride production.  Interestingly, non-
oleaginous yeasts are void of ACL which gives rise to their lipid accumulation 
limitations. More recently, this ACL gene was transferred from L. starkeyi into the 
baker’s yeast Saccharomyces cerevisiae.  Because of ACL insertion into the non-
oleaginous yeast, the production of fatty acids increased; demonstrating the central 
role ACL plays within lipid production.       
 
During nitrogen limitation, oleaginous yeast increases their triacylglyceride pool 
within their lipid bodies (see Figure 1.21, B.ii).  Such production of the neutral lipid is 
brought about via the Kennedy pathway (Figure 1.21) which initiates from PA.  The 
source of PA, G-3-P or dihydroxyacetone phosphate (DHAP) is dependent on 
whether the culture was sourced with nitrogen or not (Figure 1.21).  In order to 
produce the neutral lipids, PA is firstly dephosphorylated and this requires three 
phosphatidate phosphatase (PAP) isoenzymes (Figure 1.21).  After which the acetyl-
CoA then binds to the diacylglycerol backbone via DGAT resulting in triacylglyceride 
formation.  Generally, during nitrogen-limitation oleaginous yeasts store lipid in their 
lipid vacuoles, particularly in the TAG and FFA form – as observed in tumour cells.  
Industries now utilise these aspects of oleaginous yeasts, specifically lipid 
accumulation in terms of biodiesel applications. The conserved re-tailoring of lipid 
production in oleaginous yeast like that in tumour cells makes L. starkeyi an 
attractive paradigm for the research presented in this study.   
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1.13 RESEARCH AIMS 
 
1.13.1 Working hypothesis  
Both DHA and L-serine are involved in the development and progression of brain 
cancer. 
 
1.13.2 Main aims 
This novel research was developed to identify whether meningioma displays an 
altered lipid biochemistry and whether this was related to metabolic reprogramming.  
Previous studies have shown that meningioma displays an altered lipid profile in the 
form of an increased abundance of DHA-enriched phosphatidylserine.  This study 
attempted to provide an insight into the impact of such lipid alterations upon the 
cancerous phenotype displayed in meningioma.  In order to achieve the aims, the 
study focused on three main objectives: 
1. Are the cellular processes surrounding cancer affected by DHA and/or serine 
presence? 
2. Are the altered lipid profiles displayed within grade II meningioma related to 
a serine-derived metabolic flux? 
3. Do the altered lipid profile shown in meningioma grade II tissues, support 
cancer progression via an increased cellular viability? 
 
1.13.3 Scope of study 
Firstly, in order to establish whether the presence of phosphatidylserine enriched 
with DHA promotes a cancerous phenotype, a lipid-accruing model organism was 
developed.  Second, to monitor the impact of such DHA and/or serine presence, the 
model organism, Lipomyces starkeyi, was supplemented with these biological 
agents during lag phase.   
86 
 
The initial focus or phase of this research investigated the possibility that DHA and/or 
serine supplementation influenced cellular processes including proliferation, lipid 
accumulation, cellular metabolism and de novo lipid biosynthesis.  By monitoring the 
L. starkeyi cells during their growth cycle, the impact of such DHA and/or serine 
presence upon growth phase transition could be established.  With many cancers 
being observed to have an altered lipid biochemistry, the model organism was then 
subjected to a radiolabel study examining whether DHA and/or serine presence 
alone could influence lipid biosynthesis. Once lipids were synthesised in cancerous 
cells, they were often stored in lipid droplets in the form of triacylglycerides and sterol 
esters.  In diseased cells, multiple lipid droplets were observed, aiding lipid 
mobilisation during times of membrane biosynthesis.  Hence, to ascertain whether 
the presence of the two biological agents, L-serine and DHA, were affected, the 
number and size of the lipid droplets within a cell, a preliminary assessment via light 
microscopy during the lipid-accruing stage were carried out.  
 
The second phase of the research was deciphered to examine if the increased 
abundance of phosphatidylserine, a serine-derived lipid, within meningioma tissues 
was related to metabolic reprogramming.  An immunohistochemistry study was 
carried out in grade I and grade II meningioma tissues, examining whether glycolysis 
was diverted to serine biosynthesis. The staining profile of p53, PKM2, fascin and 
PHGDH was of interest in this part of the study. 
 
Finally, in order to investigate whether the altered phospholipid profile in meningioma 
played a role in tumourigenesis, a cellular viability study using SVG and U87 cell 
lines was developed.  The focus of this preliminary study involved the preparation of 
liposomes derived from grade I and grade II meningioma tissues as well as PC: PS. 
These liposomal preparations were then supplemented into log phase SVG and U87 
cultures.  The effect of upon phospholipid alterations with non-cancerous and 
cancerous cells could then be determined using a Presto Blue cellular viability 
reagent. The results of the studies are presented in Chapter 2, 3 and 4. 
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Chapter Two 
 
Biochemistry inter-play of DHA and L-serine via 
an oleaginous paradigm, Lipomyces starkeyi. 
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2.1 Materials and Methodology 
2.1.1 MATERIALS   
Media used for yeast inoculation and culturing for experiments include: Yeast extract 
peptone dextrose (YEPD) and NLM.  YEPD composition includes; glucose (20%, 
w/v), yeast extract (10%, w/v) and peptone (10%, w/v).  Addition of agar (2%, w/v) 
to YEPD enables the maintenance of L. starkeyi, which was sub-cultured quarterly.   
NLM as per denoted by Rolph (1989) comprises of monopotassium phosphate 
(0.7%, w/v), disodium hydrogen phosphate (0.2%, w/v), magnesium sulphate 
heptahydrate (0.15%, w/v), calcium chloride dehydrate (0.01%, w/v), ferric chloride 
hexahydrate (0.008%, w/v), zinc sulphate heptahydrate (0.0001%, w/v), yeast 
extract (0.15%, w/v), ammonium chloride (0.05%, w/v) and glucose (3%, w/v).   
 
2.1.2 METHODOLOGY 
 
2.1.2.1 Strain and culture conditions 
The yeast strain, L. starkeyi (2710) was obtained via the National Collection of Yeast 
Cultures.  The yeast strain was stored in cryopreservation plus media and stored at 
-80oC for preservation.  A Rich (YEPD) media starter culture of L. starkeyi was 
achieved by an inoculation of a single colony from a rich medium (YEPD) agar plate 
into YEPD media.  The starter YEPD L. starkeyi culture was then stored in an orbital 
shaker at; 30oC and at 2000 revolutions per minute (492 x g) of 180 overnight.   
 
Lipid accumulation was promoted during stationary phase whether the conditions 
were nitrogen- limiting.  To initiate a culture for experimental examination, the initial 
YEPD starter culture would have a proportion of the cells centrifuged at 2000 rpm 
(492 x g) for a duration of 2 minutes.  After centrifugation, the supernatant was 
discarded leaving the pellet to then be re-suspended in NLM overnight; following 
which an experiment could be initiated in NLM cultures.   
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2.1.2.2 Cellular Viability: DHA, L-serine and co-supplementation  
The determination of DHA and/or L-serine supplementation upon L. starkeyi NLM 
cultures was achieved by a viability study carried out on a 96-well plate. This was 
performed with a media-, culture-, and a culture with varying concentrations of DHA 
and/or L-serine lanes.  The effect of the solvents, dimethyl sulfoxide (DMSO) and/or 
water was also examined to determine if these solvents had an effect upon cellular 
viability.  These plates were left in a static incubator at 30oC for 48 hours and 
subjectively examined for growth.      
 
2.1.2.3 Supplementation of DHA, L-serine and co-supplementation 
In order to determine the effect of DHA (91 nM) and L-serine (95 mM) upon lipid 
synthesis, L. starkeyi cultures were cultured in NLM (pH 6.0) and supplemented 
during the initial inoculation phase.  
 
2.1.2.4 Lipid biosynthesis from [14C] Acetate: Uptake   
The rate of the metabolic carbon flux was determined by the examined of [14C] 
acetate (55.2 mCi/ mmol) administration to either DHA (91 nM) and/or serine (95 
mM) supplemented L. starkeyi NLM cultures. A time course over a 45-minute period 
examined the rate of [14C] acetate uptake via the presence remaining in the media 
(NLM).  Per time point, a 1 ml culture sample was removed and centrifuged at 2000 
rpm (492 x g).  From which, a NLM (100 µl) sample was added to 5 ml scintillant 
(EcoScint) whereby the presence of radiolabel was quantified via scintillation 
counting over a 1-minute period.       
 
In order to determine the impact of DHA and/or L-serine supplementation upon the 
uptake of radiolabelled acetate in L. starkeyi, the DPM values ascertained from the 
scintillation was corrected for cell number, specifically 10. By doing so, the DPM 
values from each culture could be compared to determine if DHA and/or L-serine 
affected radiolabelled acetate uptake. 
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2.1.2.5 Lipid biosynthesis from [14C] Acetate: Lipid De Novo synthesis  
To determine the effects upon de novo lipid synthesis, with DHA and/or L-serine co-
administration on L. starkeyi NLM cultures, a lipid extractions was performed.  
Cultures were centrifuged at 2000 rpm (492 x g), the pellet was then re-suspended 
in NLM (1 ml) and reconstituted in pre-heated methanol (70oC) for a period of 30 
minutes.  After cooling to room temperature, the extract was added to chloroform (4 
ml) and 5% sodium chloride (2 ml, w/v).  The overall mixture was then vortexed three 
times and left to stand until two phases formed. The bottom phase was kept and 
aliquoted into a new vial which was then blown down under nitrogen gas (40oC) to 
achieve complete dryness.    
  
2.1.2.6 Thin-layer Chromatography 
Lipid extracts were re-dissolved in chloroform, then spotted via the use of capillary 
tubes onto the pre-activated 25 mm thick silica gel G plates alongside the standards 
of; phosphatidylcholine, tristearin, stearic acid, lanosterol and ergosterol.  The 
solvent system comprised of hexane/diethylether/glacial acetic acid (80:20:2 (v/v)).  
After development, lipid bands were visualized using iodine vapour and scraped into 
scintillation vials containing 5 ml of scintillant (EcoScint). Quantification of [14C] 
radiolabel presence was performed via scintillation counting over a 1-minute period.    
 
2.1.2.7 Statistical analysis 
All data were analysed using SPSS programme.  Data were expressed as mean ± 
standard deviation (SD).  Test and control data were compared using ANOVA and 
student t-test, a value of p<0.05 was taken as significant.  Most experiments were 
repeated at least 3 times (n=3). 
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2.2 Results 
 
2.2.1 Effect upon NLM cultured L. starkeyi viability, with DHA and/or L-serine 
supplementation 
From previous research (Hill, 2011), two biological molecules stood out as having 
the potential to act as regulators namely, L-serine and DHA, on culture growth.  To 
establish the L. starkeyi viability with DHA and/or L-serine supplementation, a 96-
well plate viability plate was utilized.  From this, the working concentrations of 91 nM 
of DHA and 95 mM of L-serine were proposed.    
 
2.2.2 Effect upon NLM cultured L. starkeyi growth profile with DHA and/or 
serine supplementation   
The effect of DHA and/or L-serine upon growth profile was ascertained by the 
paradigmic L. starkeyi cells being supplemented with such biological molecules 
during lag-phase.  The cultivating media employed in this study were nitrogen-
limited, which promote lipid accumulation in the paradigmic oleaginous yeast during 
the stationary phase of growth, similar to that observed in cancerous cells.  A 
depiction of the full time course of growth profile demonstrated by L. starkeyi are 
illustrated in Figure 2.1 whereby, the effect upon maximal cell number and growth 
phase transition are examined with supplementation of DHA and/or serine.   
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Figure 2.1:  Full time course growth profile of NLM cultured L. starkeyi, examining the effect supplementation of DHA (A), L-
serine (B) and co-administration of both (C).  Growth conditions: orbital setting; 30oC, 180 rpm and, NLM media pH being 6.0.  
Control solvents: DMSO (0.0003%) and/or dH20 (20%).  Data presented in A, B and C are Data are mean ± SD, n=3.
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As displayed in Figure 2.1, L. starkeyi cultured in NLM did not affect the full growth 
curve characteristics of the yeast paradigm, namely the lag-, exponential- and 
stationary- growth phases from being displayed.  Lag-phased supplementation with 
DHA to NLM L. starkeyi cultures did not affect the transition and timing between each 
growth phase, nor the full growth curve profile from being displayed (Figure 2.1, A).  
Similar to that presented with L. starkeyi DHA supplemented cells, serine 
supplementation during lag-phase (Figure 2.1, B) did not affect the full growth curve 
characteristics of L. starkeyi from being achieved nor the timing between each 
growth phase, compared to the un-supplemented counterpart.  Like previous growth 
profiles displayed in Figure 2.1 co-supplementation of DHA and L-serine to lag-
phased L. starkeyi cells did not alter the growth profile of the yeast including the 
timing between growth phases (Figure 2.1, C).     
 
To characterise the effects of these biological molecules in the paradigmic model, 
the effect upon proliferation has been examined and results are outlined in Figure 
2.2. 
 
Hypothesis 
Null hypothesis: There is no relationship between the rate of log-phased growth of 
L. starkeyi supplemented with either DHA and/or L-serine. 
Alternative hypothesis: There is a relationship between the rate of log-phased growth 
of L. starkeyi supplemented with either DHA and/or L-serine. 
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Figure 2.2:  Bar chart showing the full time course growth profile of NLM cultured L. starkeyi, examining the effect supplementation 
of DHA (A), L-serine (B) and co-administration of both (C) has upon the rate of exponential growth.  Growth conditions: orbital 
setting; 30oC, 180 rpm and, NLM media pH being 6.0.  Control solvents: DMSO (0.0003%) and/or dH20 (20%).  Data are mean 
± SD, n=3; a one-tailed t-test statistical analysis compared the control with supplemented cultures; p<0.05 showed significance.  
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As shown in Figure 2.2, the presence of DHA and/or serine upon the proliferative 
nature of L. starkeyi is displayed. In comparison to the un-supplemented counterpart, 
the doubling time of L. starkeyi was reduced with DHA supplementation (Figure 2.2, 
A). However, the effect of DHA upon doubling time was not considered quite 
significant; the one-tailed t-test displayed a P value of 0.0746 (t = 2.289 with 2 
degrees of freedom).  Interestingly, serine supplemented L. starkeyi cells also 
displayed a slight reduction in the doubling time during log-phase, similar to that 
displayed in DHA supplemented cultures (Figure 2.2, A and B).  Likewise, to the 
effect of DHA supplementation, serine presence was not considered significant in 
the one-tailed t-test upon doubling time; P value of 0.2607 (t = 0.7709 with 2 degrees 
of freedom). As shown in Figure 2.2 (C) co-administration of DHA and L-serine to L. 
starkeyi cultures, reduced the doubling rate by 25% which was considered to be 
significant in the one-tailed t-test; P value of 0.0189 (t = 4.996 with 2 degrees of 
freedom). 
 
Furthermore, by a one-way ANOVA, the effect upon L. starkeyi doubling rate was 
deemed significant (p<0.0004) between those cells supplemented with serine and 
those co-administered with DHA and serine (Figure 2.2, B and C).  Therefore, the 
null hypothesis previously stated can be rejected and instead the alternative 
hypothesis can be accepted. The maximal optical density reached during stationary 
phase can also display the effects of DHA and/or seine supplementation upon the 
growth cycle.  These results are summarised in Figure 2.3. 
 
Hypothesis 
Null hypothesis: There is no relationship between the maximal growth achieved of 
L. starkeyi supplemented with either DHA and/or L-serine. 
Alternative hypothesis: There is a relationship between the maximal growth achieved 
of L. starkeyi supplemented with either DHA and/or L-serine. 
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Figure 2.3:  Bar chart showing the full time course growth profile of NLM cultured L. starkeyi, examining the effect supplementation 
of DHA (A), L-serine (B) and co-administration of both (C) has upon the maximal growth reached in stationary phase.  Growth 
conditions: orbital setting; 30oC, 180 rpm and, NLM media pH being 6.0.  Control solvents: DMSO (0.0003%) and/or dH20 
(20%).  Data are mean ± SD, n=3; a one-tailed t-test statistical analysis compared the control with supplemented cultures; p<0.05 
showed significance. 
A) Effect of DHA supplementation           B) Effect of serine supplementation               C) Effect of DHA/serine supplementation  
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The effect upon maximal optical density reached in stationary phased L. starkeyi 
cultures with/without DHA and/or serine supplementation are shown in Figure 2.3.  
Those stationary phased L. starkeyi cultures supplemented with DHA had an 
observed 30% reduction in maximal optimal density, compared to those un-
supplemented cells (Figure 2.3, A). In the one-tailed t-test, the effect upon maximal 
optical density of stationary phased L. starkeyi cultures was deemed significant with 
DHA supplementation; P value is 0.0001, considered extremely significant (t = 
61.218 with 2 degrees of freedom).  Similar to the effect shown in DHA 
supplemented cultures, those cultures supplemented with serine showed a 14% 
reduction in maximal optical density (Figure 2.3, B).  The effect serine 
supplementation had upon the maximal optical density achieved in the stationary 
phased L. starkeyi cultures was deemed significant in the one-tailed t-test; P value 
is 0.0130 (t = 6.080 with 2 degrees of freedom).  The reduction in maximal optical 
density of the L. starkeyi cultures was also observed in those supplemented with 
both DHA and serine (Figure 2.3, C), like that previously observed in both the DHA 
supplemented and serine supplemented cultures (Figure 2.3, A-B).  The effect upon 
L. starkeyi maximal optical density reached during stationary phase with dual 
supplementation of DHA and serine was also considered significant; one-tailed t-test 
displayed a P value of 0.0407 (t = 3.289 with 2 degrees of freedom).   
 
To examine whether the supplementation type influenced the maximal optical 
density achieved in stationary phased, an ANOVA was carried out. The comparisons 
between groups demonstrated specific within group differences, F (5, 12) = 27.526, 
P<0.001.  The post hoc tukey analysis displayed a between group significance on 
the effect of maximal optical density achieved between those L. starkeyi cultures 
supplemented with: 1) DHA and serine supplemented cultures (p<0.05) and 2) DHA 
and dual supplementation of DHA and serine (p<0.01).  Therefore, the null 
hypothesis can be rejected and the alternative hypothesis accepted.   
   
Overall, the presence of DHA and/or serine in the paradigmic model was shown to 
affect the proliferative nature, but also the maximal cell number achieved in 
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stationary phased cultures.  Importantly, the timings of growth phase transition 
during the growth curve was unaffected by DHA and/or serine presence (Figure 2.1) 
therefore future work on the metabolic and lipid profiles would utilize the following 
time points: 48 hours (early exponential), 72 hours (mid-exponential), 96 hours (early 
stationary) and 120 hours (stationary phase).  These time points represent the same 
distinct phases of culture growth in all supplementation types.  
 
2.2.3 Lipid vacuole accumulation in NLM cultured L. starkeyi cells 
Oleaginous yeast, like L. starkeyi accumulate lipids once nutrient sources in the 
medium are exhausted.  Hence, a NLM was used to aid such promotion once a 
stationary phase of growth was reached (Figure 2.1, A-C).  Neutral lipids are those 
observed to be altered in many disease states. In L. starkeyi cells these neutral lipids 
are stored in lipid vacuoles, which account for up to 65% of their cellular body.   
 
To examine the potential effect upon cellular incorporation and accumulation of 
lipids, morphological examination of L. starkeyi stationary-phased cells cultured in 
NLM was carried out.  The morphological examination of LD presence in cultures 
supplemented with DHA and/or serine will provide an insight as to whether these 
biological molecules are involved in cellular lipid metabolism.  Such effects upon lipid 
metabolism are observed in many cancer types and is described to be a key 
alteration by Hanahan and Weinberg (2011).  Determination of lipid accumulation in 
L. starkeyi was achieved via light microscopy alongside the utilisation of Image J 
software.  As such, the effect of DHA, serine and co- supplementation of both upon 
cellular area and the proportion of which is taken up by the lipid vacuole(s) was 
determined. Data collected from the stationary phased L. starkeyi cells are 
summarised in Figure 2.4, A-C. 
 
Hypothesis 
Null hypothesis: There is no relationship between the proportion of cellular space 
taken up by LD in L. starkeyi supplemented with either DHA and/or L-serine. 
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Alternative hypothesis: There is a relationship between the proportion of cellular 
space taken up by LD in L. starkeyi supplemented with either DHA and/or L-serine. 
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A) Morphology of stationary-phased, L. starkeyi cells via light microscopy (X40 magnification). 
 
 
 
B) Area of stationary-phased L. starkeyi cells cultured in NLM with various supplementation types. 
C) Lipid droplet proportion to cell area, of stationary-phased L. starkeyi in NLM, with various supplementation. 
Figure 2.4:  A) Morphological effects DHA and/or serine supplementation has upon stationary-phased L. starkeyi cells cultured in NLM. B 
and C) Histogram showing the effect DHA and/or serine supplementation upon the area (B) of stationary-phased L. starkeyi cells cultured in 
NLM and (C) the proportion of the cell which is taken up by the LDs. Growth conditions: orbital setting; 30oC, 180 rpm and, NLM (pH 6.0).  
Control solvents: A) NLM only, B) DMSO (0.0003%), C) dH20 (20%) and D) DMSO and dH20 (0.0003% and 20%, respectively).  All data 
are mean ± SD, n=3; an ANOVA statistical analysis compared the control with supplemented cultures; p<0.05 showed significance. 
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Lipid body development in oleaginous yeast, like L. starkeyi, is the dominant feature 
during the stationary phase of growth. Microscopy images, shown in Figure 2.4 (A) 
illustrate L. starkeyi cellular accruement of lipids during this growth phase. Lipids, 
especially neutral in type are stored in LDs, as displayed in Figure 2.4 (A).  These 
LDs appear to take up over half of the internal area in all cultured cells, indifferent of 
supplementation type.  Interestingly, supplementation of the two biological 
molecules, DHA and/or serine, had differing effects on the; number and cellular 
proportion the LDs displayed within the stationary-phased NLM cultured L. starkeyi 
cells (Figure 2.4, A and B).   
 
Cells supplemented with DHA had a large mono-LD, similar to that displayed by the 
un-supplemented counterpart (Figure 2.4, A, Control B). Whilst serine supplemented 
L. starkeyi cultures were observed to have cells with increased number of LDs 
compared to their controlled mono-LD counterpart (Figure 2.4, A, Control C).  In 
addition to increased number of LDs, cells supplemented with serine were observed 
to have LDs smaller in size compared to the larger mono-LD observed in the un-
supplemented L. starkeyi cells.  Interestingly, the dual supplemented NLM cultured 
L. starkeyi cells demonstrated multiple, smaller LDs in contrast to the control which 
contained a mono-LDs (Figure 2.4, A, Control D).   
 
The effect upon the size of the cells with DHA and/or serine supplementation are 
summarised in Figure 2.4 (B).  The cell area was shown to be affected by 
supplementation type; whether DHA and/or serine.  The ANOVA statistical test 
highlighted specific within group differences in cell area, F (6, 14) = 1.579, P>0.05.  
Specifically, those L. starkeyi cells supplemented with serine which showed an 
increased cellular area of 60% (p<0.05).  Hence, the null hypothesis can be rejected 
and the alternative hypothesis accepted in terms of serine affecting stationary phase 
cell size. 
 
102 
 
To examine whether the supplementation type influenced the portion of the 
stationary phased L. starkeyi cells which were taken up by LDs, Image J software 
was utilised. The proportion of which the L. starkeyi stationary-phased cells were 
embodied by the LD(s) are summarised in Figure 2.4 (C).  The proportion of which 
the cell was taken up by LD(s) with DHA/ serine presence, was not shown to be 
significant in the ANOVA statistical test; F (6, 14) = 1.578, p = 0.2253.  Therefore, 
the null hypothesis can be accepted and the alternative hypothesis rejected in terms 
of DHA and/or serine supplementation increasing the proportion of which the L. 
starkeyi cells are taken up by LD.   
 
Overall, L. starkeyi exhibits a large mono-LD during stationary phase.  
Supplementation of DHA to L. starkeyi increases the occupancy within the cell of this 
vacuole by up to a third, but not significantly.  Whilst, serine supplementation 
increases the number of LDs within the cell alongside significantly increasing its area 
by 61%, however the proportion of the cell occupied with LD(s) were not significantly 
affected.   
 
2.2.4 Effect of the two biological molecules upon radio-labelled acetate uptake  
To gain better insight into the effects upon cellular lipid metabolism with DHA and/or 
serine presence the cultured NLM L. starkeyi cells were incubated with radiolabelled 
acetate during exponential and stationary phases of growth.  With such incubation, 
the uptake of acetate can be traced over time giving an indication of the cellular 
nutritional requirements.  The acetate uptake profiles are depicted in Figure 2.5 – 
2.7 with the mean rates of uptake displayed on the associated figures.    
 
Hypothesis 
Null hypothesis: There is no relationship between acetate uptake of exponential and 
stationary phased in L. starkeyi cells supplemented with either DHA and/or L-serine. 
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Alternative hypothesis: There is a relationship between acetate uptake of 
exponential and stationary phased in L. starkeyi cells supplemented with either DHA 
and/or L-serine. 
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Figure 2.5:  Initial [14C] acetic acid uptake rates shown over a 45-minute period in L. 
starkeyi NLM cultures, during exponential and stationary growth phases; examining 
the effect of lag-phase supplementation of DHA.  Growth conditions: orbital setting; 
30oC, 180 rpm and, NLM media pH being 6.0.  Control solvents: DMSO (0.0003%).  
Results have been corrected for an optical density of 10.  All data are mean ± SD, n=3; 
an ANOVA statistical analysis compared the control with supplemented cultures; p<0.05 
showed significance. 
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Figure 2.6:  Initial [14C] acetic acid uptake rates shown over a 45-minute period in L. 
starkeyi NLM cultures, during exponential and stationary growth phases; examining 
the effect of lag-phase supplementation of serine.  Growth conditions: orbital 
setting; 30oC, 180 rpm and, NLM media pH being 6.0.  Control solvents: dH20 
(20%).  Results have been corrected for an optical density of 10.  All data are mean ± 
SD, n=3; an ANOVA statistical analysis compared the control with supplemented cultures; 
p<0.05 showed significance. 
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Figure 2.7:  Initial [14C] acetic acid uptake rates shown over a 45-minute period in L. 
starkeyi NLM cultures, during exponential and stationary growth phases; examining 
the effect of lag-phase supplementation of DHA and serine.  Growth conditions: 
orbital setting; 30oC, 180 rpm and, NLM media pH being 6.0.  Control solvents: co-
administration of DMSO and dH20 (0.0003% and 20%, respectively).  Results have 
been corrected for an optical density of 10.  All data are mean ± SD, n=3; an ANOVA 
statistical analysis compared the control with supplemented cultures; p<0.05 showed 
significance. 
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Figure 2.5- 2.7 summarises the radiolabelled acetate up taken from the NLM into the 
L. starkeyi cells in both phases of growth; exponential and stationary, respectively.  
The rate at which the radiolabelled acetate was up taken by the NLM cultured L. 
starkeyi cells from the media and the level which was reached over the time course 
was shown to be dependent on whether the cells were supplemented with DHA 
and/or serine.  
 
To examine the effect of DHA supplementation upon the rate of radiolabel uptake, a 
repeated ANOVA was conducted between exponential and stationary phased L. 
starkeyi cells (Figure 2.5).  The ANOVA statistical test highlighted specific within 
group differences in the maximum radiolabel up taken by the L. starkeyi cells over 
the time course, F = (3, 2) = 1.507, p = 0.0017 (Figure 2.5). In comparison to the un-
supplemented counterpart during exponential growth phase (Figure 2.5), those NLM 
cultured L. starkeyi cells supplemented with DHA displayed a 50% reduced uptake 
of acetate (p<0.05).  However, as cells transitioned to stationary phase, the maximal 
acetate taken up was unaffected with DHA presence in either growth phases 
examined (Figure 2.5).   
 
To examine the effect of serine supplementation (Figure 2.6) upon the ability of NLM 
cultured L. starkeyi cells to uptake [14C] acetic acid from the media a repeated 
ANOVA was conducted.  The ANOVA statistical test displayed a specific within 
group difference on the ability of L. starkeyi cells to uptake acetic acid when 
supplemented with serine, F = (3, 2) = 36.300, p = 0.0003 (Figure 2.6).  As depicted 
in Figure 2.6, during exponential growth phase the radiolabelled acetic acid up taken 
from the media by L. starkeyi serine supplementation cells were reduced by half in 
comparison to the un-supplemented counterpart (p<0.01). Furthermore, the growth 
phase transition from exponential through to stationary phase, displayed a slight 
increase in the [14C] acetic acid up taken, however this was not significant.  However, 
the retailoring of the [14C] acetic acid previously demonstrated in the exponential 
growth phase was carried forward as the cells transitioned into stationary phase 
(p<0.01).   
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Supplementation with both biological molecules (Figure 2.7) produced an [14C] acetic 
acid uptake profile like that displayed in those cells supplemented with serine solely 
(Figure 2.7, B).  The repeated measures ANOVA examining the effect of DHA and 
serine co-supplementation upon the ability of L. starkeyi cells to uptake acetic acid 
demonstrated significant within group differences, F = (3, 2) = 27.112, p = 0.0007 
(Figure 2.7).  
 
As Figure 2.7 illustrates, NLM cultured L. starkeyi cells supplemented with DHA and 
serine displayed a reduced maximal [14C] acetic acid uptake from the media; 32% 
and 55% during exponential (p<0.01) and stationary phases (p<0.01), respectively.  
This is paralleled to the profile displayed in L. starkeyi NLM cultured cells 
supplemented with serine solely (Figure 2.6).  Interestingly, this retailoring of acetate 
uptake is not demonstrated in DHA supplemented L. starkeyi NLM cultured cells 
(Figure 2.5).  Whereas L. starkeyi cultures supplemented with serine in some form, 
either solely or alongside DHA (Figure 2.6 and 2.7) demonstrated a preserved 
serine-dependent acetate-uptake effect on the ability of acetate to be up taken from 
the media into the L. starkeyi cells in both exponential and stationary growth phases.   
 
In summary, radiolabelled acetic acid uptake from L. starkeyi NLM cultures in both 
exponential and stationary phases of growth was shown to be hindered by the 
supplementation of serine not DHA, affecting the maximal acetate up taken from the 
media.   
 
2.2.5 Effect of the two biological molecules upon de novo lipid synthesis 
In addition to the lipid accumulation observed in many diseased states, the neutral 
lipid profile within these tissues have been displayed to be altered.  The retailoring 
of these neutral lipids via alterations in the de novo lipid synthesis pathways have 
been understood to aid the characteristics of these diseases.  In order to ascertain 
the effect of the two biological molecules upon de novo lipid synthesis, those L. 
starkeyi cells previously supplemented with DHA and/or serine and incubated with 
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radiolabelled [14C] acetic acid were extracted for lipids which were then separated 
via TLC and quantified via the [14C] acetic acid presence within each neutral lipid 
band. A summary of the effect DHA supplementation had upon the de novo neutral 
lipid profile, during exponential and stationary phased NLM cultured L. starkeyi cells 
production of neutral lipids is depicted in Figure 2.8. 
 
Hypothesis 
Null hypothesis: There is no relationship between neutral lipid de novo synthesis in 
exponential and stationary phased in L. starkeyi cells supplemented with DHA. 
Alternative hypothesis: There is a relationship between neutral lipid de novo 
synthesis in exponential and stationary phased in L. starkeyi cells supplemented with 
DHA. 
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Figure 2.8:  Bar charts showing the effect of DHA 
supplementation upon de novo lipid synthesis during exponential (A) and stationary (B) phased L. starkeyi cells via [14C] acetic 
acid incubation over a 45-minute period.  A lipid extraction followed by a TLC enables visualization thus quantification of radiolabel 
presence by scintillation counting of various lipid pools by scraping these bands. Key: PL (phospholipid), DES (desmethyl-sterols), 
MMS (monomethyl-sterols), DMS (dimethyl-sterols), FFA, TAG and SE.   All data are mean ± SD, n=3; an ANOVA statistical 
analysis compared the control with supplemented cultures; p<0.05 showed significance. Statistical analysis showed the lipid class 
synthesised to be growth phase specific, particularly the MMS proportion; F= (27, 83), p<0.0001.      The post hoc turkey test 
displayed that DHA supplementation increased the de novo synthesis of FFA during exponential phase (p<0.05).   
A) Exponential phase de novo lipid synthesis    B) Stationary phase de novo lipid synthesis 
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As displayed in Figure 2.8, the most abundant lipid class, with over 65% of 
radiolabelled presence was that of the phospholipids, independent of growth phase.  
On closer examination, there is a growth-phase specific trend with those L. starkeyi 
cells supplemented with DHA in comparison to the un-supplemented counterpart. 
During the exponential growth phase (Figure 2.8, A), DHA supplemented NLM 
cultured L. starkeyi cells had an increased incorporation of [14C] acetic acid the 
following lipid pools; MMS, FFA and TAGs and SE by 70%.  On closer examination, 
this was constituted mainly by the doubling of FFA and TAG de novo synthesis with 
DHA supplementation in comparison to the non-supplementation L. starkeyi culture. 
However, with this supplementation, the proportion of phospholipids were reduced 
by 13%, DES by 40% and DMS by 4%.   
 
As the L. starkeyi cells transitioned from exponential to stationary phase, the newly 
synthesized phospholipid pool reduced slightly by 5%, but this is still the overriding 
lipid pool of abundance with over 60% of total radiolabel presence (Figure 2.8, B).  
De novo lipid pool rearrangement with growth phase transition can also be observed 
in the un-supplemented culture with the reduction in the following lipid pools; DES, 
MMS, FFA and SE by approximating 27%.  This is in contrast to the quadrupled de 
novo synthesis of DMS and TAG with growth phase.  It is worthy to note, that TAG 
radiolabel presence increased 5.5-fold with transition into to stationary phase alone.   
 
As Figure 2.8 demonstrated, those cells supplemented with DHA displayed this lipid 
pool rearrangement with growth phase transition however, to a greater extreme.  
Once DHA supplemented cells transitioned into stationary phase, the phospholipid 
pool reduced greatly by 20%; like the un-supplemented culture this is the dominant 
lipid pool of radiolabel presence (Figure 2.8, B).  When compared to the exponential 
phase those cells supplemented DHA, unlike the un-supplemented control, 
displayed a 47% reduction in de novo synthesis in the following lipid pools; DES, 
MMS and FFA. This contrasts with, DMS and TAG lipid pools which increased 3.2-
fold with stationary phase transition. Additionally, whilst TAG presence increased 
4.5-fold in the un-supplemented cultures with transition from an exponential to a 
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stationary phase of growth, DHA supplementation enhanced this further to a 12-fold 
increase in TAG de novo synthesis, which equates to a 3-fold increase when 
compared to the non-supplemented stationary phase culture.    
 
Overall, DHA supplementation was shown to influence de novo lipid synthesis in 
NLM cultured L. starkeyi cells.  Hence, the previously stated null hypothesis can be 
rejected and the alternative hypothesis accepted. To determine if serine presence 
within the culture can also influence de novo lipid synthesis, NLM cultured L. starkeyi 
cells were supplemented with radiolabelled acetate over a time course, then the 
neutral lipids were measured for radiolabel presence.  
 
Hypothesis 
Null hypothesis: There is no relationship between neutral lipid de novo synthesis in 
exponential and stationary phased in L. starkeyi cells supplemented with L-serine. 
Alternative hypothesis: There is a relationship between neutral lipid de novo 
synthesis in exponential and stationary phased in L. starkeyi cells supplemented with 
L-serine. 
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Figure 2.9.  The effect upon de novo lipid synthesis during exponential (A) and stationary (B) phase NLM cultured L. starkeyi 
cells with serine supplementation via [14C] acetic acid incubation over a 45-minute period.  A lipid extraction followed by a Thin-
layer chromatogram enables visualization thus quantification of radiolabel presence by scintillation counting of various lipid pools 
by scraping these bands.  Key: PL (phospholipid), DES (desmethyl-sterols), MMS (monomethyl-sterols), DMS (dimethyl-sterols) 
FFA, TAG and SE. All data are mean ± SD, n=3; an ANOVA statistical analysis compared the control with supplemented cultures; 
p<0.05 showed significance. Statistical analysis showed the lipid class synthesised to be growth phase specific, particularly the 
TAG proportion; F= (27, 83), p<0.0001. The post hoc turkey test displayed that serine supplementation decreased the de novo 
synthesis of TAG during stationary phase (p<0.05).   
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Resembling cells supplemented with DHA (Figure 2.8, A-B) the effect upon lipid de 
novo synthesis is shown in Figure 2.9 examining the effect L-serine supplementation 
has on NLM cultured L. starkeyi cells. The most abundant lipid class as shown in 
Figure 2.9 with over 50% of the [14C] acetic acid presence was that of the 
phospholipids, independent of growth phase.  In-depth growth-phase examination 
however reveals specific trends with serine supplementation in comparison to the 
un-supplemented counterpart (Figure 2.9, A-B).  As displayed in Figure 2.9 the [14C] 
acetic acid presence within the lipid pools changed in L. starkeyi cultures with the 
transition from exponential through to stationary phase.  In the un-supplemented 
NLM cultured L. starkeyi cells, a de novo lipid synthesis reduction with growth phase 
transition was observed in the following lipid pools; PL, DMS and TAG. This 
reduction of [14C] acetic acid presence with the non-supplemented culture entry into 
stationary phase was paralleled with a 9% increase in de novo lipid synthesis of the 
remaining lipid pools (Figure 2.9, A-B).   
  
During the exponential growth phase, serine supplemented NLM cultured L. starkeyi 
cells had increased incorporation of [14C] acetic acid the following lipid pools; MMS, 
DMS, FFA and SE approximating 2.7-fold (Figure 2.9, A).  However, as displayed in 
Figure 2.8 (A), serine supplemented cells had a reduced [14C] acetic acid presence 
within the DES and TAG pools by 25%. This trend in radiolabel presence was unlike 
that displayed with DHA supplementation (Figure 2.8, A) whereby de novo TAG 
synthesis is doubled compared to the non-supplemented counterpart; contrary to the 
38% reduction observed with serine supplementation (Figure 2.9, A).  However, the 
presence of [14C] acetic acid in both SE and FFA lipid pools are increased in cultures 
supplemented with serine (Figure 2.9, A) and DHA (Figure 2.8, A). 
 
Growth phase transition from exponential to stationary phase, as depicted in Figure 
2.9 alters the [14C] acetic acid presence within the lipid pools. Transition into 
stationary phase (B), increases phospholipid de novo synthesis by 15% that is unlike 
both the un-supplemented counterpart.  This is in part, due to the coupled reduction 
of [14C] acetic acid in the following lipid classes; DES, MMS, DMS, TAG and SE 
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approximately to 23%.  To make note of is the proportion of FFA within the stationary 
phased L. starkeyi cells, which increased 1.5-fold compared to the exponential 
phase of growth.  Examining the [14C] acetic acid profile of stationary phased L. 
starkeyi cells further in comparison to the un-supplemented counterpart, those cells 
supplemented with serine display a 51% reduction in the de novo synthesis of DES 
and TAG lipids during stationary phase whereas the remaining lipid pools are 
increased by a third (Figure 2.9, B)  
 
Overall, serine supplementation (Figure 2.9) appears to affect de novo lipid synthesis 
differently than DHA supplementation (Figure 2.8). As displayed in Figure 2.8 de 
novo synthesis of TAG was reduced with serine supplementation in both growth 
phases examined in contrast to DHA supplementation (Figure 2.8), however SEs 
were increased (Figure 2.8, A-B). Therefore, the previously stated null hypothesis 
can be rejected and the alternative hypothesis accepted.  The effect of co-
administered serine and DHA supplementation upon NLM cultured L. starkeyi cells 
de novo lipid synthesis during exponential and stationary phases are depicted in 
Figure 2.10.  
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Figure 2.10:  Bar charts showing the preliminary examination of the effect upon de novo lipid synthesis during exponential (A) 
and stationary (B) phased L. starkeyi cells upon serine and DHA supplementation via [14C] acetic acid incubation over a 45-
minute period.  A lipid extraction followed by a Thin-layer chromatogram enabled visualization. Quantification of radiolabel 
presence was determined via scintillation counting of lipid pools.  Key: PL (phospholipid), DES (desmethyl-sterols), MMS 
(monomethyl-sterols), DMS (dimethyl-sterols), FFA, TAG and SE.  Data obtained from n=1.  
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The preliminary study into the effect of both biological molecules of interest, DHA 
and serine, upon L. starkeyi de novo lipid synthesis has demonstrated a morphed 
profile previously displayed in those cultures individually supplemented with DHA 
(Figure 2.8) and serine (Figure 2.9). Like previous de novo lipid synthesis profiles, 
the most abundant class as shown in Figure 2.10 is that of phospholipids.  The 
abundance of the phospholipid lipid pool is independent of whether the L. starkeyi 
culture was incubated with [14C] acetic acid during exponential (Figure 2.10, A) 
or in a stationary (Figure 2.10, B) growth phase; with over 50% [14C] acetic acid 
presence.   
 
DHA and serine co-supplementation reproduced the growth-phase specific trend 
previously encountered with individual DHA and serine supplemented cultures in 
comparison to their un-supplemented counterparts.  As displayed in Figure 2.10, 
during exponential phase (A) in the un-supplemented culture, heightened de 
novo lipid synthesis included the; phospholipids, DES and FFA lipid pools which 
accounted for over 95% of the total [14C] acetic acid presence.  In contrast with 
co-supplemented DHA/serine L. starkeyi culture which these same lipid classes 
displayed a 7% total reduction.  On closer view of the effect of dual 
supplementation of DHA/serine in comparison to the un-supplemented culture, 
the following lipid pools demonstrated an increased [14C] acetic acid presence; 
DES (10%), TAG (2-fold) and SE (tripled) during exponential phase hence de 
novo synthesis.   
 
With growth cycle progression, from exponential to stationary phase alterations 
in de novo lipid synthesis is apparent (Figure 2.10, A-B).  The most abundant lipid 
class in the control culture with [14C] acetic acid presence, the phospholipids, 
gained 15% abundance with growth phase transition from exponential to 
stationary phase. On closer view, other lipid classes which have increased 
radiolabel presence include; phospholipids, DES, TAG and FFA which together 
have quadrupled in their de novo synthesis.  Interestingly, with DHA/serine co-
supplementation these same lipid classes increase by half in comparison.  
However, when comparing their radiolabelled presence during the exponential- 
(Figure 2.10, A) to that of stationary phase (Figure 2.10, B), these lipid pools are 
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double that displayed in the un-supplemented counterpart.  Lipid classes, which 
have in fact reduced their de novo synthesis with growth phase transition, include 
DES and FFA, which between exponential and stationary phase in the un-
supplemented cultures loose ~61% of their [14C] acetic acid presence.  However, 
with serine and DHA co-supplementation the reduction from the exponential 
profile is only 40%.  When directly comparing the stationary cultures (un-
supplemented vs DHA and serine co-administered) there is a 60% increase in 
the presence of these lipid classes.   
  
Comparison of the individually supplemented DHA (Figure 2.8) or serine (Figure 
2.9) L. starkeyi cultures to the dual administered DHA and serine culture (Figure 
2.10) has illustrated some similarities in their de novo lipid synthesis profiles of L. 
starkeyi during exponential and stationary phases of growth.  To name a few, the 
reduced phospholipid presence observed in both phases is also displayed with 
DHA supplementation (Figure 2.8). Furthermore, the limited TAG increase with 
transition into stationary phase is displayed with serine supplementation (Figure 
2.9).       
 
Overall, the proportion of de novo lipid synthesis is NLM cultured L. starkeyi cells 
during exponential and stationary growth phases is dominated by the acyl lipids.  
The supplementation of the biological molecules of interest (Figure 2.10, A-C), 
DHA and/or serine, re-tailored the de novo synthesis of acyl lipids, sterols and 
SEs within the L. starkeyi cultures resulting in an increased isoprenoid presence 
compared to the control cultures.   
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2.3 Discussion 
The main findings from this chapter suggest that serine, rather than DHA 
influences cellular processes.  Serine supplementation resulted in the altered 
uptake of radiolabelled acetate in L. starkeyi.  In addition, with serine 
supplementation, lipid accruement during stationary phase was altered. L. 
starkeyi supplemented with serine accrued lipids in multiple, rather than mono 
lipid droplets.  Data from this chapter, suggest that the presence of serine can 
enhance the availability of neutral lipids needed for energy generation and cellular 
membrane biosynthesis.  Such requirements are essential components of a 
cancerous phenotype.       
2.3.1 OLEAGINICITY: MODEL ORGANISM  
In many human diseases, like cancer, ectopic lipid accumulation is observed in 
the lipid body (Coller, 2014; DeBerardinis et al., 2008b; DeBerardinis et al., 
2008a; DeBerardinis and Chandel, 2016).  The ability to accumulate lipids has 
been conserved thru evolution in higher eukaryotes, including fungi.  Results 
gained by Peregrin-Alvarez et al. (2009)  have demonstrated to fulfil life, the 
enzymes involved in amino acid, energy, carbohydrate and lipid metabolism are 
required. However, some yeast strains specifically those, which are of non-
oleaginous in type do not have the capacity to accrue lipids.  An example of which 
is the Baker’s yeast, S. cerevisiae, which is often used as a genetic model in 
various studies (Mager and Winderickx, 2005).    To model the lipid accumulation 
observed in diseased cells, the paradigmic model organism, L. starkeyi, was 
cultured in NLM.  The abundance of L. starkeyi lipid accumulation during 
stationary phase was shown in Figure 2.4.  Light microscopy images of the 
stationary phased, nitrogen limited L. starkeyi cells demonstrated the yeasts 
capability to accrue lipids via the large mono-lipid body, which it houses.   The 
high proportions of the cell, shown in Figure 2.4 (A), which is taken up by the lipid 
body demonstrates the L. starkeyi strain’s oleaginicity; the dry cell of which has 
been reported to be >65%.    L. starkeyi’s mono-lipid body will be storing the 
neutral lipids, triacylglycerides and sterol esters, surrounded by a phospholipid 
membrane also housing sterols. 
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The lipid accumulation observed in L. starkeyi in Figure 2.4 (A) is because of the 
nutrient exhaustion exhibited on the cells during stationary phase.  Nutrient 
exhaustion is because of the cellular processes taking place during the log phase 
of growth.  Such processes requiring nutrient input from the media include, 
proliferation and protein and nucleic acid synthesis.  Hence, with increasing L. 
starkeyi cellular density with growth curve progression, levels of nutrients in the 
media reduce, specifically nitrogen which was already limited in the NLM media.  
Due to nutrient exhaustion, protein and nucleic acid synthesis in L. starkeyi halts 
which is similar to that observed in mammalian cells.  Subsequently, metabolic 
retailing as per described in Figure 1.21 is promoted leading the lipid 
accumulation observed in Figure 2.4.   
 
The metabolic retailoring responsible for the lipid accumulation observed in L. 
starkeyi as opposed to a non-oleaginous yeast stems from their taxonomic 
hierarchy.  L. starkeyi is one out of 1000 known ascomycete yeasts and is part of 
the Lipomycetaceae family.  A parsimonious tree (Appendix 2) illustrates the 
genetic divergence between Lipomycetaceae members, of which L. starkeyi 
belongs (Kurtzman et al., 2007).  The genetic divergence between L. starkeyi and 
S. cerevisiae is great, hence explaining why during stationary phase S. 
cerevisiae, divert the excess carbon into the production of polysaccharides 
(glycogen, glucan and mannan) whilst L. starkeyi produces and subsequently 
stores intracellular lipids in a lipid body.  In mammalian cells, during diseased 
states, cells accumulate lipids, hence an oleaginous yeast is better biochemically 
suited to study the effect of lipid accumulation with DHA and/or L-serine 
supplementation.  
 
2.3.1.1 Oleaginous vs non-oleaginous yeasts: energy metabolism 
One of the major differences between the yeast strains, L. starkeyi and S. 
cerevisiae, is their energy metabolism preference.  Growth in high glucose 
environments would be observed in Crabtree positive yeasts like S. cerevisiae.  
Crabtree positive yeasts aerobically ferment alcohol when sugar is in excess.  
Whereas non-fermentative yeasts, like L. starkeyi, under nutrient exhaustion lead 
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to be metabolic retailoring via increased AMP-activated protein kinase (AMPK) 
resulting in the accruement of lipids once the stationary phase of growth is. The 
enzymatic differences between the two types of yeasts, Crabtree positive and 
negative, provide reasoning for this.  Many studies have used the lipid 
accumulating benefits of oleaginous yeast, like L. starkeyi, to increase the lipid 
production in non-oleaginous yeasts like S. cerevisiae by genetically improving 
the strain.  In disease states, like cancer, lipolysis is described to be ‘reactivated’.  
As a result, the products of which including, triglycerides and phospholipids are 
increased and subsequently result in the traits of a cancerous cell becoming 
enabled, as per described by Hanahan and Weinberg (2011) (Beloribi-Djefaflia 
et al., 2016).   These neutral lipids are housed in a lipid body within L. starkeyi, 
which during nitrogen limitation over half of the cell was shown to be taken up by 
(Figure 2.4, A-C).   
 
Considering the focus of the research in addition to the details above, the lipid 
enzymatic capabilities of the model needs to be taken into account.  One of the 
lipids increased during diseased states is the neutral lipid, triacylglyceride, for 
which the rate-limiting step involves the ACC enzyme.  The study by Wang et al. 
(2016) demonstrated how the expression of ACC from L. starkeyi improved the 
oleaginicity of S. cerevisiae, not only via the lipid content (24%) but also the 
productivity of which it was made (22%).  Other studies have demonstrated other 
key enzymes (ACL) which are involved in triacylglyceride production to be void in 
non-oleaginous yeast strains like S. cerevisiae but present in oleaginous yeasts 
like, L. starkeyi. However, due to the easy genetic manipulation of the S. 
cerevisiae strain, metabolic engineering of the ACL gene has been shown to 
increase the fatty acid synthesis within this model (Tang, 2013).        
 
Considering all factors, L. starkeyi was therefore used as the model organism, 
examining the effect of the two biological molecules surrounding cellular events 
leading to lipid accumulation, as opposed to the Bakers yeast, S. cerevisiae.   
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2.3.2 INFLUENCE OF DHA SUPPLEMENTATION  
 
Several studies on the human diet, have shown to reduce the risk of cancer, 
including colon, when the ratio of polyunsaturated fatty acids are higher in ω-6 
compared to the ω-3.     
 
2.3.2.1 Effect on growth 
The 22 carbon, six-double bonded biological molecule, DHA has been shown in 
several studies to inhibit not only cancer cellular proliferation but also induce cell 
death (Song and Kim, 2016).  From the results shown in Figure 2.03, L. starkeyi 
cells supplemented with DHA (90 nM) resulted in a reduction in the overall culture 
density by a third.  This is in line with previous findings with concentrations 
between 10-100 mM (Fasano et al., 2012; Abdi et al., 2014).  In this study, L. 
starkeyi cells were exposed to a much lower concentration of 90 nM as higher 
concentrations induced premature senescence, which made the determination of 
culture growth impossible.  This may suggest that in fact, those L. starkeyi cells 
supplemented with DHA had an increased demand for nutrients from the culture 
media.  This in turn would lead to the premature limitation of nutrients in the media 
which would cause activation of several upstream signalling pathways including 
mTOR and Raf.  Because of signalling pathway activation, premature entry into 
stationary phase would occur. Subsequently, a reduction in cellular density would 
be demonstrated, as was in Figure 2.4 (A).     
 
Conversely, DHA has been shown to promote apoptosis in mammalian cells 
(Abdi et al; 2014) which may account for the reduction in cell number witnessed 
in our experiments. However, under osmostress the viability of those cells 
supplemented with DHA was increased.  This increased cellular viability under 
stress, suggests a thicker cell wall during stationary phase with DHA 
supplementation. 
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2.3.2.2 Effect on lipid accruement 
In disease states, such as neurodegeneration and cancer lipid accumulation is 
observed to be altered.  Studies have focused their attention on the storage unit 
of these neutral lipids, the LD.  Within these units, the neutral lipids, 
triacylglyceride and sterol esters, are stored awaiting mobilisation. As 
demonstrated in Figure 2.4, DHA supplementation had no effect on cell size (A) 
but the proportion of which was taken up by the LD (B) was increased by a third 
compared to the un-supplemented counterpart.  The influence DHA has upon 
lipid droplet formation has been documented in several studies (Tremblay et al., 
2016).  One factor to consider would be whether the L. starkeyi cells 
supplemented with DHA had an altered phospholipid nomenclature, which would 
therefore impact on the intrinsic curvature of the LD, which in turn would increase 
its area within the cell.  A study by Shi et al. (2013) has shown that the size of the 
LD can be regulated via stearoyl-CoA desaturase (SCD) which is also found in L. 
starkeyi.   As a key conversion enzyme for mono-desaturation of fatty acids, 
SCD1 regulates lipogenesis providing lipids required for rapid proliferation and 
cellular structure observed in cancer cells.  This would result in the reduction in 
lipid mobility once triacylglyceride and sterol esters are stored in the LD.   
 
The effect of DHA supplementation upon de novo lipid synthesis was gained with 
the incubation and quantification of radiolabelled acetate within L. starkeyi 
exponential and stationary phased cultures.  
 
2.3.2.3 Effect on lipid metabolism  
The results of this study have shown that un-supplemented stationary phased 
cultures were able to take up radiolabelled acetate at a faster rate than their 
exponential phase counterparts (Figure 2.4). Once taken up by the cells, acetate, 
in the form of acetyl-CoA, was used as a precursor for both isoprenoid and acyl 
lipid biosynthesis, hence the labelling of the sterol and combined acyl lipid 
(phospholipids and triglyceride) pools, respectively. Approximately, 75% of 
labelled carbon were shown to accumulate in the acyl lipid pool whilst the 
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remaining 25% was utilized for isoprenoid synthesis. Consequently, it may be 
postulated that for every four acetate molecules converted to acetyl-CoA, three 
of these molecules are used to support acyl lipid synthesis. This feature has been 
shown to be independent of the growth phase, whether exponential or stationary. 
In addition, the biosynthesis of triglycerides relative to that of phospholipids 
increased as the cells moved into a more quiescent period (stationary phase). 
Furthermore, those L. starkeyi cells supplemented with DHA had a raised 
triglyceride: PL ratio, which increased further with stationary phase entry, 
compared to the control.  These results are in line with the studies of Rolph et al 
(1989) on lipid accumulation in another oleaginous yeast, R. gracilis.  Therefore, 
the depiction of a larger mono-LD in Figure 2.4 (A) in those cells supplemented 
with DHA support this raised de novo production of triglyceride during stationary 
phase (Figure 2.8, B).  This raised neutral lipid production observed with DHA 
supplementation demonstrated an increased flux through the Kennedy pathway 
(Figure 1.21).    
 
The rate at which the radiolabelled acetate was taken from the NLM media by 
those cells supplemented with DHA had little effect on the rate at which it was up-
taken in proliferating cells, whilst stationary-phase cells exhibited a slight 
decrease (Figure 2.5-2.7, A). However, despite the reduced rate of uptake, more 
of the radiolabel accumulated in the form of triglycerides in the DHA treated cells 
(Figure 2.8). Also, to note, the increased amount of radiolabelled sterol ester upon 
DHA treatment (Figure 2.8). However, at this stage it is impossible to determine 
the biosynthetic origins of the enhanced production of sterol esters.  
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2.3.3 INFLUENCE OF SERINE SUPPLEMENTATION 
 
2.3.3.1 Effect of growth  
As relatively little is known about the uptake of serine by L. starkeyi, it was 
decided to use as high a concentration as possible for the serine supplementation 
studies. Consequently, L. starkeyi cultures were grown in media supplemented 
with 91 mM serine. The use of such a high serine concentrations would provide 
a serine concentration, which could mimic the transfer of L-serine from the 
astrocytic producers to the glial cells of the brain (see Chapter 1). Another issue 
which needed to be addressed was also the fact that the yeast paradigm was 
also surrounded by a cell wall, whose thickness would increase as the cultures 
aged. As with DHA supplementation, serine supplementation had little effect on 
the timing of growth phase transitions but did reduce the final cell density reached 
by 14%.   
 
2.3.3.2 Effect on lipid accruement 
Those cells supplemented with serine exhibited an altered number of LDs within 
those cells, which reached stationary phase (Figure 2.4). The yeast paradigm, L. 
starkeyi, accumulates lipids in a mono-LD; however, serine supplementation 
resulted in the formation of several LDs (Figure 2.4).  Observations of several 
LDs have been reported in diseased cells.  It has been postulated that the 
budding off from the endoplasmic reticulum into the cystol is altered in these 
states.  In addition to the multi-LD occupancy within the stationary phased serine 
supplemented L. starkeyi cells, the size of these cells were also increased by 
61% (Figure 2.4, B).  This like those cells supplemented with DHA, may suggest 
an altered phospholipid nomenclature of the phospholipid membranes, resulting 
in an increased cell size due to the impact upon intrinsic curvature of the 
membranes.  Likewise, the increase in cell size could also be explained by the 
cellular response to prevent lipotoxicity due to the raised LD occupancy observed.   
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2.3.3.3 Effect on lipid metabolism  
Similar to the effect of DHA supplementation, serine supplemented L. starkeyi 
cells showed an increase in the amount of radiolabelled acetate which was taken 
up in stationary phase compared to exponential phase (Figure 2.5, 
B).  Approximately, 90% of labelled carbon was shown to accumulate in the acyl 
lipid pool whilst the remaining 10% was utilized for isoprenoid synthesis. 
Consequently, it may be postulated that for every ten acetate molecules 
converted to acetyl-CoA, one of these molecules are used to support acyl lipid 
synthesis. This feature has yet to be shown to be independent of the growth 
phase, but is the same for incubation with serine from exponential and stationary 
phases. The biosynthesis of phospholipids relative to that of triacylglycerides was 
interestingly increased during stationary phase in comparison to the exponential 
cells.  This may, in part, be due to the proportion of the cell which is taken up by 
the LDs. However, as the levels of triacylglycerides and sterol esters are relatively 
unchanged upon stationary phase entry, this is unlikely.  Therefore, the increased 
proportion of PL to TAG is more likely to be because of the mobilisation of the 
phospholipids surrounding the LDs in aid of supporting the demands for 
membrane biosynthesis.  This is further evidenced with the increased cell size 
observed in cells supplemented with serine during stationary phase in Figure 2.4.   
 
In comparison to DHA supplementation which had little effect upon rate of 
radiolabelled uptake, serine supplementation reduced uptake in both proliferating 
and stationary L. starkeyi cells by half (Figure 2.5, B). Furthermore, the ratio of 
triacylglyceride: phospholipid de novo synthesis during stationary phase was also 
greater in those DHA treated cells. However, as previously stated, at this stage it 
is impossible to determine the biosynthetic origins the enhanced production of 
sterol esters.  
 
 
2.3.4 INFLUENCE OF SERINE AND DHA SUPPLEMENTATION 
 
127 
 
2.3.4.1 Effect of growth  
With the relationship between DHA and L-serine being well documented, the 
effect of dual supplementation to L. starkeyi during lag phase was examined. As 
with DHA and serine supplementation, co-supplementation had little effect on the 
timing of growth phase transitions but the culture density was slightly reduced by 
8%. 
 
2.3.4.2 Effect on lipid accruement 
Those cells supplemented with both DHA and serine exhibited an altered number 
of LDs within those cells, which reached stationary phase (Figure 2.4), similar to 
that observed in those cells solely supplemented with serine. The yeast 
paradigm, L. starkeyi, accumulates lipids in a mono-LD; however, co-
supplementation resulted in the formation of several smaller LDs (Figure 2.4).  
The observation of several smaller LDs was also shown in those cells 
supplemented with serine alone.  In addition to the multi-LD occupancy within the 
stationary phased L. starkeyi cells, the size of the L. starkeyi cells were also 
increased by 22% (Figure 2.4).  This like those cells supplemented with DHA, 
either demonstrated an altered phospholipid nomenclature, which results in a 
larger cell due to the affected intrinsic curvature.  However, unlike those cells 
supplemented with DHA or serine solely, the proportion of which the stationary 
phased cells which were taken up by the LDs were unaffected.  This therefore 
suggests that the LDs have either been mobilised for their phospholipids for 
membrane biosynthesis, which would explain the larger cell size. 
 
These LDs function within the L. starkeyi cells is to store the neutral lipids, 
triacylglycerides and sterol esters.  Hence, to see the effect of supplementation 
of both serine and DHA upon de novo lipid synthesis, exponential and stationary 
phased cells were incubated with radiolabelled acetate.             
128 
 
2.3.4.3 Effect on lipid metabolism  
As the effect observed with serine supplementation, dual supplementation to L. 
starkeyi showed an increase in radiolabelled acetate uptake with the transition of 
the oleaginous L. starkeyi from late exponential to stationary phase (Figure 
2.6).  Approximately, 90% of labelled carbon were shown to accumulate in the 
acyl lipid pool whilst the remaining 10% were utilized for isoprenoid synthesis, 
like that demonstrated with serine supplementation alone. Consequently, it may 
be postulated that for every ten acetate molecules converted to acetyl-CoA, one 
of these molecules are used to support acyl lipid synthesis. This feature has yet 
to be shown to be independent of the growth phase, but is the same for incubation 
with serine/DHA from exponential and stationary phases. The biosynthesis of 
phospholipids relative to that of triacylglycerides was interestingly increased 
during stationary phase in comparison to the exponential cells.  This may in part 
be due to the proportion of the cell, which is taken up by the LDs, as it requires a 
mono-phospholipid bilayer. However, as the levels of triacylglyceride and sterol 
esters are relatively unchanged with stationary phase entry from exponential 
phase this is unlikely.  Therefore, the increased proportion of phospholipid to 
triacylglycerides are more likely to be as a result of the mobilisation of the 
phospholipids surrounding the LDs for membrane biosynthesis.  This is further 
evidenced with the increased cell size observed in cells supplemented with both 
serine and DHA during stationary phase in Figure 2.4.   
 
In comparison to those cells supplemented with DHA, those cells supplemented 
with both DHA and serine exhibited an altered upon of radiolabelled uptake.  
Similar to that observed in serine-supplemented cells, those L. starkeyi cells 
supplemented with both DHA/serine had a reduced uptake by half in both 
proliferating and stationary phases (Figure 2.7, C). Furthermore, the ratio of 
triacylglyceride: phospholipid de novo synthesis during stationary phase was 
lower compared to the profile shown in DHA treated cells (Figure 2.8 and 2.9, B).  
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2.4 CONCLUSION  
In conclusion, the results of the study have shown that it is possible to employ a 
yeast model to study phospholipid synthesis using radiolabelled 14C- acetate 
uptake mechanism.  The data further show that DHA and/or serine presence 
within cells can alter metabolic pathways including lipid biosynthesis and lipid 
droplet formation, both are associated with a cancerous phenotype.   
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Chapter 3 
 
 Serine-directed metabolic flux, an 
immunohistochemical study of meningioma 
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3.1 INTRODUCTION 
One of the many key features of cancer is ectopic lipid synthesis, which can be 
modulated by a variety of factors including the amino acid, serine.  This non-
essential amino acid has been implicated to be the orchestrator of the metabolic 
reprogramming observed in many cancerous cells to sustain their growth and 
proliferation (Tsun and Possemato, 2015).  The ability of cancerous cells to 
enable their survival is their ability to generate lipids, nucleic acids and proteins 
(Amelio et al., 2014b).  An overview of the serine biosynthetic pathway observed 
during tumourigenesis is depicted in figure 3.1. 
Figure 3.1:  Diagram showing how glycolysis is diverted during de novo serine 
biosynthesis in cancerous cells to fulfil the cellular demands.  There are several 
enzymatic reactions leading up to serine biosynthesis: 1) 3P pyruvate a glycolytic 
intermediate would be converted to the serine precursory, 3P serine, by PHGDH 
and nicotinamide adenine dinucleotide (NAD). After which 2) a PSTA1 and 3) a 
PSPH reaction converts 3P serine into serine (Adapted from Amelio et al., 
2014a). Legend: 3-phosphoglycerate (3P pyruvate), 3-phosphohydroxypyruvate 
(3P serine), transamination reaction (PSTA1) and phosphate ester hydrolysis 
(PSPH). 
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In cancerous cells the serine biosynthesis, shown in Figure 3.1, is central to the 
metabolic reprogramming which enables the sustained demand for cellular 
nutrients including amino acids, lipids and nucleic acids. Serine acts a precursor 
for such cellular nutrients and hence, the diversion from glycolysis to serine 
biosynthesis provides such sources. The enzyme profile of key enzymes 
surrounding serine biosynthesis within cancerous tissues are tabulated in table 
3.1. 
 
Table 3.1: Table showing key serine-biosynthetic enzymes associated with 
cancer prevalence. 
Enzymes Cancer types References 
PKM2 Solid tumours  (Zhu et al., 2016) 
PHGDH Colorectal and gastric cancer (Jia et al., 2016; Xian et al., 2016) 
p53 Colorectal adenocarcinoma  (Akshatha et al., 2016) 
Legend: pyruvate kinase isoform 2 (PKM2) and phosphoglycerate 
dehydrogenase (PHGDH). 
Studies shown in Table 3.1 examined the key enzymes involved in serine 
biosynthesis.  By doing so, it is possible to show a paralleled relationship between 
the levels of enzyme expression and patient prognosis.  A review by Zhu et al. 
(2016) on the rate-limiting glycolytic enzyme, PKM2, whose activity is vital for 
metabolic reprogramming observed in cancer was found to be correlated with 
patient prognosis.  The review examined 27 studies, with 4,796 cases, from which 
the paralleled relationship between increased PKM2 expression and poor 
prognosis was ascertained.   
 
Another enzyme, which is believed to be involved in the remodelling of cancer 
metabolism is PHGDH and it has been associated with several tumours including 
melanoma and breast cancer. A study by Jia et al. (2016) on colorectal cancer 
found that the expression of PHGDH was related to the individuals prognosis.       
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Hence, current data suggests a correlation between the metabolic 
reprogramming of glycolysis to de novo serine biosynthesis and reduced cancer 
prognosis. Enzymes involved in this metabolic reprogramming have several roles 
and therefore, mutations or altered expressions of these enzymes can result in 
tumourigenesis. Subsequently, research has focused on the possible treatment 
avenues, which may lie within the serine biosynthetic pathway investigating 
whether the effects of the enzymes themselves can be hindered to reduce cellular 
growth and proliferation. A summary of studies which have demonstrated the use 
of enzyme inhibitors in a cancerous model to aid prognosis is shown in table 3.2. 
 
Table 3.2. A summary of possible treatment avenues for altered serine-
biosynthesis via enzyme inhibitors. 
Enzyme Potential treatment References 
PKM2 Compound 3 
Small interfering RNA (siRNA) 156 
(Vander Heiden et 
al., 2010; Goldberg 
and Sharp, 2012) 
PHGDH Allosteric inhibitors  
CBR-5884 
(Wang et al., 2017; 
Mullarky et al., 2016) 
p53 Small molecules such as CP-31398 (Wang and Sun, 
2010) 
  
PKM2 expression in cancerous cells enables aerobic glycolysis and therefore it 
is an ideal target for inhibition for treatment.  Initial studies developing potential 
PKM2 inhibitors by Vander Heiden et al. (2010) and Goldberg and Sharp (2012), 
have shown increased rates of cancerous cell death due to the loss of growth 
signalling and decreased viability.  Furthermore, the PHGDH treatments showed 
specific tumour site action due to the serine metabolic reprogramming not to be 
found in non-cancerous cells (Wang et al., 2017, Mullarky et al., 2016).   Clinically, 
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these findings are promising, as those cancers which show a heightened serine 
biosynthetic profile can also be treated in future with other treatments which will 
reduce chemo-resistance and reduce the availability of such resources to the 
cancer including; lipids, nucleic acids and amino acids.  Therefore, taking into 
consideration previous findings (Chapter 2), this part of the study was designed 
to uncover evidence of whether serine biosynthesis is activated within 
meningioma. 
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3.2 MATERIALS AND METHOD 
 
In this study, the paraffin embedded, formalin fixed tissue blocked of surgical 
specimens were retrospectively evaluated. These contained 16 cases of 
Meningioma, 8 of Grade I and II, from the files of Royal Preston Hospital (RPH).  
All patients had given their consent prior to this study. Clinical data including 
Simpson Grades of sections were also provided from RPH.  Hematoxylin and 
eosin (H&E) slides from the paraffin blocks were reviewed by Pathologists and 
graded per the 2007 WHO Graded system.  See Appendix 3 and appendix 4 for 
the ethical approval and histological characteristics of the meningioma tissue 
sections. 
 
3.2.1 Materials list 
Patient samples from grade I and grade II meningioma (8 patients per grade) 
were used to measure serine biosynthesis.  Enzyme presence was achieved by 
immunohistochemistry. Reagents used for the experiments included:  histoclear, 
ethanol, hydrogen peroxide, methanol, phosphate-buffered saline (PBS), diluted 
blocking serum, primary antibodies (p53, PKM2, PHGDH and fascin), diluted 
biotinylated secondary antibody, VECTASTAIN Elite ABC Reagent, 
diaminobenidine (DAB), peroxidase substrate solution, hematoxylin and eosin. 
 3.3 METHODOLOGY 
3.3.1 Immunohistochemical staining 
Representative blocks of paraffin-embedded tissues were selected and cut at 4-
6µm.  The slides were de-paraffinised in histoclear, rehydrated through an alcohol 
series and subsequently hydrated in tap water for a period of 5 minutes.  After 
treating with 3% hydrogen peroxide (H2O2) in methanol for 10 minutes, sections 
were washed in phosphate-buffered saline (PBS) buffer for 5 minutes followed 
by a 20-minute incubation of diluted normal blocking serum, which was then 
blotted and followed, by a 30-minute incubation of primary antibody diluted in 
PBS buffer.  Primary antibodies used in this study were purchased from Abcam 
and of Anti-rabbit origin.  Based on recommendations from Abcam, the following 
dilutions of antibody (in diluent) were used the study: p53 1:8000, PKM2 1:50, 
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Fascin 1:250 and PHGDH 1:40. After incubation in primary antibody, slides were 
then washed for 5 minutes in PBS buffer and incubated for 30 minutes with diluted 
biotinylated secondary antibody.  After this time, this was rinsed off with PBS and 
further incubated with VECTASTAIN Elite ABC Reagent for a period of 30 
minutes.  The slides were then rinsed again with PBS buffer (5 minutes), then 
incubated with diaminobenidine (DAB) containing peroxidase substrate solution 
(6 minutes) and finally rinsed with tap water.  Slides were then counterstained 
with H&E; then cleared and mounted.  Immunohistochemical evaluation was 
achieved by the utilization of Image J software.  
 
3.3.2 Statistical analysis 
All data were analysed using SPSS programme.  Data were expressed as mean 
± standard deviation (SD).  Test and control data were compared using a one 
way and two way ANOVA, a value of p<0.05 was taken as significant.  Most 
experiments were repeated at least 3 times (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
3.4 RESULTS 
 
Out of the 16 meningiomas, 8 were Grade I and 8 were Grade II.  Regarding 
histological characteristics, the meningioma consisted of microcystic (n=1), 
meningothelial (n=4), transitional (n=2), atypical (n=5), choroid (n=1), benign 
(n=1) and not stated (n=2). In Grade I meningioma samples, there is a 1:7 male 
to female ratio in comparison to Grade II with a 3:5 split.   
 
In the current study, the meningioma tissues were evaluated for the expression 
of several key enzymes involved in the tumourigenic phenotype during metabolic 
reprogramming namely; p53, PKM2, fascin and PHGDH.  The positive expression 
of PKM2 and PHGDH would indicate a metabolic swift from glycolysis to serine 
biosynthesis.  The association of such antibody expressions via IHC evaluation 
was correlated per meningioma grade (I and II) as well as histological variance.  
The expression profiles of each antibody was measured in the 
immunohistochemical study, Figures 3.2 and 3.3 demonstrate the staining of 
such antibodies in the meningioma tissues.  The full photographic visualization of 
all the tumour sections stained are shown in Appendices 5- 20.    
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Figure 3.2:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 1, a grade I meningioma patient (n=1).  Antibodies 
of stained for include; p53 (A), PKM2 (B), Fascin (C) and PHGDH (D).  Incubation with DAB (6 minutes) enables the antibody presence, 
appears brown.  H&E counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies. 
A B 
C D 
X10 magnification X40 magnification 
X10 magnification X40 magnification X10 magnification X40 magnification 
X10 magnification X40 magnification 
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To determine the antibody expressions within meningioma, all patient sets were 
collated indifferent of grade and variance. The expression profile was determined 
using Image J software.  A summary of the results are shown in Figure 3.3.   
 
Hypothesis 
Null Hypothesis: There cannot be a serine-directed metabolic flux profile 
displayed in the meningioma grade I and grade II tissues. 
Hypothesis: There can be a serine-directed metabolic flux profile displayed in the 
meningioma grade I and grade II tissues. 
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A) Meningioma antibody expression profiles of p53, PKM2, fascin and PHGDH. 
  
B) Meningioma cellular abundance of p53, PKM2 and fascin PHGDH.
 
C) Meningioma antibody expression profile of p53, PKM2 and fascin PHGDH.
 
Figure 3.3:  Bar charts showing a summary of the immunohistochemistry 
antibody expression profiles in the meningioma tissues using light microscopy 
(x40 magnification).  Expression profiles shown for: positive expression (A), 
abundance of positivity within the cellular bodies (B) and the intensity of the 
cellular body positive expression (C). All data are mean ± SD, n=16; an ANOVA 
statistical analysis compared enzyme expressions within the meningioma tissue 
sections; p<0.05 showed significance.  Legend: fluorescent unit (FU). 
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The immunohistochemistry profiles shown in Figure 3.3 of the meningioma 
sections demonstrate the positive presence of all the enzymes examined 
including p53, PKM2, fascin and PHGDH.  To establish whether meningioma 
tissue sections can be classified further using expression profiles surrounding 
serine biosynthesis, a methodological optimization using Image J software was 
carried out. Firstly, the positive stain intensity of the tissue sections was viewed 
and subsequently examined at x40 magnification using the Image J software 
(Figure 3.3, A).  By doing so, an area of the tissue section was analyzed positive 
staining of p53, PKM2, fascin and PHGDH by using the software.  A one-way 
ANOVA between the antibody groups was conducted to compare their staining 
intensity within all the meningioma patients, irrespective of grade.  However, there 
was no significant effect between the antibodies examined, F= (3, 50) = 0.7349, 
p = 0.5362.   
   
To gain a better insight and understanding into staining location within the 
meningioma tissue sections, they were then examined for the abundance of 
antibody presence within cellular bodies (Figure 3.3, B).  A one-way ANOVA 
analysis was carried out to compare if the positive cellular abundance was 
antibody specific.  The statistical test showed a significant difference between the 
antibodies measured and their cellular abundance, F = (3, 50) = 7.450, p = 
0.0003. Specifically, between the high abundance of PKM2 (p<0.01) and PHGDH 
(p<0.001) compared to that of p53 within the cellular bodies.   
 
By using the Image J software, these cellular bodies were then examined for their 
staining intensity of the antibodies examined.  However, as shown in Figure 3.3 
(C), there was not a significant difference between the intensity of the antibody 
profile within the cellular bodies of the meningioma tissue sections, F= (3, 50) = 
1.979, p = 1.291.   
 
To gain a better insight into whether the de novo serine biosynthesis via glycolysis 
diversion is altered in meningioma, the antibody profiles previously collated 
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together in Figure 3.3 have been examined per grade of meningioma and 
summarized in Figure 3.4 (A-C).   
 
Hypothesis 
Null Hypothesis: There cannot be a serine-directed metabolic flux profile 
displayed in meningioma grade I tissues and meningioma grade II tissues. 
Hypothesis: There can be a serine-directed metabolic flux profile in both 
meningioma grade I tissues and meningioma grade II tissues. 
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A) Meningioma antibody expression profile of p53, PKM2, fascin and PHGDH.  
 
B) Meningioma antibody expression profile, on both x10 and x40 magnifications, 
examining p53, PKM2, fascin and PHGDH.  
 
C) Meningioma antibody expression profile, on both x10 and x40 magnifications, 
examining p53, PKM2, fascin and PHGDH.  
Figure 3.4:  Bar charts showing a comparison of the immunohistochemistry 
antibody expression profiles of meningioma grade I and II tissues.  Expression 
profiles shown for: positive expression (A), abundance of positivity within the 
cellular bodies (B) and the intensity of the cellular body positive expression (C). 
All data are mean ± SD, n=8; an ANOVA statistical analysis compared the control 
with supplemented cultures; p<0.05 showed significance. Legend: fluorescent 
unit (FU). 
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To establish whether meningioma tissue sections of differing grades can be 
classified further using expression profiles surrounding serine biosynthesis, 
sections were analysed per grade (Figure 3.4). Firstly, the positive stain intensity 
of meningioma grade I and II tissue sections were viewed and subsequently 
examined at x40 magnification using the Image J software (Figure 3.4, A).  A two-
way ANOVA between the antibody groups was conducted in comparison to 
meningioma grade, however, there was no significant (p> 0.05) effect between 
these groups.   
   
To gain insight into the staining location within grade I and II meningioma tissue 
sections, samples were then examined for their antibody abundance within 
cellular bodies (Figure 3.4, B).  A two-way ANOVA analysis was carried out to 
compare if the positive cellular abundance was antibody and grade specific.  The 
statistical test showed a significant difference between the grade of meningioma 
and the cellular abundance of antibodies measured; F = (7, 46) = 4.573, p = 
0.0006.  There was a significant increase in the abundance of PKM2 (p<0.05) in 
comparison to p53 in grade I meningioma tissue sections.  Whereas, in grade II 
meningioma tissue sections, there was a significant increase between the 
abundance of cellular body abundance of PHGDH staining compared to PKM2 
(p<0.05).  
 
By using the Image J software these cellular bodies were then examined for their 
staining intensity of the antibodies examined.  However, as shown in Figure 3.4 
(C), there was not a significant difference (p> 0.05) between the intensity of the 
antibody profile within the cellular bodies of grade I and II meningioma tissue 
sections.  From the data displayed in Figure 3.4, the null hypothesis can be 
rejected and the alternative hypothesis accepted. To examine if there is a 
correlation between meningioma histological grade and glycolytic diversion to 
support de novo serine biosynthesis, the enzyme profiles of p53, PKM2, fascin 
and PHGDH were collated and summarized in Figure 3.5. 
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Hypothesis 
Hypothesis: There can be different serine-directed metabolic flux profiles 
displayed in the various histological meningioma variants. 
Null Hypothesis: There cannot be different serine-directed metabolic flux profiles 
displayed in the various histological meningioma variants.
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Figure 3.5:  Bar charts showing a comparison of the immunohistochemistry antibody expression profiles of meningioma tissues of various 
histological variance namely; microcystic (n=1), meningiothelial (n=4), transitional (n=2), atypical (n=5), benign (n=1) and choroid (1).  
Expression profiles shown for the abundance of positivity within the cellular bodies.  All data are mean ± SD an ANOVA statistical analysis 
compared the expressions of p53, PKM2, PHGDH and fascin; p<0.05 showed significance.  
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From the 16 meningioma tissues examined, the histological variants included 
microcystic (n=1), meningothelial (n=4), transitional (n=2), atypical (n=5), choroid 
(n=1), benign (n=1) and not stated (n=2). Figure 3.5 summarizes the 
immunohistochemical profile of p53, PKM2, fascin and PHGDH across these 
meningioma variants in grade I and grade II meningioma.  The expression of p53 
was shown in all of the meningioma variants apart from patients 99, 286 and 395 
which were of varying histological variance; meningothelial, choroid and atypical.   
 
From Figure 3.5, an immunohistochemistry profile specific to meningioma 
variants are demonstrated.  For example, the expression profiles of microcystic, 
meningothelial, transitional and choroid meningioma variants show the same 
overall trend in the abundance of positivity; increased PKM2 and PHGDH 
compared to that of p53 and fascin expression.  However, in the atypical and 
benign variants of meningioma, the relationship between the antibodies are 
different to the other histological variants displayed.       
 
Taking a closer look at the expression profiles displayed in Figure 3.5, there is a 
strong positive correlation shown between the expressions of PKM2 and PHGDH 
in the following meningioma variants; microcystic, meningiothelial, transitional 
and choroid.  Interestingly, benign and atypical meningioma variants 
demonstrated a reduction in PKM2 expression compared to the other variants 
examined.   
  
In order to establish whether meningioma tissue sections of differing histological 
variance can be classified further using expression profiles surrounding serine 
biosynthesis, a two-way ANOVA test between the antibody groups was 
conducted in comparison to the histological variant. However, due to the sample 
set, only a statistical analyse between atypical and meningiothelial meningioma 
tissue sections were carried out. The two-way ANOVA analysis showed a 
significant difference between the histological variant of meningioma and the 
cellular abundance of antibodies measured; F = (5, 23) = 3.515, p = 0.0266.  
There was a significant increase in the abundance of PKM2 (p<0.05) within 
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meningiothelial tissue sections as opposed to PKM2 within atypical. From the 
data displayed in Figure 3.5, the null hypothesis can be rejected and the 
alternative hypothesis accepted.   
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3.5 DISCUSSION  
 
Metabolic reprogramming is a recognized hallmark in tumourigenesis (Hanahan 
and Weinberg, 2011).  The ability of a cell to produce lipids, nucleic acids and 
proteins is thought to be the limiting factor in the ability of cancerous cells to 
proliferate.  Despite the numerous studies of the fundamental hallmark of 
metabolic reprogramming in tumours, such metabolic alterations have not yet 
been confirmed in meningioma.  Since PHGDH diverts glycolysis to produce 
serine via the de novo serine biosynthetic pathway, it may act as an initiator of 
serine production in meningioma tumours.  Serine biosynthesis in tumours is 
essential for the production of lipids, secondary messengers and proteins; aiding 
cellular survival (Amelio et al., 2014b).  The expressions of several key enzymes 
involved in tumourigenesis and serine biosynthesis namely, PKM2, p53, fascin 
as well as PHGDH were determined in meningioma grade I and grade II tissues 
to see if there was a histological correlation with histological grade and/or variant.   
 
In this Immunohistochemical study, the expression of PHGDH was high in 
meningioma and indifferent of grade and variant examined (Figures 3.2-3.5).  The 
meningioma patients with the highest PHGDH expression tended to have grade 
I (Figure 3.4).  Moreover, this study demonstrated that the high levels of PHGDH 
were associated with the positive expression of PKM2, fascin and p53 in tissue 
matched meningioma sections (Figure 3.2-3.5).  Additionally, there was a positive 
correlation between the PHGDH and PKM2 expression profiles; indifferent of 
grade and variant type. 
 
3.5.1 Diversion of glycolysis to serine biosynthesis 
Several studies have associated the levels of PHGDH expression found in 
tumours with the promotion of serine biosynthesis (Possemato et al., 2011; 
Locasale et al., 2011).  A recent study by Liu et al. (2015) using isotope labelling 
provided an insight into the influence PHGDH upon colorectal cancer in terms of 
cellular metabolic flux from glycolysis towards serine biosynthesis.  Hence, 
demonstrating the importance of PHGDH within cancerous cells for serine 
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biosynthesis.  Within meningioma, PHGDH expression was found within grade I 
and grade II tissue sections; 75% and 82%, respectively (Figure 3.4).   
 
3.5.2 Tumourigenesis aided by heightened PHGDH expression 
The positive expression of PHGDH in grade I and II meningioma, might not only 
be linked with just de novo serine biosynthesis since other studies have 
implicated PHGDH expression with several other cancerous attributes.  In a study 
by Liu et al. (2015), there was a paralleled relationship between the cancerous 
cell protein levels and PHGDH expression.  Furthermore, there have been 
positive correlations between those breast cancers, which are ER-negative 
displaying heightened PHGDH expression.  There have also been studies 
showing the association of malignant transformation in those tumours with 
PHGDH expression, due to the maintenance of an anchorage-dependent fashion 
of their proliferation Liu et al. (2015).  Therefore, the positive expression observed 
in the grade I and II meningioma tissue sections may also be associated with 
other tumourigenic factors including protein synthesis, endoplasmic reticulum 
status of the tumour and an indicator of malignant transformation.  This may be 
an indicator of tumour transformation in the grade I meningioma tissues which 
showed an increased PHGDH expression compared to grade II (Figure 3.4). 
 
3.5.3 Relationship between glycolysis and serine biosynthesis 
The diversion of glycolytic intermediates into the de novo serine biosynthesis 
pathway via PHGDH has been displayed in this study (Figures 3.2-3.5).  To fully 
appreciate the relationship of the diversion from glycolysis to serine production, 
the glycolytic flux was also examined via the expression of PKM2.   In this 
Immunohistochemical study, the positive expression of PKM2 was shown in 
100% of the meningioma tissue sections examined varying from 7% positive 
presence to 92% presence.  From Figure 3.4 the expression of PKM2 was shown 
to be indicative of grade and an indicator of histological variance (Figure 3.4).  
The meningioma patients with the highest PKM2 expression tended to have 
meningioma grade I (Figure 3.5).  The comparison of PKM2 expression and 
histological variant demonstrated the meningiothelial, transitional and choroid 
tissues to contain over 70% positivity over the tissue section compared with 
151 
 
atypical meningiomas which only displayed 20% tissue section positivity for 
PKM2 (Figure 3.4).  Moreover, this study demonstrated a paralleled relationship 
between PKM2 and PHGDH expression in the meningioma tissues specifically; 
meningiothelial, transitional and choroid variants (Figure 3.5).  These data 
suggest a possible synergistic relationship between glycolytic flux and de novo 
serine biosynthesis within these meningioma tissues.   
 
3.5.4 Relationship between glycolytic flux and de novo serine biosynthesis 
One avenue, which might explain the increased expression of PKM2 in the 
meningioma tissues examined, may be due to their proliferating cancerous 
nature.  Studies have shown that the M2 isoform of pyruvate kinase is expressed 
in proliferating cells (Dong et al., 2016).  It is thought that this switch to the M2 
isoform from the M1 pyruvate kinase isoform is initiated during transformation.  
Therefore, alongside the PHGDH expression demonstrated in the meningioma 
tissues, the heightened PKM2 presence may also be indicative of tumour 
transformation.   
 
The switch between the pyruvate kinase isoforms can affect the rate of enzymatic 
activity in glycolysis.  For example, the M2 isoform has a lower conversion rate 
of phosphoenolpyruvic acid (PEP) to pyruvate compared to the M1 isoform.  
Hence, it can be postulated that in PKM2 positive meningioma, tissues have a 
reduced conversion rate of PEP to pyruvate.  Because of the reduced flux to 
pyruvate, glycolytic intermediates may build-up as shown in Figure 3.1.  From 
other studies, it has been shown that these intermediates are diverted into other 
pathways including the pentose phosphate pathway (PPP) and serine 
biosynthesis.  Therefore, the observation of positive correlations of PKM2 and 
PHGDH expressions in the meningiothelial, transitional and choroid meningioma 
variants may be indicative to the build-up of glycolytic intermediates because of 
the switch to the M2 pyruvate kinase isoform.  The expression of PKM2 rather 
than PKM1 may then lead to the diversion of glycolytic intermediates into the de 
novo serine biosynthesis pathway, which is enabled by the rate-limiting enzyme 
PHGDH for which the meningioma tissues have shown positive expression.    
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3.5.5 Serine presence alone can regulate PKM2 activity 
Another avenue to consider is the ability of serine presence alone to allosterically 
regulate PKM2 activity (Chaneton et al., 2012).  Such studies have shown that 
with serine availability, PKM2 activity is facilitated, whereas during states of 
serine depletion, PKM2 activity is reduced.  This mechanism of allosteric 
regulation therefore suggests that the meningioma tissues could contain high 
levels of the non-essential amino acid which in turn enables aerobic glycolysis 
and lactate production, both of which are vital for cell growth and survival.  It has 
also been shown that the nutrient status of the cell, including that of serine, can 
affect tumour suppressors, including p53.   
 
3.5.6 p53 response to serine 
Studies are highlighting the implication of tumour suppressors regulating cellular 
metabolism, therefore p53 expression was examined across the meningioma 
grade I and grade II tissue sections.  Alongside its role as a tumour suppressor, 
p53 has been implicated in several cellular processes, which occur in both non-
cancerous and cancerous cells including stress responses associated with 
hypoxic conditions and DNA damage (Pflaum et al., 2014).  Furthermore, studies 
have associated the cellular status of serine cellular to the activation of the 
cellular stress response, which is aided by p53.  In one study, p53 was shown to 
respond to serine starvation by enabling the cellular antioxidant capacity 
therefore aiding cellular viability and proliferation (Maddocks et al., 2013). 
 
In this study, p53 expression was found to be indicative of meningioma 
histological variance, especially between meningiothelial, transitional and choroid 
variants that displayed positivity of 33%, 49% and 14%, respectively (Figure 3.5).  
This therefore suggests, in terms of serine status, that meningioma tissues have 
metabolically adapted to counteract reactive oxygen species produced under 
such metabolic stress as serine depletion. The notion of cancerous cells 
protecting themselves from such metabolic stress fits in with observations of the 
Warburg effect, which would avoid metabolic reactive oxygen species (ROS) from 
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being produced. Therefore, with the presence of p53 in 80% of the meningioma 
tissues examined, it would appear that the implication of tumour suppressor 
involvement with metabolic stress due to serine depletion may be indicated as 
the non-essential amino acid plays an important role in cellular processes within 
these tissues. To assess the proliferative nature as well as nutrient supply into 
the tumour, the enzyme expression profiles of fascin were undertaken in the 
meningioma tissues. 
 
3.5.7 Promotion of angiogenesis aids serine supplies 
Meningioma by nature is a tumour with good blood supply. To gather the 
proliferative nature of the tumour in addition to its exposure to a blood supply 
would provide insight into the cellular status and nutrient availability.  Fascin 
expression has been previously shown to promote cancer progression in breast 
and pancreatic cancer (Xing et al., 2011; Li et al., 2014a).  The expression of 
fascin within meningioma was indicative of the histological variance of the tissue; 
especially between the transition, meningiothelial and choroid variants (Figure 
3.2-3.5). Hence, fascin expression may be used as an indicative marker of 
meningioma histological variance, which in turn, related to the tumours 
progression.  
 
3.6 CONCLUSION 
 
In conclusion, the result of this chapter of the thesis has clearly demonstrated the 
presence of enzymes involved in the diversion of glycolysis to serine 
biosynthesis.  
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Chapter 4 
 
Preliminary study into the effect of tumour-
derived liposomes upon cellular viability 
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4.1 INTRODUCTION  
 
One highly researched area of drug-delivery now surrounds the blood-brain 
barrier (BBB). As previously, discussed in Chapter 1, the blood-brain barrier is 
tightly regulated in the body ensuring that the conditions for optimum neuronal 
function are maintained in the brain.  However, in brain pathologies, including that 
of Alzheimer’s disease, the BBB is observed to be dysfunctional (Chakraborty et 
al., 2017; Zenaro et al., 2016).  The dysfunctional BBB observed in Alzheimer’s 
disease leads to the entry of substances, which were previously prevented 
access.  Due to the observed increase of undesirable substances crossing the 
BBB, non-optimum conditions for neuronal functions are met. Because of the 
dysfunctional control of substances crossing the BBB, inflammatory responses 
are activated which lead to neuronal damage.  
 
The inaccessibility of drug-delivery into the brain, via the blood brain barrier, has 
somewhat hindered therapeutic advances.  To overcome such inaccessibility to 
the brain, research has focused on novel treatment avenues with the aim of 
crossing the BBB.  This idea of specific drug-delivery was described as far back 
as the 1900s by Paul Ehrlich (Tavano and Muzzalupo, 2016).  Since then, several 
studies have used an array of therapeutic delivery models however, due to their 
rapid clearance and toxicity these therapeutic avenues were without success 
(Spencer and Verma, 2007; Banks, 2009).  Subsequently, a new delivery models 
that can cross the BBB are still sought.  One potential avenue is the utilization of 
lipids, specifically that of phospholipids, which have several appealing 
characteristics for the foundation of a drug-delivery model. 
 
4.1.1 Drug-delivery system: model concepts   
The design and production of an efficient therapeutic delivery system is based on 
the foundations that the drug-delivery system can do the following by: 1) increase 
drug bioavailability; 2) control and maintain the delivery to the site of action and 
3) avoid non-diseased tissues (Sun et al., 2017).    Several carrier systems 
currently researched include the utilization of phospholipids. One of the desirable 
156 
 
traits of phospholipids is their biocompatibility in the mammalian system making 
them an ideal drug-delivery system (Isaac et al., 2006; Yamashita et al., 2014).   
 
4.1.2 Liposomes 
In 1965, Alec Bangham described the use of phospholipids in a drug-delivery 
system referring to them as  liposomes (Deamer, 2010).  The advantage of using 
phospholipids in a drug-delivery model is that the mammalian biological 
membranes mainly consist of phospholipids. Liposomes are structurally like 
biological membranes as they are comprised of phospholipids in either a mono- 
or bilayer arrangement. One of the main advantages of using phospholipids in a 
drug-delivery system is their amphiphilic nature in aqueous environments, 
resulting in the formation of spherical shells.   The desired drug can then be 
carried either within the spherical shells’ aqueous core and/or within the 
phospholipid layer itself (Calandra et al. 2015).     
 
The liposome drug-delivery model has demonstrated several positive attributes 
they include: (a) prolonged blood circulation therefore drug bioavailability to the 
specific site of action, (b) tumour site accumulation observed aiding specific drug-
delivery to cancerous cell, (c) ligands enable site-specific recognition to the 
cancerous cells’ surface providing a therapeutic dose of the drug and, (d) the 
ability of the liposomes to entry the cancerous cells via peptide channels enables 
drug-delivery. 
 
4.1.3 Liposomes as an anti-tumour therapy  
During disease states, both the size of the pores and the permeability of the 
blood-brain barrier are observed to be increased in line with enhanced 
vasculature permeability (Azzi et al., 2013).  The increased permeability has been 
postulated to be related to the angiogenic switch in many solid tumours, including 
that of glioma (Ribatti, 2014; Xu et al., 2016).  As a result of this increased 
permeability, the observed range of pore size diameter are increased to ranges 
between 100- 780 nm in solid tumours (Wang et al., 2011).  Studies using drug-
encapsulated liposomes of a diameter ranging between 60- 500 nm have shown 
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an accumulation of these liposomes at the tumour site (Bozzuto and Molinari, 
2015).  Subsequently, the drug is delivered to the tumour cells more specifically 
aided their effectiveness.   
 
Once the liposome has reached the site of action, it then has to interact with the 
cell to release the drug for the end result i.e. anti-proliferative effect.  There are 
several ways a drug-encapsulated liposome can bind onto the cell surface they 
include receptors activation, electrostatic interaction, incorporation of the drugs 
via endocytosis and, incorporation of the liposomal membrane into the cellular 
membrane facilitating the drug into the cell. The ability of the drug in the liposome 
to interact with the cell is because of the presence of lipases, which degrade the 
membrane of the liposomes allowing the release of the drug into the extracellular 
fluid.  In this way, not only does it prevent clumping of cells due to the repulsion 
of cellular charge and drugs, but also the uptake of the drug via receptors into the 
cells (Bozzuto and Molinari, 2015).   
 
4.1.4 Other applications  
The amphiphilic nature of phospholipids has also given rise to other model 
systems including the use of blood cells specifically; erythrocytes as a potential 
drug-delivery carrier system.  Generally, blood cells have several appealing 
advantages as a model drug-delivery system these include; long circulation, 
natural adhesion and targeted release.  However, even taking these advantages 
on board, the storage and mass production required of such blood cells would 
potentially hinder such a concept.  Many studies have used blood cells to 
investigate the potential use of these as a drug-delivery system (see Sun et al. 
2017 for a detailed review).  By using the amphiphilic nature of the phospholipids, 
a variety of drug classes have been encapsulated into these erythrocyte-based 
carriers including, but not restricted to; anti-cancer agents, anti-inflammatory 
agents, anti-infective agents, cardiovascular agents and immunosuppressive 
agents (Jin and Jiang, 2002; Staedtke et al., 2010; Alanazi et al., 2011; Harisa et 
al., 2012; Biagiotti et al., 2011).   
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The utilization of erythrocytes has also been expedited more recently in other 
research avenues.  A review by McNeil and Steinhardt (2003) described the 
ability of the erythrocyte membrane to re-form.  Researchers use this ability of 
the erythrocyte membrane to, repair after disruption (haemolysis) to produce 
ghost cells.  After which, these ghost cells can be adapted to act as a circulatory 
‘sponge’ absorbing specific pore-forming toxins from the circulation.  These are 
now known as nanosponges (Hu et al., 2013).  One study by Chhabria and 
Beeton (2016) employed this concept using ovine erythrocytes as a model 
system which would absorb the pore-forming toxin, streptolysin-O, which is 
observed in individuals suffering from sepsis.   
 
Therefore, with such combinations, there are potential phospholipid-based drug-
delivery systems exist, with varying combinations of head group and molecular 
species (saturated and unsaturated).  Therefore, the characteristic of the 
liposomes produced can reflect the properties of the phospholipids themselves 
(Calandra et al. 2015).  Furthermore, phospholipids used in formulations can 
either be gathered from natural or synthetic sources from a research perspective, 
naturally sourced phospholipids are lower in cost.  Due to the desirable 
characteristics phosphatidylcholine possess, many carrier systems use this as 
their structural foundation (Li et al., 2015).      
 
Over the past few years, the focus of cancer therapy research has aimed to 
minimize the associated side effects of anti-tumour drugs i.e. chemotherapy 
alongside increasing its’ clinical therapeutic index.  Due to chemotherapies focus 
on high proliferating cells, a low specificity to the tumour site is often observed.  
Subsequently, higher chemotherapy doses are required across multiple sessions 
leading to multiple adverse side effects.  Therefore, a more specific drug-delivery 
system, a magic bullet, to the designated tumour site has been sought.  In this 
study therefore the aim was to investigate whether the lipid profile of a cell can 
support its cellular viability as per shown in cancerous cells. 
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4.2 MATERIALS AND METHODOLOGY 
 
4.2.1 Materials 
Cells used in this part of the study include U87-MG and SVGp12.  Media used 
for cell line maintenance and growth curve initiation was Eagle's Minimum 
Essential Medium (EMEM) (Lonza).  Additional supplementations as per cell line, 
as recommended by ECACC and ATCC comprised of; Fetal Bovine Serum (FBS) 
(10%, w/v), L-glutamine (2 mM), sodium pyruvate (1 mM) and non-essential 
amino acids (1%, w/v).    The basal EMEM was stored at 4oC and replaced every 
3 months.  Other constituents include PBS and trypsin.  See Appendices 3 and 4 
for the ethical approval and histological characteristics of the meningioma tissue 
sections.  
 
4.3 METHODOLOGY 
4.3.1 Cell line: Description  
The effect of exogenous lipids of varying type and origin upon viability was 
determined via the utilization of U87-MG and SVGp12 commercial cell lines 
namely; human glioblastoma astrocytoma epithelial grade IV and human non-
tumourigenic, respectively.  U87-MG cells are fibroblastic-like cells, which are 
bipolar in morphology; elongated and bipolar in shape.  Contrary to SVGp12, an 
epithelial-like cell line that is polygonal in morphology.  Both were purchased from 
ECACC and ATCC (UK) with no evidence of infectious viruses present.  
Cryopreservation of both, are aliquoted and stored in the protective agent, 
DMSO, in liquid nitrogen; allowing for continual cultured cells to be maintained.     
 
4.3.2 Culture environment   
Physiological and physiochemical environment for U87-MG and SVGp12 cell 
propagation during these studies included EMEM pH of 7.4 with incubator 
conditions of 37oC and 5% carbon dioxide in air.   As both were anchorage-
dependent, sub-culturing for growth curves etc. was performed using solid 
surfaces i.e. T75 flasks etc.      
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4.3.3 Thawing frozen cells  
The frozen aliquots of both U87-MG and SVGp12 cell lines were thawed in a pre-
warmed water bath (37oC) and placed in a T75 flask with EMEM (37oC).  After 24 
hours the media were renewed and DMSO was removed from the 
cryopreservation media.      
 
4.3.4 Sub-culturing  
Sub-culturing aided the space provided in the solid surface, in order to allow 
adequate nutrient uptake for proliferation.  Passaging was performed for both cell 
lines during log-phase growth.  EMEM was removed such that the monolayer of 
cells could be washed with PBS solution (37oC).  Cells were then exposed to 
trypsin (x1, 37oC) and kept in the incubator (37oC and 5% carbon dioxide in air) 
for 2-3 minutes.  Cellular de-attachment quantity was then visualized under the 
light microscope (magnification, x40) before the neutralization step of EMEM was 
initiated (2:1 EMEM to x1 trypsin-EDTA).  The cells were then divided (i.e. 1 in 4) 
into fresh EMEM media (37oC) and kept in the 37oC and 5% carbon dioxide in air 
incubator in order to generate growth curves (Figure 4.1). 
 
    
Figure 4.1: Time course graph showing the growth curves of SVG and U87 cell 
line.  Culture conditions: cells were kept in a 37oC and 5% carbon dioxide in air 
incubator.  All data are mean ± SD, n=3. 
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4.3.5 Cell quantification   
Cellular quantification of both cell lines were performed in a 1 in 2 dilution of a 
subculture sample with Trypan Blue.  Cells were counted and visualized under a 
light microscope with a haemocytometer.         
 
4.3.6 Growth curve determination   
The U87-MG and SVGp12 cell line growth profile was performed over a 5-day 
period in a 96 well plate kept in an incubator (37oC and 5% carbon dioxide in air); 
rate of growth determination.  Cells were seeded using (cells/per well); 500, 1000, 
2000, 2500, 5000 and 10,000 over this period of time examining affect seeding 
density on growth to determine optimum.  Per 24 hours, cell viability was 
performed via PrestoBlue assay (see following section).   
 
4.3.7 PrestoBlue: Cell Viability Assay   
PrestoBlue Cell Viability Reagent (Thermo Fisher Scientific) was used in the 
growth profile determination of U87-MG and SVGp12.  Varied seeding densities 
over the 5-day period, as described above was examined to take into 
consideration the linearity of such an assay in addition to the cell line growth 
profile.  As recommended by Molecular probes by life technologies, each 90 µl 
well which contained EMEM and cells of a particular seeding density was 
incubated with PrestoBlue (10 µl) for 10 minutes in an incubator (37oC and 5% 
carbon dioxide in air).  After which, the 96 well plate was bottom-read for 
fluorescence (535 nm excitation and 612 nm emission).           
 
4.3.8 Tissue lipid extraction  
In order to determine the effects upon cellular viability of SVG and U87 cell lines, 
lipid extractions were performed with various meningioma and glioma tissue of 
various grade and histological variance (see Appendix 3).  The mammalian tissue 
(75 mg) was reconstituted in pre-heated methanol (70oC) for a period of 30 
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minutes.  After cooling to room temperature, the extract was added to chloroform 
(4 ml) and 20% sodium chloride (2 ml, w/v).  The overall mixture was then 
vortexed three times and left to stand until two phases formed. The bottom phase 
was kept and aliquoted into a new vial, which was then blown down under 
nitrogen gas (40oC) to achieve complete dryness.   After which, the lipid film was 
then reconstituted in 1 ml bovine serum albumin (BSA) buffer (pH 7.4) where the 
liposomal preparation continued.  
 
4.3.9 Liposomal preparation 
After the reconstitution of the sample in BSA buffer (pH 7.4, 1 ml), the sample 
was subjected to sonication (37oC) and freezing cycles over a period of 90 
minutes.  To make sure the vesicles were uniform in size, they were then serially 
extruded through a 400 nm to a 100 nm polycarbonate membrane.   
 
4.3.10 Statistical analysis 
All data were analysed using SPSS programme.  Data were expressed as mean 
± standard deviation (SD).  Test and control data were compared using a one 
way and two way ANOVA, a value of p<0.05 was taken as significant.  Most 
experiments were repeated at least 3 times (n=3). 
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4.4 RESULTS 
 
To establish whether the tumours lipid composition effects its viability and 
therefore drug resistance and disease progression, the effect upon U87 and SVG 
cellular viability was ascertained with various tumour-derived and PC: PS 
liposomes being supplemented during log-phase growth.  Hence, in order to 
determine the effect upon cellular viability the PrestoBlue cellular viability reagent 
was utilised.  A depiction of the effect upon U87 and SVG cellular viability with 
various tumour-derived liposomal supplementations after 12-hours incubation are 
shown in Figure 4.2.   
 
Hypothesis 
Null hypothesis: There is no relationship between cellular viability of U87 and 
SVG cell lines supplemented with tumour-derived liposomes. 
Alternative hypothesis: There is a relationship between cellular viability of U87 
and SVG cell lines supplemented with tumour-derived liposomes. 
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Figure 4.2:  Bar chart showing the utilization of a cultured SVG and U87 model system to examine the effect tumour derived lipids upon 
cellular viability.  Tumour derived lipids (from patients 118, 145, 154, 143, 392 and 198) were made into liposomes and supplemented to 
SVG and U87 cells during log-phase. After 12 hours of liposomal supplementation, PrestoBlue reagent enabled the effect of the tumour-
derived liposomal supplementation upon SVG and U87 cellular viability.  Culture conditions: cells were kept in a 37oC and 5% carbon 
dioxide in an air incubator.  All data are mean ± SD an ANOVA statistical analysis compared the control cell line (SVG) to the cancerous 
cell line (U87); p<0.05 showed significance. 
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From figure 4.2, the effect upon cellular viability with the supplementation of 
tumour-derived liposomes displayed a significant effect on the U87 and SVG cell 
line depending on the originating patient sample; ANOVA statistical test; F (11, 
3) = 173.83, p <0.001. From Figure 4.2, 5 out of the 6 liposomal preparations 
showed a significant increase in the viability of the log-phased U87 cells 
(p<0.001) compared to the control cell line, SVG. The liposomal preparation 
which significantly enhanced the cellular viability of the SVG cell line by a third 
(p<0.001) as opposed to the SVG cell line, originated from a meningioma grade 
I patient (145).   
 
From previous research by Hill (2011), it was observed that meningioma grade II 
had an increased abundance of PS with enriched DHA. To examine the effect of 
PS upon cellular viability, a range of PC: PS liposomes were prepared and 
supplemented in the log-phased U87 and SVG cultures. The results of the affect 
PC: PS derived liposomes upon log-phased SVG and U87 cellular viability is 
shown in Figure 4.3. 
 
Hypothesis: 
Null Hypothesis:  There would be no difference in U87 and SVG cellular viability 
with various PC: PS-derived liposomal supplementations. 
Alternative Hypothesis:   There would be a difference in U87 and SVG cellular 
viability with various PC: PS -derived liposomal supplementations.   
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Figure 4.3:  Bar chart showing the utilization of a cultured SVG and U87 model system to examine the effect of log-phase supplementation 
of PC:PS liposomes of various concentrations upon cellular viability. PrestoBlue reagent enabled the effect of the liposomal 
supplementation upon SVG and U87 viability to be determined, after the 12 hours of liposomal supplementation.  Culture conditions: 
cells were kept in a 37oC and 5% carbon dioxide in air incubator.  All data are mean ± SD an ANOVA statistical analysis compared the 
control cell line (SVG) to the cancerous cell line (U87); p<0.05 showed significance. 
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From figure 4.3, the effect upon cellular viability was aided by the liposomal 
supplementation of various PC and PS content. The repeated measures ANOVA 
determined that the cellular viability was significantly affected by the liposomal 
preparation which was supplemented to the cell lines; F (11, 3) = 576.39, p 
<0.001.  As shown in Figure 4.3, as the ratio of PS in the liposomal preparation 
increases, the greater the increase in SVG viability during log phase (p<0.001).  
The cellular viability of the SVG cell line, increased as the proportion of PS within 
the liposomal preparation increased (p<0.001).   
 
Overall, the results show how the cellular viability can be affected with liposomal 
supplementation. Interestingly, the tumour-derived liposomes positively affected 
the cellular viability greater in the SVG and U87 cell lines, compared to the 
manufactured PC: PS liposomes.    
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4.5 DISCUSSION 
 
In order to gain an insight and an understanding into the potential affect an altered 
membrane composition may give cancerous and non-cancerous cells in terms of 
cellular viability; liposomes of various origin were prepared.  The scientific 
reasoning behind this has been shown in previous research by Sleight and 
Pagano (1985) whereby lipid-rich media led to an altered cellular lipid 
biochemistry, suggesting that the membrane composition may be transformed.  
 
4.5.1 Liposomal preparation and supplementation 
There were several parameters to consider during this preliminary study 
including: the particle size, particle shape and surface charge which can all affect 
the liposomal interaction with the cell surface of the U87 and SVG cells.  Due to 
the amphiphilic nature of phospholipids they produce differing liposomal shapes 
when they are comprised of particular lipids; cylinder (PS/PC), cone (PE/ 
cholesterol) and inverted cone (sphingomyelin) (Peetla et al., 2013).  The various 
liposomal shapes are due to the differing phospholipid head size and tail present 
in the membrane.  To enable liposomal uniformity, a method of serial extrusion 
from a 400 nm to a 100 nm polycarbonate membrane was implemented.  As a 
result, the stability of particle size was maintained at 37oC during the study.  This 
is of benefit, as studies have shown that liposomal phospholipids can be 
incorporated into the nuclear membrane, mitochondria and the golgi apparatus 
at 37oC using a fluorescence probe (Sleight and Pagano, 1985). 
 
Membrane biosynthesis in cancer cells is upregulated as a result of the increased 
rate of fatty acid biosynthesis (Currie et al., 2013).  The upregulation of fatty acid 
biosynthesis enables the cancerous cell to proliferative at a faster rate (Rashid et 
al., 1997).  Studies by Spector et al. (1980) demonstrated how mammalian cells 
in culture have the capacity to uptake lipids from the culture medium which in turn 
was observed to alter the lipid biochemistry of the cell.   Hence, in this preliminary 
study, liposomes were supplemented during the log phase of the SVG and U87 
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cellular growth where the chances of uptake by the nutrient-demanding cells 
would be greatest. 
 
4.5.2 Liposomal supplementation and cellular viability 
The phospholipid bilayer of mammalian cells houses not only phospholipids but 
also receptors, transporter and membrane-bound enzymes (Spector and Yorek, 
1985).  Lipids are classed as primary and secondary messengers (van Meer et 
al., 2008). Therefore, any changes in phospholipid cellular membrane 
composition may affect cellular biological properties.  During this preliminary 
study, cellular viability was shown to be affected by liposomal supplementation 
(Figure 4.2 and 4.3).  This may be due to the lipid membrane composition 
alteration of the U87 and the SVG cells by the incorporation of the liposomal 
phospholipids and/or by the cell death mechanisms being altered as a result of 
the treatment.   
 
Cultured cells have previously been supplemented with lipids, which have 
resulted in a cellular membrane profile alteration.  Spector and Yorek (1985) 
discussed studies which had utilized cells in culture and which upon serum 
supplemented, the cellular membrane displayed a differing PUFA cellular 
membrane content compared to those cells which had no serum supplementation 
in the medium.   Other studies have also postulated the idea of modifying cellular 
phospholipid membranes by the observations of  20-30% of the unilamellar 
vesicle-derived phospholipids remaining in the cellular membrane (Spector and 
Yorek, 1985).  Therefore, in this preliminary study, it can be suggested that some 
of the phospholipids from the liposomal preparations, whether from the tissue or 
from the synthetic formulations were incorporated into the U87 and SVG cell 
phospholipid membranes.  Subsequently, properties associated with the fluid 
mosaic model could have been affected leading to the increased cellular viability 
observed as a result.  
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4.5.3 Membrane fluidity, ratios of omegas and cellular viability 
Alongside the observation the present results have shown that the lipid 
composition could be modified with serum enriched PUFA.  Another 
consideration was examined further, as per discussed by Liu et al. (1994), 
whereby the ratio of the omegas upon membrane composition was determined.  
Subsequently, it was shown that differing omega -3 and -6 ratios, affected the 
efficiency of the membrane transporters due to altered membrane fluidity.  Thus 
highlighting, as the ratio of phospholipid chain length increases alongside the 
proportion of those unsaturated the membrane fluidity increases (Spector and 
Yorek, 1985).  The fluidity of the plasma membranes has been used as a 
prognostic factor in lung carcinoma patients, whereby those with increased 
plasma membrane fluidity have a poorer prognosis (Sok et al., 2002).  Therefore, 
the differing effects of particular tumour-derived liposomes upon SVG and U87 
cellular viability may be because of the differing tissue, U87, and SVG lipid 
profiles to start with; which in turn will affect the membrane fluidity differently.    
 
Other studies have shown the importance of the ratio between omega-3 and 
polyunsaturated fatty acids surrounding the function of membrane receptors (Liu 
et al., 1994).  Hence, it is very important to demonstrate how altered lipid 
composition may have on cellular mechanisms.  The effect of modifications to the 
cellular membrane lipid composition are related to the resulting affect to the 
conformational changes which can, in turn affect the binding sites of the 
membrane receptors and transporters, and the active site of the enzymes.  
Subsequently, the tumour-derived liposomes may contain differing ratios of 
omega-3 and omega-6 fatty acids, which may result in differing alterations of the 
SVG and U87 membrane composition when incorporated into the cellular 
membranes during the log-phase.   
 
4.5.4 Relationship between the mitochondria and cellular viability  
Previous research, as far back as the 1980s, has shown phospholipid-derived 
liposomes residing in the mitochondrial membrane as well as other cellular 
organelles of the intact cells (Sleight and Pagano, 1985).  Therefore, the affect 
shown to the U87 and SVG cellular viability (Figure 4.2 and 4.3) with various 
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liposomal supplementations may be as a result of an altered mitochondrial 
function due to an altered mitochondrial membrane composition.  The 
mitochondria are involved in several roles surrounding; cellular energy 
generation, redox regulation, ROS production, Ca2+ buffering and apoptosis 
initiation (Wang and Youle, 2009).  Involvement of the mitochondria in cancer 
was first described by Warburg (1956) with the observation that cancerous cells 
undertake aerobic glycolysis.  Therefore, the altered U87 and SVG cellular 
viability shown with liposomal supplemented may occur as a result of an altered 
mitochondrial response to apoptosis.   
 
In diseased states, such as in cancerous cells, dysfunction in the normal 
responses to stimulation which would normally result in cell death have been 
observed by drug resistance (Peetla et al., 2013).  However, another explanation 
may also be involved as a result of mitochondrial adaptation to promote survival.  
This was noted in a study by Zhou et al. (2005) on brain mitochondria.   
 
4.5.5 Considerations and limitations 
Several considerations during the preliminary study of the effect supplementation 
of various lipid-derived liposomes upon cellular viability need to be addressed.  
Firstly, the research has detailed how cell lines have differing phospholipid 
membrane compositions. Hence, the cellular viability changes between SVG and 
U87 may occur as a result of the membrane fluidity between each cell line being 
affected differently due to the differences between the membrane compositions 
pre-supplementation.  Furthermore, the effect of membrane composition 
modifications between the cell lines may affect the efficiency of the membrane 
proteins differently.  For example, the effect of unsaturation levels between two 
differing cell lines affected receptor efficiency differently showing cell line 
differences to membrane compositions.  Hence, the affect upon cellular viability 
between SVG and U87 will need more detailed analysis before any conclusions 
can be made.   
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4.6 CONCLUSION 
During diseased states, cells are observed to have an altered phospholipid 
membrane composition.  Previous research has highlighted the differential 
differences between cancerous and non-cancerous phospholipid membrane 
compositions (Eberlin et al., 2013).  Subsequently, the altered phospholipid 
signature observed by Hill (2011) in meningioma grade II, may provide an insight 
into the effect an altered phospholipid membrane profile may have upon cellular 
events.  One of the many hallmarks of cancer is the resistance to cell death 
including apoptosis.  During this preliminary study to postulate whether the 
altered membrane composition observed in cancerous cells can promote 
hallmarks of cancer, cellular viability was shown to be affected with both 
meningioma and glioma tumour-derived and PC: PS liposomes.  This would 
suggest that the phospholipids were incorporated into the cellular and 
mitochondrial membrane which in turn would affect the membrane fluidity, 
curvature and a number of downstream events, including cell death. However, 
the exact membrane phospholipid profile of each cell line pre- and post- liposomal 
supplementation is unknown. Additionally, the exact phospholipid profile of the 
tumour-derived liposomes are unknown.  Hence, the effect upon membrane 
fluidity therefore membrane protein efficiency to function may affect each cell line 
differently.    
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Chapter 5 
 
 General Discussion  
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5.1 INTRODUCTION 
 
Per year, out of the >125 brain tumour types diagnosed, gliomas and 
meningiomas are the most common (Eberlin et al., 2013; Taylor et al., 2009).  
However, advances in meningioma diagnosis and treatment have somewhat 
lacked behind that of glioma.  This is reflected in the new 2016 WHO edition, 
which included several new considerations for diagnosing glioma, such as 
molecular parameters, but no such considerations were mentioned for 
meningioma (Louis et al., 2016).  Studies into meningioma have displayed altered 
lipid profiles, specifically that of phospholipids and their associated molecular 
species (Hill, 2011).   
 
The study by Hill (2011) of an altered phospholipid profile within meningioma 
highlighted a serine-derived lipid, PS to be enriched with a neuroprotective agent 
(DHA).  In this study, using yeast as a model the potential influence of these 
molecules within meningioma has displayed that serine, rather than DHA may 
direct the metabolic reprogramming observed in cancerous cells (Chapter 2).  
The suggestion that meningioma has an altered state of metabolism, is in line 
with the work by Otto Warburg in the late 1920s (Warburg, 1925; Warburg, 1956).  
 
At present, metabolic reprogramming is a recognized feature of tumourigenesis 
(Hanahan and Weinberg, 2011).  The ability of cancerous cells to survive is 
limited to the production of lipids, nucleic acids and proteins.  In cancerous cells, 
the sustained demand for such cellular nutrients has been shown to surround 
serine biosynthesis (Amelio et al., 2014b).  Due to the observed role serine plays 
in cancer metabolic reprogramming, research into serine biosynthesis has come 
to the forefront.  This discussion will now concentrate on the following 
parameters: (a) meningioma need for serine by metabolic reprogramming, (b) 
altered lipid biosynthesis and lipid droplet formation with serine presence and (c) 
the role lipids play in cellular viability. 
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5.2 MENINGIOMA’S NEED FOR SERINE 
 
In this study the immunohistochemical study has demonstrated serine 
biosynthesis to be altered within meningioma tissue.  In cancerous tissues, such 
serine biosynthesis is met by the diversion away from the glycolytic pathway.  The 
flux through the glycolytic pathway is enabled by glucose availability.  Therefore, 
glucose itself is described as the precursor of L-serine within these cancerous 
tissues (Hirabayashi and Furuya, 2008). The diversion observed from glycolysis 
to serine biosynthesis during tumourigenesis is a sequential, enzyme-regulated 
process. Several enzymes associated with serine biosynthesis have been shown 
to be expressed within those meningioma tissues examined, as per displayed in 
Figure 5.1.   
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Figure 5.1:  Flow diagram showing an immunohistochemical study using Image 
J software has shown a glycolytic diversion to serine biosynthesis within 
meningioma tissues.  Such enzymes associated with serine biosynthesis 
showing positive expression within the meningioma cellular bodies include; 
PHGDH (79.15%), PKM2 (61.85%) and p53 (32.10%) (Adapted from Amelio et 
al., 2014a).  
Legend: 3-phosphoglycerate (3P pyruvate), 3-phosphohydroxypyruvate (3P 
serine), transamination reaction (PSTA1) and phosphate ester hydrolysis 
(PSPH). 
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As shown in Figure 5.1, serine biosynthesis has been shown to be activated 
within meningioma. The key enzyme associated with serine biosynthesis is 
PHGDH, which catalyses the diversion from glycolysis to serine biosynthesis 
(Figure 5.1).  Within the meningioma samples examined, over 80% of the cellular 
bodies displayed a positive PHGDH expression within the tissue (Figure 3.2, B). 
As shown in Figure 5.1, such strong PHGDH expression within these meningioma 
cellular bodies would result in the redirection of the metabolic flux from glycolysis 
to serine biosynthesis via the rate limiting step; 3P pyruvate to 3-
phosphohydroxypyruvate. Similar PHGDH expression profiles have been 
demonstrated in several other cancers, including melanoma, breast and 
colorectal (Jai et al., 2016).  One possible explanation, for the PHGDH expression 
is provided by the increased expression of the glucose transporter, found in brain 
tissues (Owen et al., 2002).  Therefore, the glucose required for sustained flux 
through glycolysis would enable the continual production of L-serine via PHGDH.      
 
Supporting this notion of meningioma metabolic reprogramming surrounding 
serine biosynthesis, is the expression of the PKM2 isoform within the cancerous 
tissues.  Such expressions of PKM2, as opposed to PKM1, are indicative of 
proliferating transformed cells.  Within meningioma, over 60% of the cellular 
bodies showed positivity for PKM2 (Figure 3.3, B).  Several studies within solid 
tumours have also demonstrated an increase in the expression of PKM2 (Zhu et 
al., 2016).  With the knowledge of serine acting as an allosteric regulator of PKM2, 
altered glycolytic flux enabling serine biosynthesis within meningioma is 
apparent. A summary of the allosteric regulation of PKM2 in cancerous tissues is 
shown in Figure 5.2. 
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Figure 5.2:  Flow pathways showing PKM2 expression within cancerous cells (B 
and C) as opposed to PKM1 (A) displays the presence of cancerous 
transformation.  Such expressions of PKM2 and PHGDH have been 
demonstrated within meningioma. Therefore, demonstrating a serine-dependent 
PKM2 activation within meningioma (B and C).   Suggesting that when serine 
stores are depleted within meningioma tissue, the catalytic rate of PKM2 will 
reduce, leading to the accumulation of upstream glycolytic intermediates.  These 
intermediates will then be diverted from glycolysis to serine production via 
PHGDH (C).  When serine stores are replenished, serine will then activate PKM2 
activity; restoring the glycolytic flux (B).  Thus highlighting, that the presence of 
serine can allosterically regulate the glycolytic flux, therefore the production of 
ATP.   
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As described in Figure 5.2, within tumours, serine presence alone can regulate 
PKM2 expression and therefore enhances the catalytic conversion rate of PEP 
to pyruvate.  Such allosteric regulation within meningioma is displayed by the 
synergistic relationship between PKM2 and PHGDH expressions (see Chapter 
3). This mechanism of allosteric regulation surrounding PKM2 and serine 
suggests that meningioma tissues must contain high levels of the non-essential 
amino acid, serine.  Such levels of serine would then enable aerobic glycolysis 
and lactate production both of which are vital for cell growth and survival (Diaz-
Ruiz and Zhou, 2011).  Several cancerous phenotypical advances are promoted 
with such aerobic glycolysis including the upregulation of glycolysis to sustain 
cellular survival during intermittent hypoxia.    
 
Within cancerous cells, the status of such nutrients like serine, have also been 
shown to be affected by the expression of tumour suppressors. Such tumour 
suppressors like p53 have been show to inhibit serine biosynthesis by targeting 
PHGDH (Ou et al., 2015).  In human melanoma, over 80% of cases have been 
shown to retain their p53 expression. In such tissues, PHGDH activity is observed 
to be reduced resulting in serine depletion. Consequently, upon serine starvation, 
p53-mediated cell death was enhanced in response to Nutlin-3 treatment (Ou et 
al., 2015). However, those melanoma cells which demonstrated an 
overexpression in PHGDH inhibited the apoptotic response to such nutrient 
stress. Therefore, taking into consideration the overriding expression of PHGDH 
in correlation to p53 within the meningioma’s examined in this study (Figure 3.3), 
it would suggest that serine biosynthesis is not suppressed and in fact, with serine 
depletions, the meningioma tumour would not be sensitive to p53-mediated cell 
death.   
 
Subsequently, the altered serine biosynthetic pathway observed in meningioma 
would lead to the production of key molecules involved in cellular survival 
including lipids, secondary messengers and proteins (Amelio et al., 2014b).  In 
order to identify the phenotypical advances, such tumours may gain with directed 
serine biosynthesis a study utilising a model organism was developed.   
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5.2.1 The influence of serine on metabolic reprogramming  
In meningioma, in order to sustain such a cancerous phenotype, metabolic 
programming has to be altered (Tsun and Possemato, 2015).   Such metabolic 
reprogramming surrounds lipid metabolism, specifically that of neutral lipids 
(Hanahan and Weinberg, 2011).  These neutral lipids provide an energy source 
to the cells during nutrient depletion and hypoxia conditions.  To support the 
notion that the observed serine biosynthesis within meningioma supports a 
cancerous phenotype, an oleaginous yeast model was established (see Chapter 
2).  The discussion will now detail the findings of this study.  
 
An oleaginous yeast model, in the form of L. starkeyi, provided insight into the 
potential influence an increased serine presence may provide meningioma.  With 
such capacity of yeast to uptake serine, the cellular events, which are recognised 
to be altered in a cancerous state were examined.  A summary of the major 
findings are displayed in Figure 5.3.  
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Figure 5.3:  Growth curve showing that serine supplementation can alter lipid 
accruement during stationary phase (4, B) once cells have depleted nutritional 
resources during log phase (2).  Consequently, Ras and Tor signal transduction 
pathways are activated (3) leading to ectopic lipid accumulation (4, A and B).   
 
Like the CNS where serine is taken up by ASC transporters (Figure 1.18), yeasts 
also have the capability to uptake serine by transporters (Grenson and Hennaut, 
1971).  With serine being up taken as any other nutrient source in the media, 
alterations in the cellular characteristics of those supplemented were observed.  
Such alterations in cellular characteristics are pertinent to a cancerous phenotype 
in terms of proliferation, maximal cellular community and lipid storage (Figures 
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2.1- 2.4).  To sustain proliferation, nutrients are required at an enhanced rate in 
cancerous cells.  With serine presence, such increases in proliferation were 
observed (Figure 2.2, B) suggesting that serine presence within the cell affects 
cellular processing surrounding the cell cycle. 
 
In response to the depleting sources of nutrients (nitrogen, phosphorus and 
carbon), the Ras and Tor signal transduction pathways are initiated (Figure 5.3).  
After such activation of Ras and Tor, to prevent lipotoxicity neutral lipids are then 
encapsulated into storage organelles known as LDs (Figure 5.3 and 5.4).  The 
storage of neutral lipids within LDs is observed within many disease tissues, 
including cancer (Coller, 2014; DeBerardinis et al., 2008b; DeBerardinis et al., 
2008a; DeBerardinis and Chandel, 2016).    Studies by Yen et al. (2008b) have 
described storage of neutral lipids in LDs to enable a source of energy for cellular 
events and a source of phospholipids, which are required for membrane 
biosynthesis.  However, with serine presence, there is an uncharacteristic 
observation of multiple LDs per cell (Figure 5.3, A and B).  The proposed 
mechanism of LD formation and LD mobilization is illustrated in Figure 5.4.  
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Figure 5.4:  Flow diagram and chemical structures showing how the presence of 
serine alters the stages (1-7) of storage and mobilization of neutral lipids.  The 
number of lipid droplets increase with serine presence, leading to an increased 
surface area to volume ratio, which the LD occupies within the cell.  Hence, the 
mobilization of lipids via lipolysis may be enhanced (Images adapted from Thiele 
and Spandl, 2008 and Yen, 2008). 
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The observed increase in the number of smaller LDs within serine-enriched cells 
are in line with the observations that Accioly et al (2008) made when comparing 
cancerous to non-cancerous cells.  LDs are produced by the endoplasmic 
reticulum (Figure 5.4, stage 1) when the cytosolic lipid content is raised. By 
incorporating these cytosolic lipids within a membrane bound compartment, 
lipotoxicity is prevented (Walther and Farese Jr, 2009).  With serine presence, 
the observed alterations in LD formation may be due to an overexpression of 
lipases involved in lipolysis (Figure 5.4, stage 4). In cancerous tissue, the 
overexpression of lipases, such as MAGL, have been shown to produce 
increasing levels of free fatty acids after lipolysis (Beller et al., 2010).  However, 
with serine presence, the expression of such lipases does not appear to be 
increased as de novo free fatty acid synthesis was not significantly increased 
(Figure 2.9).   
 
Subsequently, the alterations in LD formation with serine presence may be a 
knock-on effect from cellular stress produced by presiding dysfunctional 
mitochondria as observed on Drosophila by Liu et al. (2015).  As LD formation is 
an orchestration between the endoplasmic reticulum and mitochondria, such 
increases in cellular stress may impact on the size of LD, therefore, suggesting 
that serine presence may influence mitochondrial function.   In either situation, 
due to the enhanced LD surface area to volume ratio, the mobilization of lipids 
via lipolysis would be increased (Figure 5.4, stage 4).  A radiochemical study in 
this thesis (see chapter 2) provided insight into the effect serine presence may 
have upon de novo lipid synthesis.  A summary of the metabolic pathways related 
to de novo lipid synthesis is illustrated in Figure 5.5.  
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Figure 5.5:  Biochemical diagram showing that with serine presence, metabolic 
re-tailoring surrounding de novo lipid synthesis and accumulation occurs in 
relation to nutrient depletion (highlighted in red).  The conversion of serine to 
pyruvate by CHA1 also provides a flux to the Kennedy pathway enabling the 
production of triacylglycerides and phospholipids.  The ratio of phospholipid: 
triacylglyceride de novo synthesis is increased with serine presence to house the 
multiple LDs within the cell (Image adapted from Herman, 2002). 
 
186 
 
With serine presence, an altered de novo synthesis of acyl lipids and isoprenoids 
were observed (Figure 2.9).  From the current radiochemical study, it can be 
suggested that for every ten acetate molecules converted to acetyl-CoA, one of 
these molecules are used to support acyl lipid synthesis and the other 9 support 
isoprenoid synthesis.  Such increases in isoprenoid synthesis reflect the 
requirement for membranes surrounding the multiple LDs (Figure 2.4).   With 
stored energy in the form of multiple LDs within the cell, only half of the acetate 
was taken up by the cells (Figure 2.6).  This demonstrates how serine presence 
alone can further re-tail metabolic pathways within a cancerous phenotype, 
enabling sources of energy and phospholipids to be abundant.    
 
5.2.2 Serine’s influence on cellular viability 
One of the many derivatives of serine, is the phospholipid, phosphatidylserine 
which resides in the plasma membranes of the cell.  In the study by Hill (2011), 
the phospholipid signature of meningioma was altered in comparison to other 
areas of the brain. Alterations were particularly noted within the 
phosphatidylserine portion, which was observed to be enriched with DHA.  
Previous studies have highlighted the beneficial relationship between 
phosphatidylserine and DHA within diseased cells, including neuronal survival 
and differentiation (Kim et al., 2010; Kim, 2008; Steelman et al., 2011).  
Considering that meningioma has been shown to promote serine biosynthesis, 
production of such serine-derived lipids like phosphatidylserine will be enhanced 
in such tissues which is in line with Hill (2011) observations.   
 
Once produced, phospholipids are incorporated into a variety of cellular 
membranes. The phospholipid bilayer of mammalian cells houses not only 
phospholipids but also receptors, transporter and membrane-bound enzymes 
(Spector and Yorek, 1985). Lipids are classed as primary and secondary 
messengers (van Meer et al., 2008). Therefore, any changes in the composition 
of phospholipid cellular membranes may impede on cellular events.  
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One such organelle surrounded by a membrane, the mitochondria, play a central 
role in cellular events including; energy production, regulation of redox, the 
production of ROS, Ca2+ buffering and the initiation of apoptosis (Wang and 
Youle, 2009).  Within the mitochondrial plasma membrane, several receptors and 
transporters reside.  The function of such receptors and transporters can be 
easily influenced by alterations in the phospholipid composition of membrane (Liu 
et al., 1994).  Hence, the notion that meningioma has a phospholipid signature 
different to other areas in the brain (Hill, 2011) may influence the cancerous 
phenotype observed. 
 
5.2.3 U87 and SVG cell line study 
Supplementation of PS liposomes increased the viability of the non-cancerous 
SVG cell line as well as the cancerous U87 cell line (Figure 4.2).   Meningioma-
derived liposomal preparations also increased cellular viability of both cell lines 
(Figure 4.2).  Such liposomes have been shown to incorporate not only in the 
plasma membrane of cells but also within the; nuclear membranes, mitochondrial 
membranes and the golgi apparatus (Sleight and Pagano 1985).   The observed 
liposomal incorporation within such membranes has been shown to alter their 
composition (Spector and Yorek, 1985). Incorporation of meningioma-derived 
lipids increased the viability of the non-cancerous SVG cell line like that observed 
with PS supplementation (Figures 4.2- 4.3). This observation suggests that in fact 
the phospholipid (PS), rather than the fatty acid (DHA), plays a role in cellular 
viability. This may be in part, due to the altered phospholipid composition of the 
cellular and organelle membranes.  Such altered membrane composition will 
impact the fluidity and the entry and exit of substances into the cell.    
 
5.3 CLINICAL IMPLICATIONS AND SPECULATIONS  
 
The results gained from this study can be used clinically in the diagnosis and 
management of meningioma as well as other diseased cells displaying ectopic 
lipid accumulation.  As previously discussed, meningioma is currently graded in 
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accordance with the WHO organization classification (Figure 1.3).  The 
observation that serine biosynthesis is promoted within meningioma provides 
additional insight into the behaviour of the tumour in terms of proliferation and 
potential chemotherapy resistance.  The observation that meningioma has an 
altered biochemistry, may provide guidance when histologically grading the 
tumours.  
 
The requirement for serine biosynthesis within meningioma supports the 
observation that some cancerous cells have a preference to serine, rather than 
glycine, for one carbon metabolism (Labuschagne et al., 2014).  Those tumours 
expressing enzymes involved in serine biosynthesis, such as PKM2 and PHGDH, 
can be targeted with treatment in the form of inhibitors.  A review by Zhu et al. 
(2016) associated PKM2 expression with poor prognosis, however the effects of 
such PKM2 expression can be inhibited. Studies by Vander Heiden et al. (2010) 
and Goldberg and Sharp (2012) have shown that the flux through aerobic 
glycolysis can be reduced by targeting PKM2.  Subsequently, the increased 
demand for energy in cancerous cells enabled by aerobic glycolysis would be 
hindered.  
     
Another potential avenue for meningioma treatment would aim to prevent serine 
biosynthesis, therefore reducing serine-derived lipid production, which has been 
implicated with increased cellular viability as well as lipid accruement.  To reduce 
serine biosynthesis, meningioma tissues exhibiting PHGDH expression can be 
targeted (Wang et al., 2017; Mullarky et al., 2016).  By doing so, the observed 
correlation of PHGDH expression and prognosis in the study by Jia et al. (2016) 
would be reversed.  The observation that PHGDH is expressed solely in 
cancerous cells aids the treatment to be tumour site specific (Wang et al., 2017; 
Mullarky et al., 2016).   By hindering the capability of cancerous cells producing 
serine, the dysfunctional formation of LDs observed would also be hindered.  
Such LD alterations in breast, cervical and colon cancers have been correlated 
with increased chemotherapy resistance (Zhu, 2016).  By targeting serine 
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biosynthesis, the resources needed to enable a cancerous phenotype are 
depleted.    
5.4 CONCLUSION 
 
Previous studies by Hill (2011) determined how meningioma tissues were 
enriched with the phospholipid, PS and the fatty acid, DHA.  Within this thesis, 
the interaction between DHA and / or L-serine upon metabolic pathways have 
been examined.  In Chapter 2, the oleaginous yeast L. starkeyi displayed how 
the metabolic reprogramming surrounding neutral lipid and lipid droplet formation 
were altered with L-serine presence. In Chapter 3, the immunohistochemical 
study illustrated a glycolytic diversion towards serine biosynthesis in both grade I 
and II meningioma.  In Chapter 4, the phenotypical cellular viability of cancerous 
cells were enhanced with the supplementation of both PS and tumour-derived 
liposomes.    
 
In conclusion, serine the non-essential amino acid has been implicated as an 
orchestrator of cancerous metabolic reprogramming in this study on meningioma.  
Meningioma has been shown to promote serine-directed metabolism, which in 
turn increases the abundance of serine-derived lipids promoting a cancerous 
phenotype.  Such metabolic alterations have been implicated with poor prognosis 
in other types of cancer due to chemotherapy resistance.  Hence, the implications 
surrounding such metabolic alterations can be considered clinically in terms of 
proliferation, response to treatment and subsequently prognosis.   
 
5.5 SCOPE FOR FUTURE STUDIES 
 
To take forward this present study on meningioma, the relationship between 
serine biosynthesis and the presentation of an altered state of metabolism can 
be explored further.  To establish if serine can influence phospholipid profiles 
within cancerous cells, an analytical study can be carried out.    To analyse the 
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effect of serine, the model organism, L. starkeyi, can be supplemented with 
serine.  During stationary phase, the phospholipid profile of such cells can then 
be analysed using high-performance liquid chromatography.  Such 
methodologies exist (Pang et al., 2008) where the phospholipid as well as its 
assigned molecular species can be examined.  This analytical study would 
provide an insight into the relationship between serine supplementation and the 
production of serine-derived lipids i.e. phosphatidylserine.  Additionally, the 
relationship between phosphatidylserine and DHA during times of proliferation 
and lipid accumulation can be exploited.  To gain an insight into the impact serine 
has upon glycolytic flux within cancerous cells, a study utilizing radiolabeled 
glucose can be performed upon those L. starkeyi cells supplemented with/without 
serine.   
 
To determine whether the formation of lipid droplets in those cells supplemented 
with serine was related to a dysfunctional mitochondria and/or endoplasmic 
reticulum, a transmission electron microscopy study of L. starkeyi cells during 
stationary phase can be developed.  Furthermore, the identification and semi-
quantification of such lipid droplets can be achieved using fluorescent microscopy 
utilising Nile red as opposed to light microscopy.   
 
To determine whether serine biosynthesis within meningioma can be reduced 
using enzyme inhibitors, a study using such treatments as supplements to the 
model organism, L. starkeyi and/or U87 and SVG cell lines can be optimized. By 
using enzyme assays to gain an insight into the flux through glycolysis and serine 
biosynthesis with such treatments, the clinical implications in terms of chemo 
resistance and cellular viability can be examined. 
 
To determine if the metabolic reprogramming observed with the presence of L-
serine is observed in other cancer types, the amino acids levels within cancerous 
tissues could be measured alongside their incorporation into phospholipids.  
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7.1 APPENDIX 1 
The incidence of cancer has increased over the past few decades; Figure 7.1 
shows the number of diagnoses of brain cancer in those individuals over the age 
of 90 in the UK. 
 
Figure 7.1:  Graph showing how the number of people in the UK aged >90 (per 
100,000) being diagnosed with brain cancer increasing from 1985 till 2015.  
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7.2 APPENDIX 2  
The phylogenetic relationship between this studies model organism, L. starkeyi 
and the well researched Baker’s yeast, S. cerevisiae.  Figure 7.2 shows the basis 
as to why the two yeasts accrue lipids differently.  
 
Figure 7:  A parsimonious tree summarising the phylogenetic relationship 
between Lipomycetaceae (Kurtzman et al., 2007). 
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7.3 APPENDIX 3 
Ethical approval for the thesis was gained from Brain Tumour North West in 
accordance with Royal Preston Hospital.  The STEM reference number for this 
research was 121.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 
 
 
 
 
Application for clinical samples/data from the 
Brain Tumour North West and  
the Walton Research Tissue Banks 
 
Applicant:     Duration of Project: Till March 2016 
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Email:  hhatchell@uclan.ac.uk 
Project Title:  Tumour associated lipid signatures in Brain Tumours- Metabolic 
clues to reveal potential therapeutic targets. 
Funding: 
Is the funding for the project    
b) internal (eg funded from a researchers laboratory or institutional budget) 
If the project has been submitted as a grant application for external funding?   N/A
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Was the application successful?      yes / no 
Was the project externally peer-reviewed?     yes / no 
External Funding body: N/A 
Details of Funding:  Total £N/A (staff N/A and consumables N/A) 
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A preliminary study involving human meningioma tissue revealed unusually high 
levels of phosphatidylserine (PS) enriched with Docosahexaenoic acid (DHA) 
compared to other areas of the Brain. In order to study this phenomenon further 
in terms of cellular proliferation, metabolism and apoptosis, we have developed 
an oleaginous yeast paradigm.  
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Examine the expression of several key markers which can possibly further 
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7.4 APPENDIX 4 
Table 7.1 shows the meningioma tissue sections used in Chapter 3 and 4. 
Table 7.1:  Histological classifications of meningioma tissue sections provided by 
Royal Preston Hospital.  
BTNW Sex Type Grade PR status ER status Ki67 
1 F Microcystic I 5% +ve Cytoplasmic 
blushing 
1-2% 
36 M Meningothelial I Patchy 
weak/mod 
30-40% 
+ve 
-ve <5% 
88 F Meningothelial I >90% +ve -ve 1-2% 
91 F Meningothelial I >90% +ve -ve Not 
stated 
95 F Not stated I 30-40% 
+ve 
-ve Not 
stated 
99 F Not stated I -ve -ve 5-8% 
118 F Transitional I Mod/strong 
>60% +ve 
Occ weak 
+ve 
Not 
stated 
145 F Transitional I 50% +ve Not stated 5-
10% 
143 F Atypical II Weak, 
scant 
-ve 5% 
198 F Atypical II 5% +ve -ve 20% 
286 F Choroid II Strong 
>75% +ve 
Not stated ~5-
8% 
392 F Atypical II +ve -ve 15% 
395 F Atypical II 75% +ve Not stated 15% 
457 M Meningothelial II Most cells 
strongly 
+ve 
-ve 10% 
677 M Atypical II 50% -ve 7% 
708 M Benign II 25% -ve <1% 
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Figure 7.3:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 1, a grade I meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B), Fascin (C) and PHGDH (D).  Incubation with DAB (6 minutes) enables antibody presence, appears 
brown.  H&E counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies. 
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X10 magnification X40 magnification 
X10 magnification X40 magnification X10 magnification X40 magnification 
X10 magnification X40 magnification 
7.5 APPENDIX  5 
 
217 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 88, a grade I meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B) and Fascin (C).  Incubation with DAB (6 minutes) enables antibody presence, appears brown.  H&E 
counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.  
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Figure 7.5:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 91, a grade I meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B) and Fascin (C).  Incubation with DAB (6 minutes) enables antibody presence, appears brown.  H&E 
counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.   
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Figure 7.6:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 95, a grade I meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B) and Fascin (C).  Incubation with DAB (6 minutes) enables antibody presence, appears brown.  H&E 
counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.   
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Figure 7.7:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 99, a grade I meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B) and Fascin (C).  Incubation with DAB (6 minutes) enables antibody presence, appears brown.  H&E 
counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.    
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Figure 7.8:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 118, a grade I meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B) and Fascin (C).  Incubation with DAB (6 minutes) enables antibody presence, appears brown.  H&E 
counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.   
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Figure 7.9:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 145, a grade I meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B), Fascin (C) and PHGDH (D).  Incubation with DAB (6 minutes) enables antibody presence, appears 
brown.  H&E counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.    
A B 
C D 
X10 magnification X40 magnification 
X10 magnification X40 magnification X10 magnification X40 magnification 
X10 magnification X40 magnification 
7.11 APPENDIX  11 
 
223 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 7.10:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 36, a grade I meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B), Fascin (C) and PHGDH (D).  Incubation with DAB (6 minutes) enables antibody presence, appears 
brown.  H&E counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.  
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Figure 7.11:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 395, a grade II meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B) and Fascin (C).  Incubation with DAB (6 minutes) enables antibody presence, appears brown.  H&E 
counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies. 
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Figure 7.12.  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 457, a grade II meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B), Fascin (C) and PHGDH (D).  Incubation with DAB (6 minutes) enables antibody presence, appears 
brown.  H&E counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies. 
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Figure 7.13:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 677, a grade II meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B) and Fascin (C).  Incubation with DAB (6 minutes) enables antibody presence, appears brown.  H&E 
counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.   
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Figure 7.14:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 708, a grade II meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B), Fascin (C) and PHGDH (D).  Incubation with DAB (6 minutes) enables antibody presence, appears 
brown.  H&E counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.  
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Figure 7.15:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 286, a grade II meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B) and Fascin (C).  Incubation with DAB (6 minutes) enables antibody presence, appears brown.  H&E 
counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.  
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Figure 7.16:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 198, a grade II meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B) and Fascin (C).  Incubation with DAB (6 minutes) enables antibody presence, appears brown.  H&E 
counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.  
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Figure 7.17:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 143, a grade II meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B) and Fascin (C).  Incubation with DAB (6 minutes) enables antibody presence, appears brown.  H&E 
counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.  
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Figure 7.18:  Photographic visualisation via light microscopy of the immunohistochemistry antibody expression profiles associated with 
serine biosynthetic and glycolytic pathways in the tissue sections belongings to patient 392, a grade II meningioma patient (n=1).  Antibodies 
of interest include; p53 (A), PKM2 (B), Fascin (C) and PHGDH (D).  Incubation with DAB (6 minutes) enables antibody presence, appears 
brown.  H&E counterstain followed DAB incubation, appearing blue in color allowing indication of cellular bodies.
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